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Introduction 
1.1 FOLLICLE-STIMULATING HORMONE 
1.1.1 History 
Vesalius (1515-1564) described the hypophysis as 'glandula pituitaria 
cerebri excipiens', 'the gland that extracts mucus from the brain'. Several 
centuries later, the anterior part of this small organ at the base of the 
hypothalamus embedded in the sella turcica appeared to produce specific 
gonad·stimulating substances. Injections of pituitary extracts in infantile rats 
(Smith & Engle, 1927) demonstrated that effects of hypogonadism were 
reversible. Similar effects on gonads were reported in animals in response 
to injection of urine of pregnant women (Aschheim & Zondek, 1927). These 
two German scientists described the pars anterior of the hypophysis as 
'den Motor der Sexualfunktionen'. However, confusing results were obtained 
administering this urine to immature animals, achieving merely luteinization, 
whereas combining it with pituitary extracts also induced ovarian growth 
and ovulation (Engle, 1929). Simultaneously, the hypothesis of two gonad-
influencing factors; Prolan A and Prolan B ('Follikelreifungshormon' and 
'Iuteinisierendes hormon', respectively) was postulated (Zondek, 1930). It 
was found that Prolan B was not produced by the hypophysis but present in 
urine of pregnant women as an 'anterior pituitary-like hormone' (eollip et aI., 
1933). Luteinizing gonadotropins in urine of pregnant women were found to 
be of placental origin, whereas urine of climacteric women predominantly 
induced stimulation of follicle development in the ovaries (Leonard & Smith, 
1934). Partial separation of two different gonadotropins was reported in 
extracts of the anterior lobe of the hypophysis (Fevold et aI., 1933). One of 
these two gonadotropins was found to affect growth of ovarian follicles, 
whereas the second was capable of inducing luteinization ('gonad-stimulating 
hormone' = follicle-stimulating hormone [FSH] and luteinizing hormone [LHJ). 
Wide clinical application of gonadotropins derived from human pituitary 
extracts and pregnant mare serum (PMSG) was hampered by scarcity of 
the original substrate. The clinical use was stopped following detection of 
anti-gonadotropin antibody formation (Leathum & Rakoff, 1948). Almost 
twenty years following isolation of gonadotropins from the pituitary gland, a 
novel way of extracting FSH-like substance from postmenopausal urine 
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was published (Borth et aI., 1954). Gel-electroforesis of urine provided a new 
way to improve the purification and extraction process (Albrecht, 1956; Borth 
et aI., 1957). This innovation in the production process of gonadotropins 
caused the wide introduction of these hormones as therapy for various 
disease states; primarily to induce follicle growth in infertile anovulatory 
women. 
It is now possible to produce human recombinant FSH (rhFSH) through 
the transfection of Chinese hamster ovary cell lines with human ex and P 
protein subunit genes (Keene et aI., 1989). This technology provides the 
opportunity to modulate the chemical structure of FSH and develop FSH 
agonists as well as FSH antagonists (Boime, 1990). This may disclose a 
whole new era of clinical applications. 
1.1.2 Structure and function 
The group of pituitary glycoprotein hormones includes FSH, LH, thyroid-
stimulating hormone (TSH) and placental human chorionic gonadotropin 
(hCG). The gonadotropins (molecular weight 28,000 for LH and 33,000 for 
FSH), produced by the anterior lobe of the pituitary gland are structured as 
a heterodimer of two noncovalently associated protein subunits, ex and p, 
encoded by separate genes located on different chromosomes (Boim et aI., 
1992) in the human. The structure of the ex subunits of all pituitary 
glycoproteins is identical. However, the p chains are unique and after linkage 
to the ex chain determine specific hormone function (Fauser & Hsueh, 1989). 
Modification of glycosylation (carbohydrate additions to proteins) during the 
intracellular translational and posttranslational period appears to be the basis 
for heterogeneity of FSH molecules with respect to biochemical structure 
and biological potencies (Chappel et aI., 1983). Differences in carbohydrate 
moieties of the glycoprotein (linkage of sialic acid/sulfate) cause differences 
in metabolic clearance and biologic activity (serum half-life as well as 
receptoraffinity)(Boime et aI., 1992). Changes in isoform distribution represent 
a potential way of modulating FSH biopotency (Fauser et aI., 1989). The 
assembly and modification of glycoprotein subunits to produce functional 
heterodimers is a complex process which takes place in the endoplasmatic 
reticulum and the Golgi apparatus. Ultimately, the hormone is stored in 
secretory granules before secretion into the peripheral vessels. Finally, FSH 
and LH exert their effects by binding to specific membrane receptors on 
granulosa cells (Midgley et aI., 1973), activating the second messenger (G 
protein and cAMP-system) and subsequently protein kinase A, resulting in 
stimulation of gene expression (Spiegel et aI., 1985). Serum gonadotropin 
concentrations can be estimated using radioimmunoassays (RIA) containing 
radioactively-labelled antigens raised against specific parts of the dimers. 
Initially, clinical application of RIA was hampered by cross-reactivity (affinity 
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to ex subunit as part of other glycoprotein dimers or to free-circulating 
biologically inactive exsubunit). Presently, immunoassays have been improved 
and additional techniques for hormone assays are available: e.g. 
immunoradiometric assays (IRMA) and immunofluorimetric assays (IFMA). 
These tests use two highly specific monoclonal antibodies raised against 
amino-acid sequences of each of the glycoprotein subunits (Fauser et aI., 
1991). However, these "sandwich assays" (they enclose the glycoprotein 
from different sides) can still show cross-reactivity by attachment to non-
specific epitopes. This illustrates some potential causes for discrepancies 
between results of immunological assay methods and actual biological 
activity. In-vivobioassays serve to compare biological effects of gonadotropin 
preparations in a quantitative manner in animals. In the widely used 
Steelman-Pohley assay (Steelman & Pohley, 1953), 21 day-old female 
Sprague-Dawley rats are injected subcutaneously for 3 days and ovaries 
weighed on the 4th day. Disadvantages of this assay are that sensitivity is 
too low to detect small the amounts of FSH in serum, reproducibility is poor 
and the procedure is cumbersome (Fauser & Hsueh, 1988). However, the 
ability to take metabolic half-life of the hormone into account is an important 
advantage of the in-vivo test. Therefore, biopotencies of commercially 
available urinary gonadotropin preparations are still measured using the 
Steelman-Pooley assay. In-vitro bioassays were introduced in order to 
improve sensitivity and to develop easier tests with improved reproducibility. 
Various in-vitro cultures, using different animal or human target tissues and 
different end points, have been tested (Van Damme et aI., 1974 [LH bioassay 
in mouse leydig cells]; Padmanabhan et aI., 1987 [FSH bioassay in granulosa 
cells]; Dahl et aI., 1989 [modified FSH bioassay in human granulosa cells]). 
Circulating levels of the gonadotropins as measured at any given 
moment represent the balance between pituitary release and metabolic 
clearance. Following intravenous injection, the half-life of urinary FSH was 
demonstrated to be approximately 2 hours (Franchimont, 1971). FSH 
disappearance following hypophysectomy resulted in a fast part of the 
disappearance curve showing a half-life of approximately 4 hours, whereas 
the slow part demonstrated a half-life of approximately 70 hours (Yen et aI., 
1970). In contrast to FSH, LH was reported to have a rapid disappearance 
(half-life about 20 minutes for the fast part of the curve, about 230 minutes 
for the slow component, following hypophysectomy (Yen et aI., 1968). Half-
life of hCG varied between 6-9 hours during the first part of the curve and 24 
to 37 hours during the second part (Franchi mont & Burger, 1975). Serum 
half-life of intramuscularly administered hCG was determined to be 
approximately 32 hours, whereas after subcutaneous administration half-life 
was extended (38 ± 3 hours) (Saal et aI., 1991). Following intramuscular 
injection of urinary FSH preparations, the half-life was estimated to be 
approximately 35 hours (Diczfaluzy & Harlin, 1988). Maximum serum 
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concentrations and area under the curve (AUC) appeared to be dose-
dependent following a single injection, whereas time to reach maximum FSH 
serum levels was dose-independent. 
The long half-life of purified follicle-stimulating hormone (pFSH) after 
intramuscular administration (>24 hours) induces accumulating serum FSH 
levels (Sharma et aI., 1987; Mizunuma et aI., 1990). In addition, 
pharmacokinetic data show gradual but distinct accumulation of circulating 
FSH in the majority of patients (Diczfaluzy & Harlin, 1988); steady state 
levels were demonstrated following approximately 4-5 days of daily pFSH 
administration in hypogonadotropic women (Mizunuma et aI., 1990). Based 
on these data, computed simulation patterns of the time-concentration profile 
of serum FSH exhibited steady state levels following approximately 2 to 3 
days after decreasing the gonadotropin doses. Half-life of recombinant 
human FSH appeared to be around 44 hours following a single intramuscular 
injection in hypogonadotropic female volunteers and was related to body 
weight (Mannaerts et aI., 1993). Following weekly increasing administration 
of doses of rhFSH, steady state levels appeared after approximately 4 to 5 
days (Section 2.3). Despite the unknown biochemical basis, significant 
differences between various lots of commercially available urinary 
gonadotropin preparations were reported concerning their ability to stimulate 
follicular development and ovulation in an in-vivo hamster ovulation bioassay 
(Cook et aI., 1988). 
1.2 REGULATION OF OVARIAN FUNCTION 
1.2.1 Initiation of growth of primordial follicles 
Approximately two million primordial follicles are present in the human 
ovaries at birth (Peters, 1979). At menarche not more than 400,000 to 
500,000 are left (Hillier et aI., 1981). These follicles are characterized by an 
oocyte in the prophase of the first meiotic division, surrounded by a single 
layer of granulosa cells. Transformation of granulosa cells from a flat to 
a cuboid shape and simultaneous oocyte growth leads to formation of a 
primary follicle (for review see Pache, 1993). This initiation of growth is 
thoughtto be a continuous process independent from gonadotropins (Hisaw, 
1947; Peters et aI., 1973), although some animal studies suggest that minute 
amounts of gonadotropins need to be present. The assumption that primordial 
follicles can develop in the absenceof gonadotropins is based on observation 
of ovarian changes during childhood, and continued early folliculogenesis 
following hypophysectomy (Edwards et aI., 1977). Secondary or preantral 
follicles are typified by an increase of granulosa cell layers (stratum 
granulosum). Formation of an antrum within the granulosa cell layers 
characterizes the advancement to the antral stage. The maturing follicle can 
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either continue its development or undergo atresia, The process of initiation 
of growth and subsequent atresia is responsible for the overall decrease in 
numbers of follicles present in the ovary, Apoptosis ('programmed cell 
death') appears to underlie this atretic process, occurring predominantly in 
antral follicles (Billig et aI., 1993), The time elapsed between the primordial 
stage and development of a preovulatory follicle is not yet clearly defined in 
the human, Morphological studies (Gougeon, 1982) suggest that successive 
waves of growing follicles ensure a continuous process of folliculogenesis, 
The overall life-span of a maturing ovulatory follicle can be estimated by 
summation of: a) 60 days (until a size of 1 mm), b) 2 weeks (during the 
preceding luteal phase [until a size of 4 to 6 mm]), and c) 2 weeks 
(corresponding to the follicular phase of the ovulatory cycle [until a size of 
approximately 20 mm]) (Gougeon, 1982), 
1,2,2 Granulosa and theca cell steroid production 
Early investigations (Fevold, 1941) pointed towards the synergism of both 
gonadotropins for stimulation of ovarian estrogen production, The 
observation that two different ovarian cell types (the theca cells stimulated 
by LH, and the granulosa cells controlled by FSH) are involved in estrogen 
synthesis, was initially reported by Falck (1959), Subsequently, this 
hypothesis was confirmed using highly purified urinary FSH in a 
hypogonadotropic model; in rodents (immature rats [Eshkol et aI., 1967J 
and in females [Couzinet et aI., 1988]), Administering highly purified urinary 
FSH preparations (containing only minute amounts of LH) resulted in 
diminished estrogen production but normal follicle growth, The concept that 
both theca cells and granulosa cells are needed for adequate estrogen 
biosynthesis is referred to as the 'two-cell, two-gonadotropin' hypothesis, 
FSH membrane receptors are exclusively present on granulosa cells 
(Menigish et aI., 1991), whereas LH receptors can be observed on both 
theca (Rajaniemi & Vanha-Perttula, 1972) and granulosa cells (Erickson 
et aI., 1979b), LH stimUlates theca cells to convert intracellularly stored C27 
steroids (cholesterol), by the cytochrome P450 side-chain cleavage enzyme 
complex (P450 SCC) to pregnenolone, This rate-limiting first conversion 
process is followed by two possible routes; a) the predominant pathway in 
the human (delta-4 pathway) leading to biosynthesis androstenedione (AD) 
(Ryan & Smith, 1965), and the delta-5 pathway resulting in formation of 
dehydroepiandrosterone (DHEAS) (Aakvaag, 1969) (for comprehensive 
review see Gore-Langton & Armstrong, 1988), AD will transverse the basal 
lamina and accumulate in the antral fluid of the developing follicle (McNatty 
& Baird, 1978), This provides granulosa cells with the substrate wrlich can 
subsequently be converted by the cytochrome P450 aromatase enzyme 
complex in 17p-estradiol (E,), SpecifiC enzyme activities are limited to 
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different types of ovarian tissue (theca cells or granulosa cells). Estrogens 
in turn promote FSH receptor proliferation on granulosa cells, amplify 
aromatase activity and enhance the ability of FSH to induce LH receptors 
(Hillier et aI., 1988). E, concentrations in pooled fluid obtained from large 
follicles appeared to be >1000-fold higher as compared to simultaneously 
pooled fluid from small follicles « 8 mm) and levels correlate with follicle 
size (Westergaard et aI., 1986). It was also shown that granulosa cell 
numbers correlate with follicular size and E, concentrations in follicular fluid 
(McNatty et aI., 1976; McNatty et aI., 1979a; McNatty et aI., 1979b; McNatty 
et aI., 1979c, Westergaard et aI., 1986). 
1.2.3 Estrogens and follicle development 
The selection of a single dominant follicle is associated with increased 
aromatase activity and a subsequent rise in intrafollicular E, production 
(Erickson et aI., 1979; Hillier et aI., 1981). Confirmation that E, is produced 
by the dominant follilcle was provided by the observation of elevated E, 
levels in venous plasma draining the ovary bearing a follicle larger than 10 
mm as compared to concentrations at the contralateral side (Baird & Fraser, 
1975). In this way, the selected follicle is able to maintain a highly estrogenic 
local environment. Due to incremental E,levels in peripheral blood, negative 
feedback actions are exerted, leading to decreasing FSH serum levels and 
securing single dominant follicle development. Local actions of E, - as a 
potential autocrine regulator- are: a) increase of mitogenic activity (causing 
further granulosa cell proliferation and growth of the follicle) (Williams, 1940), 
b) inhibition of atresia (Richards, 1975), c) increment of FSH and induction 
of LH receptor content of granulosa cells (Rao et aI., 1978), d) enhancement 
of FSH-induced aromatase activity, and e) stimulation of production of 
follicular fluid. This autocrine up-regulation by E, could underlie continued 
development of follicles in the presence of decreasing FSH serum levels. 
An increasing number of potential local modulators of FSH action, such as 
activiniinhibin (Miro & Hillier, 1992), insulin-like growth factor (IGF) and 
binding proteins (Fauser & Hsueh, 1988; Adashi et aI., 1989) may play 
important roles with respect to intrafollicular estrogen synthesis. However, 
to a large extent these observations are based on in-vitro animal studies, 
and it is unclear as yet what their role is in human ovarian physiology. 
Several pathophysiological conditions suggest that elevated E, 
concentrations are not mandatory for the induction of follicular growth 
(Rabinovici et aI., 1991, chapter 2.2). More recently, a difference in in-vitro 
function of FSH and LH was delineated; FSH appeared to support steroid 
production as well as cell proliferation and LH solely stimulated 
steroidogenesis (Yong et aI., 1992). An additional observation questioning 
the possibility of direct actions of estrogens include the absence of E, 
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receptors on granulosa cells in the primate ovary (Hild-Petito et aI., 1988). 
A local direct role of estrogens remains questionable and the need for 
coordinate action of both FSH and LH leading to estrogen production and 
follicle growth needs to be reexamined. The minimal requirements of LH to 
achieve steroidogenesis and FSH to stimulate fOllicle growth need further 
elucidation. 
1.2.4 Dynamics of follicle growth and selection during the menstrual 
cycle: The FSH-'threshold'/'window' concept 
Initially, developmental characteristics of the dominant follicle were 
documented by sequential scanning throughout the normal cycle using 
transabdominal ultrasound (O'Herlihy et al. 1980, Queenan et al. 1980, 
Kerin et al. 1981). Under optimal conditions, a varying number of small 
follicles will be visible at a size of 6 to 8 mm in the early follicular phase (day 
3 to 5). In a longitudinal study using transvaginal ultrasound in regularly 
menstruating women, it was possible to discriminate the dominant follicle 
by its size (>9 mm) (pache et aI., 1990; van Santbrink et aI., 1995). 
Furthermore, serum E, levels increased significantly only after a dominant 
follicle could be discriminated by sonography (Fauser et aI., 1993c, van 
Santbrink et aI., 1995). These data correspond with in-vitro findings (Erickson 
et aI., 1979a, Hillier et aI., 1981) demonstrating significant induction of 
aromatase activity only in granulosa cells obtained from fOllicles beyond a 
size of 6-8 mm. Cross-sectional (non-dynamic) morphological studies 
(Chikazawa et aI., 1986, McNatty et aI., 1983) assume that selection starts 
at approximately 4 to 8 mm in follicular size. Nevertheless, in-vitro granulosa 
cell studies indicate that there is a distinct moment at which up-regulation 
of granulosa cell function may be observed. Beyond a diameter of 9 mm, 
the mean diameter of the selected follicle will increase by approximately 1 
to 2 mm daily (Yl6stalo et aI., 1979; van Santbrink et aI., 1995a), until 
ovulation at approximately 18-26 mm (Wetzels 1983; Leerentveld et aI., 
1984). Remaining antral follicles from the recruited pool will lack sufficient 
stimulation by FSH (due to decreasing concentrations during the late follicluar 
phase) and become atretic. 
Although mechanisms by which selection of a single dominant follicle 
occurs during the follicular fase of the normal cycle remain to be elucidated, 
the 'FSH-threshold' concept initially put forward by Brown (Brown, 1978) 
has gained wide support. Brown developed this concept as a clinician, based 
on observation of ovarian response (as monitored by urinary estrogen 
excretion) following administration of exogenous gonadotropins. The narrow 
range of requirements for FSH to initiate cyclic ovarian function was 
emphasized. His conclusions may be summarized as follows: there exists 
a threshold requirement of FSH below which follicular growth does not occur. 
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If this threshold is surpassed by increasing serum FSH concentrations (by 
approximately 10 to 30%), follicles start to grow. Recently, new insight has 
been gained concerning regulatory mechanisms during folliculogenesis 
(Schoemaker et aI., 1993; Fauser et aI., 1993b). Minimal serum FSH levels 
initiating dominant follicle growth (serum E, increment) in PCOS patients 
appeared to be the mean of serum FSH levels around the moment of 
presumed selection (Weissenbruch et aI., 1993). Based on previous 
observations (Chikazawa et aI., 1986), the day of presumed selection was 
based on retrograde extrapolation, as the day at which the first follicle that 
reached 12 mm had been approximately 5 mm in size (presumed daily 
follicle growth of 2 mm). Minimal serum FSH levels to induce dominant follicle 
growth ('above threshold-dose') during gonadotropin administration in 
infertile PCOS patients were determined using an intravenous administration 
system (van der Meer et aI., 1994). The 'FSH-threshold' theory was modified 
to a 'Three pillar model' (referring to three different stages of follicle 
development) leading to dominant follicle selection (Scheele, 1994). 
It was postulated that it takes approximately 80 days for a resting 
primordial follicle to develop up to ovulatory size (Gougeon et aI., 1980). 
Under normal conditions, the formation of FSH receptors is initiated in small 
preantral follicles (Menigish et aI., 1991). Only if the 'FSH-threshold' is 
surpassed - which takes place during the luteo-follicular transition of the 
normal menstrual cycle - a restricted number (cohort) of follicles will be 
rescued from atresia, gain gonadotropin dependence and continue to grow 
(recruitment). The longer FSH serum concentrations are above the threshold 
levels (i.e. the wider the 'FSH-window'), the more follicles will continue their 
development (Zeleznik & Hillier, 1984). In normally cycling women, this FSH-
window is restricted to allow ongoing growth of a limited number of recruited 
follicles. Diminished stimulation of non-dominant follicles by relatively low 
FSH levels plays an important role in selection of a single dominant follicle 
(Fritz et aI., 1982; Hodgen, 1982; Goodman & Hodgen, 1983; Zeleznik & 
Hillier, 1984). The leading follicle demonstrates a significant decrease in 
FSH dependency (due to local up-regulation) which underlies ongoing growth 
despite decremental FSH concentration (as described in 1.2.2). Enlargement 
of the dominant follicle is also accompanied by accumulation of LH receptors 
(Yong et aI., 1992). 
Various aspects of recruitment and selection of the dominant follicle have 
been substantiated in-vivo in the monkey (Hodgen, 1982; Zeleznik & Kubik, 
1986) and in sheep (Baird, 1983). A proportion of these observations have 
also been confirmed in humans. These studies have convincingly 
demonstrated that: 1) luteectomy results in a rapid rise in serum FSH which 
in turn induces follicle recruitment and normal follicle development, 
suggesting indeed that follicles are ready to be recruited once the FSH 
threshold is surpassed (Dizerega & Hodgen 1981). 2) Anti-estrogen 
antibodies administered during the early follicular phase (causing incremental 
8 
INTRODUCTION 
serum FSH levels) induce multiple follicular development (Zeleznik et aI., 
1985) which emphasizes the importance of decreasing FSH levels for 
selection of a single dominant follicle. 3) Electrocautery of the largest follicle 
during the mid follicular phase in the monkey, and observed postponement 
of a new LH surge by approximately 14 days, indicates that a non-dominant 
follicle could not regain dominance (Dizerega & Hodgen, 1982).4) In GnRH-
a pretreated macaque-monkeys demonstrating estrogenic response to a 
combined LH and FSH preparation, a subsequent infusion of decreasing 
(12.5%/day) quantities of FSH revealed further maturation of the dominant 
follicle, whereas growth of non-dominant follicles was not supported (Zeleznik 
& Kubik, 1986). In addition, a step·down human menopausal gonadotropin 
(HMG) protocol in the animal model showed better synchronization of 
follicular rupture, and reduced susceptibility to delayed ovulations (Abbasi 
et aI., 1987). This study indicates that if the FSH-window is restricted, this 
subsequently leads to a more homogeneous pool of recruited follicles and 
a reduced period of ovulations. In 3 hypo gonadotropic infertile women, 
continued growth of the dominant follicle was observed during decremental 
supply of intravenously administered FSH (10% reduction daily) (Glasier 
et aI., 1988). It was stated that FSH is above threshold levels (the 'FSH-gate') 
during a limited period (Baird, 1987). Whereas 'FSH threshold' indicates the 
minimal dose to support follicle growth, the number of days during which FSH 
is above the threshold (length of the 'FSH-window') will determine the 
number of growing follicles (for review see Fauser et aI., 1993b; Fauser, 
1994a). Consequently, multiple ovulation can occur if serum FSH 
concentration is above threshold levels for an extended period of time. 
1.3 GONADOTROPIN INDUCTION OF OVULATION 
1.3.1 History 
Initially, gonadotropin preparations were extracted from serum of pregnant 
mares (Pregnant Mare Serum Gonadotropin [PMSGj) (Cole & Hart, 1930). 
Their use in anovulatory women gave rise to non-reproducible and 
unsatisfactory results. Due to the observation that if ovulation occurred in 
PMSG cycles it was only in those accompanied by a spontaneous LH surge, 
a combinntion of PMSG and human chorionic gonadotropin (hCG) was 
advocatGd. This approach appeared to be successful (Hamblen & Davies 
1945, Finkler 1949). However, due to the inability to monitor ovarian response 
to medication, outcome was still unsatisfactory. In addition, repeated PMSG 
injections induced formation of antibodies against these non-primate 
gonadotropins. During the mid-fifties, the clinical use of gonadotropins as 
treatment of anovulatory infertility was questioned (Palmer, 1957). The first 
pregnancy following administration of human pituitary gonadotropins (HPG) 
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was established in a hypogonadotropic woman (Gemzell, 1958). Moreover, 
no anti-hormone activity was measured. A new method of extracting 
gonadotropin from urine of menopausal women (Albrecht, 1956) made 
extensive clinical application possible. Some years later, the first pregnancy 
was reported using 'menotropins' in a woman with hyperprolactinaemiaJ 
hypogonadism syndrome (Lunenfeld et aI., 1960). In Australia until 1981, 
almost 50% of the 1 056 HPG-treated patients conceived during 4008 cycles, 
whereas urinary preparations revealed similar success rates (Kovacs et aI., 
1984). However, HPG administration was stopped in 1984, due to the 
association of HPG with a slow-acting virus causing encephalitis (Jacob-
Kreutzfeld disease) (Frasier & Foley, 1994). 
1.3.2 Indications for treatment 
During the pioneering years of gonadotropin therapy, medication was 
administered to a heterogeneous group of infertile women with oligo-
amenorrhoea (Rabau et aI., 1967; Caspi et aI., 1974; Webb-Wilson & Arronet, 
1977). Initially gonadotropin therapy was expected to be the suitable 
replacement in patients suffering infertility and primary or secondary 
amenorrhea due to hypogonadotropic hypogonadism (World Health 
Organization (WHO) classification group I [Lunenfeld & Insler, 1974]). At 
present pulsatile intravenous administration of GnRH is preferred in this 
patient group. 
The major indication for treatment with gonadotropins nowadays is infertility 
due to menstrual disturbances classified as WHO group II (women with low 
to normal gonadotropin levels and normal estrogen concentrations). 
Clomiphene citrate (Greenblatt et aI., 1961) is considered treatment of first 
choice in this group with normogonadotropic amenorrhoea (MacGregor 
et aI., 1968; Gorlitzky et aI., 1972; Garcia et aI., 1977) including patients 
suffering from polycystic ovary syndrome (PCOS) (Yen et aI., 1970) because 
of reasons of efficacy, clinical results and an acceptable complication rate. 
Prospective randomized studies comparing clomiphene citrate and 
gonadotropins have not been performed (Tal, 1985). Moreover, clomiphene 
citrate might have detrimental effects on oocyte quality (Regan et aI., 1990) 
due to pharmacologically augmented LH levels (Wu, 1977) and subsequently 
increased serum testosterone concentrations. Approximately 20 to 30 per 
cent of clomiphene-citrate-treated patients do not OVUlate (MacGregor et aI., 
1968, Garcia et aI., 1977), mostly due to PC OS (Adams et aI., 1986). 
Gonadotropin therapy in PC OS patients leads to a higher incidence of 
complications than in patients suffering from other causes of anovulation 
(Gemzell & Roos, 1966; Wang & Gemzell, 1980). However, the clinical 
profile of clomiphene-resistant anovulatory infertility is poorly defined and 
many of the above mentioned conclusions are not based on well-designed 
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prospective studies. Altho' ',,;1 defining this syndrome is a subject of discussion 
(Fauser et aI., 1993a, '-'llIing·Smith & Franks, 1993), it may be hypothesized 
that in PCOS patients a local intra·ovarian dysregulation causes disturbance 
in selection of the dominant follicle (pache et aI., 1992b; Pache et aI., 1993; 
Fauser, 1994a). Next to indication for treatment, clinical outcome of therapy 
is determined by many other factors (Fauser, 1993c) which will be discussed 
later. In PCOS ovarian follicles mature normally to the stage of development 
where significant aromatase activity is induced under normal conditions 
(presumably 6 to 8 mm) (Erickson et aI., 1979; Hillier et aI., 1981; Pache et 
aI., 1992b, Fauser, 1994b). Increment of serum FSH by administering 
exogenous gonadotropins can induce sufficient aromatase activity, and 
concomitant follicular growth. Based on extensive previous study (pache et 
aI., 1993), PCOS was defined in the studies presented in this thesis as a 
pathophysiological feature present in women with infertility and oligol 
amenorrhea, scoring positive in at least three out of four of the following 
criteria: 1} obesity, 2} hirsutism, 3} elevated androgen levels (free androgen 
index [FAIJ; testosterone [TJ X 1001 sex·hormons·binding globulin) andlor 
dehydroepiandrosterone sulphate (DHEAS), and 4} polycystic appearance 
of ovaries by sonography (Pache et aI., 1991 b). In non·galactorrheic 
hyperprolactinemic women not responding to bromocryptine (Friesen & 
Tolis, 1977), application of gonadotropins alone may also be a good 
alternative (Farine et aI., 1982). In patients with anovulation and 
hypergonadotropic hypogonadism (WHO group III criteria) success rates of 
gonadotropin induction of ovulation are low (Check et aI., 1990; Johnson & 
Peterson, 1979). 
Well· established indications for the use of gonadotropins other than for 
treatment of anovulation are limited. However, gonadotropins are 
administered for improvement of cervical mucus quality (Check, 1980), luteal 
phase defect (Zimmerman et aI., 1982), induction of multiple follicles prior 
to intra·uterine insemination, and as an empirical therapy for infertility with 
unknown cause (Fauser, 1993c). 
1.3.3 Dose regimens 
Fixed or variable dose regimens of gonadotropin administration have been 
used to induce ovulation in infertile oligo· or amenorrheic women. The variable 
dosage has been used more commonly, permitting variation in the daily 
gonadotropin dosage and the duration of administration. During fixed 
administration, gonadotropins were injected on predetermined days based 
on expected steroidogeniC response (Butler, 1969). Although success of this 
economic dose regimen was comparable to variable schemes (Thompson & 
Hansen, 1970), an enhanced complication rate induced the decline in clinical 
use. Furthermore, improvement of monitoring techniques (Schoot et aI., 1992d) 
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made it possible to adjust the dose according to the observed ovarian 
response. Many dose schedules have been advocated to improve efficacy 
and reduce complications, as can be seen in the table below. 
The largest and most significant study (Thompson & Hansen, 1970) 
revealed that: 1) the success rate of different regimens was comparable, 2) 
hCG (500 to 10,000 IU) had to be administered 1 to 2 days subsequent to 
arrest of HMG stimulation, 3) the variable step-up regimen was used most 
often, probably due to reasons of efficacy. Although there is some difference 
in sensitivity to gonadotropins between cycles (Rosemberg & Nwe, 196B; 
Brown et aI., 1969), this is less variable than differences between patients 
(Marshall et aI., 1969). 
At present, 'step· up' regimens are based on admistration of increasing 
amounts of gonadotropins until ovarian response is considered to be 
'sufficient' (one large follicle or a significant rise in serum estrogen 
Major dose regimens of HMG and hCG through im injections 
FIXED REGIMENS 
- Single large dose followed by hCG 
on day 11 
- Daily HMG, starting hCG 2 or 3 days 
after stopping HMG 
- Daily HMG, last 2 or 3 days hCG 
(overlapping) 
- Daily HMG (alone) 
Marshall et aI., 1969 
Seddon, 1970 
Marshall et aI., 1969 
Thompson & Hansen, 1970 
Thompson & Hansen, 1970 
- HMG on alternate days (e.g. day I, 4, B) Radwanska et aI., 19BO 
VARIABLE REGIMENS 
- Descending doses of gonadotropins 
(hCG: (non)-overlapping) 
- Ascending doses of gonadotropins 
(hCG: (non)-overlapping) 
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concentration [Polson et aI., 1987)). A slower and less pronounced increase 
of gonadotropin doses is referred to as the 'low-dose, step-up' regimen 
(weekly changes in dose, increments no more than 'I, ampule [~ 37.5 IU]/ 
day). The method has been shown to improve treatment outcome (Seibel et 
aI., 1985; Polson et aI., 1987, Buvat et aI., 1989; Shoham et aI., 1991; 
Hamilton-Fairly et aI., 1991; Meldrum, 1991). Different results (incidence of 
ovarian hyperstimulation syndrome [OHSS] as high as 21 %) were reported 
in other studies using the low-dose protocol (Hull, 1991; Herman et aI., 
1993). It was already stressed by Brown (Brown, 1978) in his paper 
describing the 'FSH-threshold' concept that 'maturing follicles are producing 
estrogens within 2-3 days after the threshold has been reached which, 
under normal conditions, prevents overshoot of FSH through negative feed-
back mechanisms'. In contrast to the follicular phase of the normal menstrual 
cycle, FSH serum levels gradually increase during 'step-up' regimens in 
gonadotropin induction of ovulation. In the monkey model, it has been 
convincingly shown that interference with decreasing FSH serum levels 
elicits multiple follicle development (Zeleznik et aI., 1985). Preliminary 
clinical experience with decreasing doses of gonadotropins - step-down 
regimens'- for induction of ovulation (Mizunima et aI., 1991; Fauser et aI., 
1993b; Fauser et aI., 1994c; van Santbrink et aI., 1995b) are promising. 
1.3.4 HMG versus pFSH 
Two urinary gonadotropin preparations are commercially available; human 
menopausal gonadotropins (HMG [HumegonR and PergonaIR)), and purified 
FSH (pFSH [MetrodinR)). HMG preparations contain an equivalent amount 
of 75 IU FSH and 75 IU LH in-vivo bioactivity. A successive supplementary 
purification step substantially decreased LH-like activity leading to a novel 
commercial pFSH preparation. Besides obtaining a more purified product, 
the rationale of developing a pFSH preparation was two-fold. Firstly, ovulation 
induction using gonadotropins in patients with elevated endogenous LH 
serum levels could - on theoretical grounds - preferably be performed 
without a surplus of exogenously administered LH. Secondly, FSH alone 
was believed to increase folliculogenesis (Schoemaker et aI., 1978). 
Furthermore, it was speculated that LH in gonadotropin preparations could 
be responsible for the high incidence of treatment complications in patients 
with elevated serum LH levels (Raj et aI., 1977; McFaul et aI., 1990). 
However, other studies (Jacobson & Marshall, 1969; Louwerens, 1969) have 
indicated that the effectiveness of gonadotropin preparations and the 
occurrence of OHSS were not dependent on the LH/FSH ratio (Lanzone 
et aI., 1987). pFSH administration did result in decreased LH levels as 
compared to HMG in peos (Anderson et aI., 1989). Until now clinical studies 
have failed to demonstrate clear advantages of pFSH over HMG (Seibel et aI., 
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1985; Venturoli et aI., 1986; McFaul et aI., 1990; Tanbo et aI., 1990; Sagle 
et aI., 1991). However, it cannot be excluded at this stage that studies with 
larger patient numbers would disclose significant differences in clinical 
outcome due to different LH content in gonadotropin preparations. 
1.3.5 Adjuvant medication 
Initially, uncontrolled studies in pcas patients (Fleming et aI., 1985; 
Charbonnel et aI., 1987; Hedon et aI., 1991), suggested that the success 
rate of gonadotropin treatment could be improved and the complication 
rate reduced, if GnRH agonist medication was added. Improvement of 
treatment results was associated with down-regulation of elevated 
endogenous LH levels, as well as prevention of a premature LH surge 
(Dodson et aI., 1985). It was demonstrated that continuous suppression by 
a GnRH agonist during consecutive gonadotropin-induced cycles resulted 
in lower estrogen production, although folliculogenesis was unchanged 
(Remorgida et aI., 1989). Elevated LH concentrations - often seen in pcas 
- may adversely affect follicular development, and were suggested to have 
detrimental effects on oocyte quality (Stanger & Yovich, 1985; Regan et aI., 
1990). Rather few randomized, controlled clinical trials, each of them using 
limited numbers of patients, have been published (Hompes et aI., 1986; 
Dodson et aI., 1987; Fleming & Coutts, 1988; Dodson et aI., 1989; Bachus 
et aI., 1990; Homburg et aI., 1990). A beneficial effect of adjuvant treatment 
with GnRH agonist in gonadotropin ovulation induction on the pregnancy 
rate could be demonstrated only by some authors (Fleming & Coutts, 1988). 
In the remaining trials (Hompes et aI., 1986; Dodson et aI., 1987; Dodson 
et aI., 1989; Bachus et aI., 1990; Homburg et aI., 1990), clear advantages of 
additional GnRH agonist medication could not be established. A meta-
analysis combining the results of these five trials demonstrated a Significant 
difference in favor of GnRH-agonist co-administration with respect to the 
pregnancy rate only (Schoot et aI., 1992c). A large meta-analysis assessing 
the efficacy of adjuvant GnRH agonist for in-vitro fertilization (IVF) and 
gamete intrafallopian transfer showed favourable results of this adjuvant 
therapy (Hughes et aI., 1992). Effects of GnRH agonists co-treatment on 
the luteal phase are unclear (Bachus et aI., 1990). Differences in length and 
amplitude of the progesterone rise during the luteal phase as compared to 
regular cycles were reported following induction of ovulation using 
gonadotropins and GnRH agonist in PC as patients (Donderwinkel et aI., 
1993). Luteal support (hCG or progestins) is advised to prevent GnRH 
agonist-induced luteolytic effects (Bentick et aI., 1988). However, convincing 
data indicating that luteal support improves pregnancy rate following induction 
of ovulation are lacking. 
Growth hormone (GH) -dependent generation of intra-ovarian IGF-I and 
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the subsequent local potentiation of gonadotropin-dependent ovarian function 
was observed in rats (Adashi et aI., 1985; Davoren & Hsueh, 1986; Jia et aI., 
1986). GH may affect human ovarian function directly, orthrough augmented 
hepatic production of IGF-I, or by increased intra-ovarian production of 
IGF-I. Exact mechanisms of action, however, remain unclear. mRNA for 
IGF-I in human granulosa celis appeared to be absent (EI Roey et aI., 1993). 
Comparing E2 changes in normal cycling women and in patients undergoing 
controlled ovarian hyperstimulation, differences appeared to be independent 
of respective GH levels. (Stone & Marrs, 1991). Complementary roles of GH 
and FSH in patients with panhypopituitarism were evident (Blumenfeld & 
Lunenfeld, 1989). In addition, in a patient with IGF-I deficiency secondary to 
GH receptor abnormality, normal foliicle development was demonstrated 
and a rise of estrogens occurred after gonadotropin administration (Dor 
et aI., 1992). Initially, adjuvant GH treatment during gonadotropin-induced 
cycles in women with low response to gonadotropin therapy suggested a role 
for the use of GH in induction of ovulation (Homburg et aI., 1988; Ibrahim et 
aI., 1991). More recently, larger studies have failed to show additional effects 
of GH to enhance ovarian response during gonadotropin induction of 
ovulation (Jacobs et aI., 1991). 
Less often, co-treatment may include dexamethasone in the case of ad-
renal hyperandrogenemia or bromocriptine in the case of hyperprolactinemia. 
1.3.6 Monitoring treatment response 
Treatment outcome has improved substantially over the years, mainly 
because of improved treatment monitoring and the introduction of new 
dosage regimens. The purpose of monitoring induction of ovulation is two-
fold: 1) to prevent complications and risks, and 2) to improve efficacy of 
therapy. During the first years of gonadotropin treatment surveillance of 
ovarian response to gonadotropins administration was limited. The incidence 
of complications was described almost 10 years after its introduction 
(Neuwirth et aI., 1965). Initially, Gemzell and co-workers used bimanual 
palpation of the ovaries, cervical mucus changes and vaginal cytology during 
theirfirst successful series (Gemzell & Roos, 1966). Cervical mucus changes 
served as a fast but questionable in-vivo bioassay for estrogenic response 
(Igarashi & Matsumoto, 1957; Insler, 1972), whereas pregnanediol excretion 
in urine was an indicator of successful ovulation (or luteinization). Assay 
procedures for the measurement of urinary estrogens (estriol, estrone and 
estradiol) (Brown, 1956) were time-consuming, which precluded their use in 
daily clinical decision making. In a decade with emerging complications, 
clinical investigators (Hancock et aI., 1970; Crooke et aI., 1971) observed 
a correlation between the increment of excreted steroids and complications 
of gonadotropin therapy. Due to lack of sensitivity, the clinical use of steroid 
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measuremenls to predict (and prevent) complications was not generally 
accepted (Taymor et aI., 1972). The availability of a RIA forthe measurement 
of E, serum concentrations (Robertson & Steele, 1972) replaced the 
cumbersome assay of urinary estrogen excretion (Brown et aI., 1968). 
Comparing urinary estrogens and two serum E, RIAs no differences were 
found (Tredway et aI., 1974). Clinical significance - more than timing of 
hCG administration - of the new RIA for E, in serum was questioned (Wu, 
1978). In a retrospective analysis, plasma E, levels at the day of hCG 
administration did not show a significant difference comparing patients with 
multiple and single ovulation (Wu, 1976). Prompt detection of rapid E, 
increase and rate of increment appeared to be clinically useful to increase 
pregnancy rates and diminish complications (Schwartz & Jewelewicz, 1981; 
Wilson etal., 1982; Pittaway & Wentz, 1983; Haning etal., 1983). Furthermore, 
application of maximum serum E, levels during gonadotropin induction of 
ovulation was generally accepted in an attempt to reduce complication rates 
(Marrs et aI., 1980; Schwartz et al., 1981). 
A linear correlation was found between between sonographical 
measurement of follicle size and serum E, concentrations during the late 
follicular phase of spontaneous (monofollicular) cycles (Freundl et aI., 1981). 
The volume of the dominant ovary also showed a linear correlation with 
serum E,levels (Mango et aI., 1988). However, in contrast to this correlation 
during the normal cycle (Ylostalo et aI., 1979), this relationship was absent 
if multiple follicles developed during gonadotropin therapy (Cabau et aI., 
1976; Schmidt et aI., 1981; Haning et aI., 1982). 
Following visualization of Graafian follicles in the ovary using gray-scale 
ultrasound (Kratochwil et aI., 1973), real-time transabdominal sonography 
was developed (Hackeloer, 1974). Accuracy of measurement of diameter 
and volume of follicles was validated by laparoscopic puncture (Kerin et aI., 
1981; Leerentveld et aI., 1984). Intra- and interobserver variations of 
sonographic measurement appeared to be within an acceptable range 
(Leerentveld, 1984; Eissa et aI., 1985; Forman et aI., 1991). The possible 
clinical role of real-time ultrasound during gonadotropin induction of ovulation 
was investigated (Hackeloer et aI., 1977). This caused a further reduction of 
therapy-related complications (Bordt et aI., 1986). The possible relationship 
between the number of small and medium-sized ovarian follicles at the 
moment of hCG administration and the incidence of OHSS have been 
investigated (Tal et aI., 1985; Blankstein et aI., 1987). In order to reduce 
risks of therapy, the size and number of secondary follicles have to be small 
at the moment of hCG administration. 
It has been clearly established that sonographic monitoring of the ovarian 
changes using a transvaginal probe is superior to transabdominal scanning 
(HUll, 1989) due to: 1) a smaller distance from the probe to pelvic organs, 2) 
the use of high resolution of probes (5-7 mHz) and 3) an improvement of 
patient compliance and convenience (no full bladder warranted). Four main 
16 
INTRODUCTION 
parameters can be assessed in the ovary: a) volume, b) follicle number, c) 
follicle size and d) amount and density of stroma. Transvaginal sonographic 
assessment of endometrial growth in stimulated and unstimulated cycles 
demonstrated a correlation with both the diameter of the leading follicle as 
well as with serum E, level (Randall et aI., 1989). Whereas transabdominal 
scanning provided accurate information on large follicles only, the higher 
resolution of transvaginal sonography enables the systematic investigation 
of changes in the number of small and medium-sized follicles (>2 mm) during 
the early follicular phase (this thesis, section 3.2). Sonography of the ovaries 
during induction of ovulation can provide data concerning ovarian follicular 
growth, next to timing of hCG injection based on size of the dominant follicle 
(Sallam et aI., 1982; Hoffman et aI., 1985; Venturoli et aI., 1986; Lanzone et 
aI., 1987; Mango et aI., 1988; McFaul et aI., 1990). Comparison of these 
studies investigating follicular response during gonadotropin-induced cycles 
is hampered by methodologic differences (patient selection, dose regimens 
used). 
1.3.7 Treatment outcome 
Due to differences in patient selection (age, weight, anovulatory disorder, 
parity, previous medication, definition of clomiphene reSistance), applied 
dose regimens, monitoring of ovarian response or adjuvant treatment, it is 
difficult to compare results of different reports. A potential selection of the 
infertile population with a poor history in infertility treatment in research 
clinics (academic hospitals) may also bias treatment results. Moreover, the 
lack of cumulative pregnancy rates calculated using lifetime analysis (Lamb 
& Cruz, 1972), can also generate a bias in the estimation of treatment 
efficacy. In the first North American review of different gonadotropin dose 
regimens (634 patients during 1538 treatment cycles), ovulation was 
demonstrated in 68% of all cycles, whereas pregnancy rate was 12% 
(Thompson & Hansen, 1970). Reported pregnancy rates ranged between 
23% (Buttler, 1969) and 82% (Healy et aI., 1980). In addition, an average 
cumulative pregnancy rate of 44% following approximately 3 cycles was 
reported (Lunenfeld et aI., 1985). Cumulative conception rate differed 
between 90% in hypogonadotropicwomen (Lunenfeld etal., 1985) compared 
to below 40% in PCOS patients (Dor et aI., 1980). Treatment outcome seems 
to show a tendency to improve during the past 20 years (Diczfalusy & Harlin, 
1988). 
Abortion occurs in approximately 20-40% of pregnancies following 
gonadotropin induction of ovulation. Recently a hypothesis was proposed 
concerning detrimental effects of tonic high LH levels, causing premature 
onset of the last meiotic division of the oocyte which is considered to have 
a negative impact on fertilization (Homburg et aI., 1990). This could serve as 
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an explanation for the relatively high incidence of spontaneous abortion in 
PCOS patients (Regan et aI., 1990). Furthermore, obesity and elevated LH 
levels were also considered as factors Significantly decreasing success 
rates of gonadotropin treatment in PCOS patients (Hamilton-Fairley et aI., 
1991). With regard to hypergonadotropic patients with elevated FSH serum 
concentrations, decreased estrogen production can be useful in predicting 
low ovarian response (Toner et aI., 1991). 
1.3.8 Complications 
Two major complications of gonadotropin therapy include OHSS and multiple 
pregnancies. The origin of both complications can be found in sustained 
stimulation of multiple follicles. The most common complication of 
gonadotropin treatment is multiple gestation. Initial studies reported multiple 
pregnancies in up to 30 - 50% of stimulated cycles (Gemzell & Ross, 1966), 
and up to nine viable fetuses (Carey, 1976). At present, the incidence of 
multiple gestation has decreased to 10-35% (Schwartz et aI., 1981). 
Obstetrical problems and perinatal outcome of multiple pregnancies and 
their social consequences warrant careful monitoring of treatment cycles 
(Petrikovsky et aI., 1989). Selective reduction of the number of fetuses 
seems to reduce the incidence of immature and premature birth, and 
decreases maternal complications (Boulot et aI., 1993). 
OHSS has been classified based on the severity of the signs, symptoms 
and laboratory findings in 6 categories (Rabau et aI., 1967). Sonographic 
measurement of the ovaries (mean diameter) has been added to this 
traditional classification (Golan et aI., 1989). Moderate ovarian hyper-
stimulation involves enlargement of ovaries «5 cm) and minor laboratory 
disturbances, whereas a moderate grade OHSS is characterized by abdominal 
distension, nausea, vomiting and diarrhea, with ovaries usually between 
5-12 cm. Severe OHSS is a life-threatening disease, demonstrating greatly 
enlarged ovaries (> 12 cm in diameter) accompanied by pleura effusion, 
ascites, oliguria, electrolyte imbalance, hemoconcentration and thrombo-
embolic phenomena (Moses et aI., 1965; Merkus et aI., 1990). An acute fluid 
shift is caused by an increase of capillary permeability, allowing fluid to 
escape in the third space. Acute fluid accumulation in the peritoneal and 
pleural cavities leads to hypovolemia, hemoconcentration and increased 
osmolarity. Reduced renal perfusion results in oliguria, azotemia, 
hyperkalemia and acidosis. Increased hemo-concentration may lead to 
thrombosis and thromboembolism. Treatment of severe OHSS should 
include correction of the fluid shifts, whereas abdominal paracentesis can 
relieve respiratory distress. In addition, prostaglandin synthetase inhibitors 
have been successfully used to modify changes due to OHSS. The use of 
antihistamines is not generally accepted. 
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The incidence of OHSS depends on the applied dose regimen and 
monitoring technique. Furthermore, incidence is increased in case of 
pregnancy, suggesting the involvement of hCG (Rabau et ai., 1967; Golan 
et ai., 1989). The overall incidence of mild OHSS varies between 8 and 23% 
of treatment cycles. Moderate OHSS was observed up to 7% whereas 
severe OHSS was reported in less than 2% of gonadotropin-induction cycles 
(Schenker & Weinstein, 1978). The ability of ultrasound to visualize the 
ovaries allows more precise assessment of ovarian enlargement and free 
fluid (ascites) leading to early detection of OHSS (McArdle et ai., 1983). Mild 
OHSS is probably more common than previously suggested and should be 
accepted as a frequent consequence of gonadotropin-stimulated ovarian 
activity. The risk of developing OHSS can be calculated in conception and 
non-conception cycles in hypogonadotropic and PCOS patients (Haning et 
ai., 1984). Patients at risk should be stimulated using less gonadotropins. 
The 'young, asthenic, pregnant PCOS patient with previous complaints due 
to hyperstimulation by gonadotropins, demonstrating the typical necklace 
ovaries at ultrasound and obtaining hCG as luteal support' emerges to be 
risking development of OHSS (Navot et ai., 1988). The development of large 
numbers of small or medium-sized follicles at the moment of hCG 
administration may underlie complications of treatment (Tal et aI., 1985; 
Blankstein et ai., 1987). As previously described, pFSH or co-treatment with 
GnRH agonists did not alter the incidence of OHSS. 
1.4 OUTLINE OF THE THESIS 
The first objective of this study was to provide a review on previous and 
current knowledge regarding FSH regulation of ovarian function (Chapter 1). 
The second objective was to obtain data concerning ovarian 
folliculogenesis and steroidogenesis in hypo gonadotropic female volunteers 
during human recombinant FSH administration (Chapter 2). 
The third objective was to investigate in PCOS patients the role of 
decreasing doses of exogenous gonadotropins (following presumed selection 
of the dominant follicle) on serum hormone concentrations and follicle 
growth (Chapter 3). 
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2 
Ovarian response following human 
recombinant FSH administration in 
hypogonadotropic female volunteers 
2.1 BACKGROUND HUMAN RECOMBINANT FSH 
Commercially available preparations of urinary gonadotropins have been 
successfully used since the 1960's in the treatment of infertility. However, 
only 1-5% of the total protein content of HMG preparations actually exhibits 
FSH activity. This FSH shows a high degree of structural heterogeneity due 
to the presence of different glycoforms as shown by isohormone profiling 
(Storring et aI., 1992). In urinary preparations varying amounts of LH and 
HCG are present (Harlin et aI., 1986). Although the protein contaminants, as 
well as LH and HCG, have never been shown to be harmful, only FSH is 
needed for clinical use. 
Other disadvantages of urinary preparations are the theoretical risk of 
contamination and the limited supply of urine of postmenopausal women to 
purify the product. 
To achieve production of a human FSH dimer, genomic clones containing 
the complete FSH a. and ~ subunit coding sequences were transfected into 
Chinese hamster ovary (CHO) cells (Boime et aI., 1990). Subsequently 
stable cell lines synthesizing the FSH dimer were selected (Keene et aI., 
1989). CHO cells appeared able to assemble the subunits and to glycosylate 
the molecule. Due to the capacity of CHO cell lines to grow in a serum-free 
medium, high purity of the glycoprotein product was ensured. Selected cell 
lines demonstrated a high number of plasmid copies which remained well-
integrated during culturing of the cells for a period of three months. In 
addition, the isohormone profile remained stable during this interval. The 
biological activity of recombinant human FSH was ascertained using rat 
granulosa cell cultures and intact immature rats (Galway et aI., 1990; 
Mannaerts et aI., 1991). Human recFSH appears to be very similar to urinary 
and pituitary FSH although recFSH shows minor differences in the structure 
of the carbohydrate side chains and contains more basic isohormones than 
the hormone from both natural sources (Kloosterboer, 1994). This does not 
imply that recFSH differs from FSH produced by women of reproductive age 
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because the higher amount of acidic isohormones in urinary FSH may reflect 
selective metabolism by the kidney, whereas pituitary FSH has primarily 
been derived from old-age pituitaries. The more basic isohormone profile of 
recFSH and its stronger receptor binding complex! signal transduction may 
explain its higher potency compared to FSH in normal cycling women. 
Furthermore, the shorter half-life of basic recFSH explains the significantly 
lower serum FSH levels (Out et aI., 1995). 
The absence of intrinsic LH activity of recFSH provides an opportunity to 
study separate roles of FSH and LH during folliculogenesis and subsequent 
steroid production. Initial studies were performed in hypogonadotropic patients 
incapable of spontaneous endogenous gonadotropin synthesis and secretion, 
because of the reduced risks in the case of FSH-antibody formation. 
2.2 HUMAN RECOMBINANT FSH INDUCES GROWTH OF 
PREOVULATORY FOLLICLES WITHOUT CONCOMITANT 
INCREASE IN ANDROGEN AND ESTROGEN BIOSYNTHESIS 
IN A WOMAN WITH ISOLATED GONADOTROPIN DEFICIENCY 
2.2.1 Introduction 
Chinese hamster ovary (CHO) cells transfected with FSH subunit genes are 
capable of secreting the intact FSH dimer (Keene et aI., 1989). Moreover, the 
biological activity of human recombinant FSH (rhFSH) was ascertained 
using rat granulosa cell cultures and intact immature rats (Galway et aI., 
1990; Mannaerts et aI., 1991). Commercially available preparations of 
purified urinary gonadotropins may have varying molecular composition 
(Harlin et aI., 1986), and all available preparations contain varying degrees 
of LH. Although rhFSH also consists of a mixture of FSH isohormones, 
bioactivity appears identical to pituitary FSH, without LH bioactivity (Mannaerts 
et aI., 1991 a). The hypothesis of gonadotropin synergism, introduced almost 
half a century ago (Fevold, 1941) emphasized the importance of an interplay 
between LH and FSH for normal estrogen production and follicular 
development. This concept was supported by observations in infantile mice 
after injection of pure urinary FSH (Eshkol & Lunenfeld, 1967). The observed 
increase in ovarian weight in combination with absent uterine growth, 
suggested that FSH alone is incapable of initiating estrogen production but 
still leads to follicular development. Moreover, the administration of purified 
FSH in hypogonadotropic women resulted in normal follicular development 
and low serum estrogen levels (Couzinet et aI., 1988). An ongoing study 
using rhFSH in hypogonadotropic subjects, to assess safety and 
pharmacokinetical characteristics of the drug, provided an unique opportunity 
to explore whether LH exposure is essential for the induction of adequate 
estrogen production and subsequent follicle growth. 
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2.2.2 Patient and methods 
A healthy female (age; 39 years, weight; 53 kg) suffering from primary 
amenorrhea due to isolated congenital gonadotropin deficiency, volunteered 
to enter an open phase I clinical trial with rhFSH to assess its tolerance, 
safety, pharmacokinetic and pharmacodynamic properties. Serum levels 
were 0.37 lUlL for LH and 1.2 lUlL for FSH. The study was approved by the 
Ethics Review Committee of the Erasmus UniversitylDijkzigt Hospital and 
informed consent was obtained. Wish for procreation was absent. Three 
successful gonadotropin-induced pregnancies (one twin pregnancy) had 
been established previously. Physical examination and routine urinelserum 
examinations were normal. Autoimmunity was excluded by anti-nuclear 
(ANA) and specific anti-FSH (anti-Org 32489) antibody assays. She refrained 
from estrogen replacement therapy 10 days prior to this study. 
rhFSH (Org 32489; Organon International BV, Oss, The Netherlands) 
was administered in a daily dose of 75 IU (standardized according to the 
Steelman-Pohley in-vivo FSH bioassay [Mannaerts et aI., 1991]) im for 7 
days, followed by 150 IU/day during week 2. Medication was discontinued 
according to protocol criteria, because one ovarian follicle was found to 
exceed a diameter of 14 mm on day 13. On day 19, multiple follicles (n=6; 
12-18 mm) were observed. After informed consent was obtained 3 follicles 
(13, 15, and 18 mm diameter) were punctured (no oocytes were obtained, 
fluid was stored separately) and 10,000 IU human chorionic gonadotropin 
(hCG) (PregnyIR; Organon International BV) was administered im. 
Blood withdrawal and pelvic sonography on alternate days was 
continued for 3 weeks following the last rhFSH injection. Transvaginal 
sonography, using a 5 mHz transducer (Model 1550; Philips Medical 
Systems, Eindhoven, The Netherlands), was performed as published 
previously (pache et aI., 1990). Endometrial thickness was measured 
between the two parallel (opposite) hyperechogenic myometrium-
endometrium interfaces. The largest distance, measured in the sagittal 
plane, representing two layers of endometrium, was recorded. For 
reference values, fluid was obtained from 118 individual non-dominant 
follicles (3-9 mm diameter) between cycle day 2-12 in 16 regularly 
cycling women (control) (pache et aI., 1992a), and from 7 dominant 
follicles (13-24 mm diameter), between cycle day 10 and 12, from 7 
regularly cycling women. Serum and follicular fluid was centrifuged and 
stored at -20°C. Immunoreactive LH and FSH serum levels were assessed 
in one assay using a immunoradiometric assay (IRMA) kit (Delfia, 
Pharmacia, Woerden, The Netherlands). Data are expressed in terms of 
MRC 78/549 for FSH and MRC 80/552 for LH. Intra-assay coefficients of 
variation were less than 4.8% for FSH and less than 4.7% for LH. E,levels 
in serum and follicular fluid were estimated by RIA (Diagnostics Products 
Corp. Los Angeles, CAl (pache et aI., 1992a; Fauser et aI., 1991 a). 
23 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Progesterone (P) was measured in serum by RIA using an antibody 
against 11-<x-hydroxyprogesterone-hemisuccinate bovine serum albumin 
complex. Serum and follicular androstenedione (AD) levels were measured 
using the antiserum described by Frelich and coworkers (Frelich et aI., 
1976), after extraction with diethyl ether. Intra-assay coefficients of 
variation were less than 5% for E" and less than 7% for AD. The anti-FSH 
antibody assay used labelled Org 32489 as a ligand and mouse antibodies 
raised against Org 32489 as a reference (detection limit: 0.5 pmoI/L). 
ANA was measured using an immunofluorescence technique in a Hep-2 
cell line (Bio-Lab, Amersfoort, The Netherlands). 
2.2.3 Results 
Baseline hormonal parameters showed confirmation of the hypogonadotropic 
hypo gonadal state (FSH; 1.2 lUlL, LH; 0.37 lUlL, E,; 63 pmoI/L). Thyroid-
stimulating hormone, prolactin and cortisol levels were within normal limits 
(data not shown). Sonography before rhFSH administration showed follicles 
at a size below 4 mm in each ovary (Fig. 1). Follicular development started 
after the daily dosage was increased from 1 to 2 ampules rhFSH on day 7. 
Following the last rhFSH injection (day 12), multiple ovarian follicles 
increased in size (maximum 22 mm). After puncture, two follicles of more 
than 14 mm remained. Following hCG injection, follicles decreased gradually 
in size. Endometrial thickness increased by 2 mm during the treatment 
period (from 4 to 6 mm) (Fig. 1). 
A rise in serum FSH levels was obseNed during rhFSH administration 
with a maximum concentration of 8.5 lUlL (Fig. 1), followed by a decrease 
up to 1.3 lUlL on the day of hCG administration. Serum LH concentrations 
varied between 0.09 and 0.38 lUlL before hCG administration, and no 
systemic changes occurred. Serum E, levels showed a gradual increase to 
a maximum of 236 pmollL on day 15 (day of maximum follicular size) (Fig. 
2a). Serum P showed no elevation following hCG administration (data not 
shown). Fluid obtained from the largest follicle (18 mm) revealed an E, 
concentration of 9,400 pmollL, and AD was 675 nmollL. The remaining two 
follicles (15 and 13 mm) showed E, and AD concentrations of 3,800 pmoll 
L, 160 nmol/L and 3,100 pmol/L, 115 nmol/L respectively (Fig. 2b). 
Concentrations of both FSH and LH were below detection limits in follicular 
fluid (data not shown). In normal small (3-9 mm) follicles (n=118) the median 
E,level was 91 (range 1.5-7,000) x 1 ,000 pmol/L, and AD levels 3,160 (330-
9,580) nmol/L. In normal large (13-24 mm) follicles (n= 7) E,levels were 14,563 
(10,657-20,446) x 1,000 pmol/L, and AD levels 3000 (620-5,480) nmollL. 
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Figure 1 rhFSH and hCG dose regimens administered to a patient with 
isolated gonadotropin deficiency, serum FSH (lUlL) and LH (lUlL) levels in 
the upper two panels. Diameters (mm) of separate follicles as determined 
by vaginal sonography for both ovaries, and sonographic estimation of 
endometrial thickness (mm) in the lower two panels, 
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Figure 2a Serum estradiol (pmol/L) 
concentrations of a patient with 
isolated gonadotropin deficiency 
following rhFSHadministration prior to 
the day where ovarian follicles reach 
their maximum size (day 17). As a 
reference, daily serum estradiol 
(pmol/L) levels (mean ± 2SD) are 
shown in seven normally cycling 
women up to the day of LH peak. 
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follicles (n=118), and large (13-24 
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2.2.4 Discussion 
This study represents the first data on rhFSH administration in the human. 
No adverse effects and no anti·rhFSH antibody formation was observed. 
Development of follicles occurred following administration of increasing 
amounts of rhFSH, similar to that observed following exogenous 
gonadotropins used for induction of ovulation. Following the last injection of 
rhFSH follicular development continued towards pre·ovulatory sizes whereas 
FSH concentrations decreased, in keeping with previous observations 
(Schoot et aI., 1992a) suggesting that growth of dominant follicles may be 
less dependent on circulating FSH concentrations. 
Based on previous studies in the rat it is generally believed that estrogens 
are essential for normal follicular development. Recent clinical observations 
suggest that this concept may need to be revised for the human (Chappel 
et aI., 1991). For instance, ovarian follicular development could be induced 
in a woman with inadequate estrogen and androgen biosynthesis due to 
17CJ.- hydroxylase deficiency (Rabinovici et aI., 1991). In addition, it appears 
that normal follicular growth can be induced using purified urinary FSH 
preparations (Couzinet et aI., 1988). In the present study, in sharp contrast 
to normal follicular development, E, levels remained low. Observed levels 
around day 15 are similar to early follicular phase E, concentrations in normal 
cycles (Schoot et aI., 1992a)(Fig. 2a). The minor increase in endometrial 
thickness is also in favor of minimal estrogen bioactivity. E, and AD 
concentrations in 3 aspirated large follicles appeared to be extremely low, as 
compared to concentrations in small and large follicles in controls (Fig. 2b). 
This indicates that ovarian follicles are incapable of producing sufficient 
amounts of AD in the presence of minute amounts of LH (below 0.38 lUlL). 
The subsequent inability of normal estrogen production within follicles is in 
keeping with the two-cell two-gonadotropin hypothesis, indicating that FSH-
induced granulosa cell aromatase activity can only lead to augmented E, 
production if a sufficient amount of the aromatase substrate AD is available. 
This underlines the concept of a LH threshold for sufficient estrogen 
production. It was surprising, indeed, that the mitogenic activity induced by 
FSH (i.e. proliferation of granulosa cells (Rao et aI., 1978) did take place in 
a local environment with extremely low estrogen concentrations. This 
observation points to a differential regulation by FSH of steroidogenic and 
mitogenic granulosa cell activity. Direct effects of local estrogens on oocyte 
development are unknown. 
Various reasons could explain the absence of a rise in serum P level 
following the injection of hCG. It may be hypothesized, based on in-vitro 
observations (Kessel et aI., 1985), that physiological FSH levels in 
combination with low local E, concentrations, as observed in the present 
subject, were insufficient for the induction of LH receptors, and that these 
follicles were therefore not responsive to hCG. The possibility that declining 
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FSH serum levels caused a decrease in number of LH receptors (Jia & 
Hsueh, 1984) on the day of hCG administration cannot be ruled out. In 
addition, remaining follicles may have been to small for adequate hCG 
response. 
In summary, data presented in this study indicate the significance of 
sufficient amounts of LH - next to FSH - for adequate E, production by 
ovarian follicles and further suggest differential regulation of mitogenic and 
steroidogenic granulosa cell activity by FSH. Since FSH alone - in the 
absence of LH - can induce growth of preovulatory follicles, it seems 
questionable whether estrogen biosynthesis is mandatory for follicular 
development in the human. For induction of ovulation, however, sufficient 
estrogen concentrations seem important for production of cervical mucus 
and normal endometrial function. 
2.3 HUMAN RECOMBINANT FSH AND OVARIAN RESPONSE IN 
GONADOTROPIN-DEFICIENT WOMEN 
2.3.1 Introduction 
Advances in recombinant DNA engineering resulted in secretion of the intact 
human follicle-stimulating hormone (FSH) dimer by Chinese hamster ovary 
cells (Keene et aI., 1989). Subsequently, animal studies showed that 
recombinant human FSH (rhFSH) lacks intrinsic luteinizing hormone (LH) 
activity and exhibits a high specific FSH bioactivity as compared to urinary 
gonadotropin preparations (Mannaerts et aI., 1991). In order to assess safety 
and pharmacokinetical properties of this compound, initially a single dose 
study was undertaken in hypogonadotropic female and male volunteers 
(Mannaerts et aI., 1993). Administration appeared to be safe and no anti-
rhFSH formation occurred. Multiple-dose rhFSH administration in 
hypogonadotropic females provides the opportunity to study the effects of 
FSH alone - without the presence of endogenous or exogenous LH - on 
granulosa cell steroid and immunoreactive inhibin (INH) production and 
development of ovarian follicles. Information obtained may add to recent 
contentions based on case histories indicating that: a) LH is needed to 
provide the substrate for appropriate estrogen biosynthesis (Schoot et aI., 
1992b) confirming that the classical two-cell two-gonadotropin concept 
(Fevold 1941) is operational in the human, and b) follicles may fully mature 
without a concomitant increase in estrogen levels (Schoot et aI., 1992b; 
Rabinovici et aI., 1991) suggesting differential regulation of steroidogenic 
and mitogenic activity by FSH. This multicenter study describes 
pharmacodynamic effects of daily injections (with weekly increments) of 
rhFSH in 7 hypo gonadotropic females. 
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2.3.2 Materials and methods 
Subjects and Study Design: Seven gonadotropin-deficient, but otherwise 
healthy female volunteers, participated in this multicenter study. The study 
protocol was approved by the local ethics review committees and written 
informed consent was obtained from all participants. Four subjects suffered 
from congenital isolated gonadotropin deficiency (IGO) (n=3) or Kallman 
syndrome (KS) (n=I), whereas the remaining volunteers (n=3) were 
diagnosed as secondary panhypopituitarism (hypophysectomy = HX) due 
to surgical removal of a nonmalignant pituitary tumor (craniopharyngioma 
or adenoma). In the past, all 3 females with IGO received gonadotropins for 
induction of ovulation. All three showed a normal ovarian response and two 
conceived. No previous gonadotropin treatment had been given to the KS 
patient. Gonadotropins were administered in one of the females with 
previous neurosurgery resulting in a triplet pregnancy. For further clinical 
information of participating subjects see Table 1 (Results section). 
Autoimmunity was excluded by antinuclear antibody assays. All subjects 
refrained from oral estrogen replacement therapy (starting one week before 
injection up to one week after the last injection), while appropriate thyroid and 
glucocorticoid therapy (if required) was continued in the HX volunteers 
(pat# 6,7). All subjects received daily im injections of rhFSH (Org 32489; 
Organon Int. BV, Oss, The Netherlands) during a maximum period of 3 
consecutive weeks in an increasing dose regimen (week 1; 75 IU daily [=1 
ampule], week 2; 150 IU daily and week 3: 225 IU daily). 75 IU of the 
compound was dissolved in 0.5 ml of solvent (150 IU in 1 ml and 225 in 1.5 
ml) and injected at 24-h intervals in the upper quadrant of the buttock. To 
reduce the risk of ovarian hyperstimulation, daily injections of rhFSH were 
discontinued when at least one ovarian follicle attained a mean diameter of 
14 mm, and or serum estradiol (E,) concentrations were above 1,200 pmoll 
L. Sonography (transabdominal or transvaginal, using 3.5-5 mHz probes) 
was performed every other day to monitor changes in endometrial thickness 
(Shoham et aI., 1991) whereas growth of all individual ovarian follicles was 
measured (pache et aI., 1990). Blood samples were taken on alternate 
days prior to the moment of rhFSH injection (day 1, 3, 5, 8, 10, 12, 15, 17, 
19). Additional blood sampling was performed during 3 weeks following 
discontinuation of rhFSH administration - or earlier if appropriate - using 
similar intervals (day 22,24,26,29,31,33, 36, 40). Blood samples were 
centrifuged and serum was stored in 0.5 ml serovials at -20°C until 
assayed. Safety analysis included clinical observations i.e. blood pressure, 
heart rate and body temperature as well as laboratory assessments 
(urinalysis, blood biochemistry and hematology). Serum samples were 
analyzed for the presence of anti-rhFSH antibodies using a sensitive 
radioimmuno-precipitation assay and '''I-recombinant FSH as a tracer, as 
published previously (Mannaerts et aI., 1993). 
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Hormone assays: Immunoreactive FSH and LH was measured by an 
immunofluorometric assay (IFMA) using the time-resolved 
fluoroimmunoassay technique and reagent kits 1244-017 for human FSH 
and 1244-31 for human LH (Dellia: Pharmacia, Woerden, The Netherlands). 
These two-site assays employ a ~-directed capturing monoclonal antibody 
(MCA) and an a-directed europium-labeled detection MCA. The assays 
were performed as described by the manufacturer using the Dellia 
instrumentation system and MultiCalc software (Pharmacia)(Mannaerts et 
aI., 1993). FSH and LH immunoreactivity was expressed in terms of the 2nd 
International Reference Preparation (IRP) of pituitary FSH (code no. 78/549) 
and the 2nd International Standard (IS) for pituitary LH (code no. 80/552). 
The sensitivity of IFMA was 0.05 lUlL for both gonadotropins and the intra-
and interassay coefficients of variation (CV) were below 4.8% and 4.3% for 
FSH, and 4.7% and 7.5% for LH, respectively. The cross-reactivity of the 
FSH kit with LH was <0.08% and of the LH kit with FSH <0.01 %. Serum 
testosterone (T) and E, were assessed by radioimmunoassay (RIA) using a 
coat-a-count T RIA (reagent kit TKTT1 DPC, detection limit 0.27 nmol/L) and 
a double antibody E, RIA (reagent kit KE2D1 DPC, detection limit 11.6 pmol/ 
L, Diagnostic Products Corporation, Los Angeles, CAl. The intra-assay and 
interassay CV's were <9% and 13% forthe T assay and <4% and 5% forthe 
E, assays, respectively. In addition, intra- and interassay CV for the 
androstenedione (AD) RIA (Diagnostic Products Corporation, Los Angeles, 
CAl were less than 8 and 10%, respectively. Serum immunoreactive INH 
levels were measured by RIA as previously described (Lahlou et aI., 1993) 
using an antiserum (No.1989) raised against purified bovine 31 kDa INH. 
Purified bovine 31 kDa INH iodinated by the lactoperoxidase method was 
used as a tracer. The standard was a pool of human follicular fluid (280 UI 
mL) which was calibrated against a rete testis standard preparation of 
defined bioactivity. The immunoactivity of 0.121 U follicular fluid was 
equipotent to 1 ng recombinant human INH (Biotech Australia, specific in-
vitro bioactivity 51 ,060 U/~lg protein using World Health Organization (WHO) 
standard 86/690 as the standard). The recombinant a-subunit of human INH 
exhibited complete cross-reactivity in this assay system. The standard pool, 
which was diluted in plasma from castrated subjects, provided dose responses 
parallel to the plasma dilution curves. The sensitivity of the assay was 30 U/ 
L and the intra-assay and interassay CV's were <10%. 
Data analysis: Comparison of baseline and maximum hormone levels, and 
time-interval to maximum immunoreactive INH and E, elevation was 
performed by means of the Wilcoxon's test. Changes in serum FSH 
concentrations were analyzed in all subjects (n= 7). Due to the absence of 
follicle development, and absent increase in E, and immunoreactive INH 
serum concentrations in 2 HX volunteers ([#6,7J presumably due to early 
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ovarian failure), analysis of ovarian response was restricted to the remaining 
5 subjects. Data are presented as mean ±standard deviation (SO), or median 
and range. Differences were considered to be statistically significant if 
P< 0.05. 
2.3.3 Results 
Age and 8MI (weight/height') of all volunteers was 37.7 ± 6 years and 23.8 
± 2.5 kg/m', respectively (Table 1). Four women received rhFSH (#2,5,6,7) 
for 3 weeks whereas 3 women had to stop earlier because of ongoing follicle 
growth (subject #1 day 12; subject #3 day 16; subject #4 day 18). None of 
the women exceeded the upper limit of serum E, (> 1,200 pmoI/L). 
Table 1 Individual clinical and endocrine characteristics of 7 hypo-
gonadotropic female volunteers - due to isolated gonadotropin deficiency 
(IGD: n=3; #1-3), Kallman syndrome (KS: #4) or secondary 
panhypopituitarism (HX: n=3; #5-7) - participating in this multiple-dose study 
using rhFSH. 
Previous 
Volunteer Diagnosis Age 8MI HMG T4 Cortisol 
response 
(years) (kg/m') (+/-) (nmol/L) (nmol/L) 
IGD 39 20.4 
2 IGO 39 23.9 
3 IGO 38 23.6 
4 KS 25 24.2 
5 HX 42 28.6 
6 HX 45 22.0 
7 HX 36 23.9 
IGO = isolated gonadotropin deficiency 
KS = Kallman syndrome 
+ NA 
+ 89 
+ 93 
NT 160 
+ NA 
NT 207 
NT 230 
HX = secondary panhypopituitarism due to hypophysectomy 
NT = no previous gonadotropin treatment 
NA = not available 
'above normal limits due to medication 
31 
471 
190 
430 
384 
498 
1200-
536 
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Table 2 Potential theca cell stimulation and maximum androgen response 
due to multiple-dose rhFSH administration in hypogonadotropic female 
volunteers. 
Volunteer LH AD T 
(lUlL) (nmollL) (nmoIIL) 
baseline maximum baseline maximum baseline maximum 
1 0.37 0.38 4.23 4.14 0.36 0.43 
2 0.06 0.08 3.31 3.26 0.55 0.64 
3 0.23 0.47 2.05 1.92 0.57 0.50 
4 <0.05 0.05 7.76 4.73 0.89 0.50 
5 0.09 0.13 1.16 1.95 <0.38 0.52 
6 0.06 0.08 0.20 0.14 <0.38 <0.38 
7 <0.05 0.13 0.08 0.27 <0.38 <0.38 
Median [rangeJ serum concentration of FSH and LH prior to rhFSH 
administration in the overall group was 0.25 [<0.05-1.15J lUlL and 0.06 
[<0.05-0.37J U/L, respectively. Serum AD concentrations appeared to be 
lower in the group with previous surgery (0.20 [0.08-1.16J nmollL) as 
compared to the gonadotropin deficient volunteers (2.68 [2.05-7.76J nmoll 
L):p=0.07)(Table 2). Baseline levels of serum Twere not significantly different 
(p=0.06) in the HX group «0.38 nmollL) as compared to IGD women (0.56 
[0.36-0.89J nmoIlL). Initial E, serum levels did not differ between both groups 
(21.9 [<5.1-37.7J pmollL for IGD women versus: 5.1 [<5.1-7.6J pmollL) for 
the HX group (Table 3). Initial immunoreactive INH serum levels were low 
(lGD-group; 31 [<30-149J U/L, HX-group; 30 [<30-89J U/L). 
As a result of similar daily dosages during one week, changes in serum 
concentrations FSH appeared to stabilize after approximately 5 days (Fig 3). 
On the fifth day - following four injections of 75 IU rhFSH - steady state 
serum FSH levels in 7 subjects were measured ranging between 1.5 and 4.2 
(median: 3.3) lUlL. Steady state concentrations of serum FSH on the fifth day 
of week 2 (150 IU/day;n=7) varied between 4.0 and 8.5 (median 7.2) lUlL. 
Maximum FSH concentrations ranged between 5.5 and 11.8 (median 8. 1 ;n= 7) 
lUlL (Table 3). Decline to baseline FSH levels occurred within 7 to 13 days 
after cessation of administration (Fig 3). Maximum serum LH concentration 
during the period of rhFSH administration remained low (0.13 [0.05-0.47J lUI 
L) (Table 2). Peak AD concentrations during rhFSH administration tended to 
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Table 3 Granulosa cell immunoreactive INH and E, production and follicle 
development in response to rhFSH administration in 7 hypogonadotropic 
female volunteers. 
Volunteer FSH INH E, Follicle number' 
(lUlL) (U/L) (nmoIIL) <8 8-13 >14 
baseline maximum base/tne maximum baseline maximum (mm) (mm) (mm) 
1.15 8.5 <30 659 32.3 210 0 8 9 
2 0.56 11.8 <30 581 <5.1 77 0 2 1 
3 1.07 10.1 31 659 37.7 140 0 4 1 
4 0.25 7.1 149 388 11.6 49 _b _b 1 b 
5 0.07 8.3 <30 993 7.6 112 20 3 0 
6 0.10 8.8 30 69 14.3 18 2 0 0 
7 <0.05 9.9 89 143 2.3 49 0 0 0 
': number of ovarian follicles on the day of maximum rise in E, serum 
concentrations 
b: measured by abdominal ultrasound 
be higher in the volunteers with IGO (3.70 [1.92-4.73] nmoI/L), as compared 
to the HX group (0.27 [0.14-1.95) nmoI/L). No statistically significant difference 
(p~0.14) was observed between baseline and maximum AD levels. For serum 
T concentrations no difference between both groups or between baseline and 
maximum levels were observed (p~0.5) (Table 2). Maximum serum E, 
concentrations were reached (112 [18-21 0] pmoI/L;n~5) on day 19 [15-24). 
Maximum serum immunoreactive INH concentrations were 659 [388-993] 
U/L on day 15 [12-22]. In all five volunteers with ovarian follicular development, 
the day of immunoreactive INH increase appeared to be significantly earlier 
as compared to onset of E, increase (p~0.04). In four of five subjects, 
immunoreactive INH dropped sharply just after discontinuation of rhFSH (Fig. 
3). Initial transvaginal scanning of the ovaries revealed small follicles «8mm) 
in all the females of the IGO/KS group and one woman in the HX group (#5). 
No small follicles were observed in the remaining 2 HX women (#6,7). The 
presence of a single large ovarian follicle (at least 1 fOllicle <: 15mm in diameter) 
was observed by ultrasound in 4 volunteers with IGO or KS (#1,2,3,4) during 
the second or third week of administration. Moreover, one woman showed 
development of more than 5 large follicles (#1). Follicular growth in these 
patients with one single large ovarian follicle appeared to be 2.1 ± 0.9 mml 
day. 
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Figure 3 Daily dosage of rhFSH (upper panel; cessation of further rhFSH 
administration in 3 subjects is indicated) and individual serum FSH (lUlL), 
estradiol (pmoI/L) and immunoreactive Inhibin (U/L) levels in 7 
hypogonadotropic female volunteers participating in a multiple-dose study. 
Changes in sonographic size of the largest ovarian follicle (above 10 mm) 
during rhFSH administration are indicated in the lowest panel. 
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2.3.4 Discussion 
This study deals with multiple-dose rhFSH administration in 7 hypo gonadotropic 
female volunteers, either due to the selective decrease of gonadotropin 
biosynthesis (IGO, or KS) or hypophysectomy (HX). The absence of 
endogenous and exogenous LH allows us to study the effects of FSH alone 
on ovarian steroid and INH production and follicle development. A discrepancy 
between E, response and follicle growth of three of these women has recently 
been reported as case histories (Schoot et aI., 1992b; Shoham et aI., 1993). 
To examine the pharmacokinetical properties of rhFSH following im 
administration, a single-dose (300 IU rhFSH) study has been published 
recently concerning B hypogonadotropic females (Mannaerts et aI., 1993). 
Highest FSH levels were observed after 27 ± 5h and t", was 44 ± 14 h. 
From the present study it is clear that rhFSH exhibits no intrinsic LH 
activity since no rise in serum LH nor AD or T concentrations (Table 2) 
occurred. rhFSH is administered im daily, with weekly increments (from 1 to 
3 amp [equivalent to 75 lUI/day). The observed steady-state serum FSH 
levels around 5 days is in agreement with the calculated half-life based on 
previous bolus studies. Maximum FSH levels as observed in the present 
study (median B.B lUlL) are in the same order of magnitude as compared to 
peri menstrual concentrations in spontaneous cycles (Fauser et aI., 1993a) 
and maximum serum FSH levels during gonadotropin Induction of ovulation 
according to a step-down dose regimen (Schoot et aI., 1992a). FSH 
stimulation resulted in an immunoreactive INH rise (median 659 U/L) after 15 
days which was similar to regularly cycling women (McLachlan et aI., 19B7). 
In contrast, only a minimal increase in E, (median 112 pmol/L) concentrations 
could be observed following 19 days of rhFSH administration. This discrepancy 
in hormone biosynthesis by granulosa cells can be explained by the absence 
of androgen substrate availability mandatory for adequate estrogen 
production. Normal immunoreactive tNH rise provides proof of normal 
granulosa cell function. Immunoreactive INH is used as a marker for 
granulosa cell function in this stUdy, but it should be realized that considerable 
doubt has been raised (Miro & F Hillier, 1992) recently concerning its 
biological relevance. It should also be emphasized that 2 patients (#6,7) 
have been excluded from analysis of ovarian response, since an increase in 
serum immunoreactive INH levelS and follicle growth as monitored by 
ultrasound was absent - presumably due to early (age 36 and 45 years) 
menopause - in these women. To further study the potential significance of 
androgen substrate availability, subjects were divided into groups based on 
absent or intact adrenal function. Indeed, a difference in AD and T 
concentrations was observed comparing 4 individuals suffering from IGO/ 
KS versus 3 women that underwent hypophysec tomy. However, no difference 
was observed with regard to maximum E, responses following rhFSH 
stimulation. In addition, no correlation between serum AD and E, 
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concentrations could be observed. This may come as no surprise, since AD 
concentrations in follicle fluid (representing the amount of substrate available 
for aromatization within ovarian follicles) are 1 ,ODD-fold higher (pache et aI., 
1992a) and therefore minor differences in serum AD levels may not influence 
local concentrations. Another intriguing observation is that the observed 
increase (doubling of baseline levels) in immunoreactive INH starts on day 
12, whereas the minor rise in E, concentrations begins thereafter (day 15). 
This difference is statistically significant (p=0.04). It may be hypothesized 
that immunoreactive INH produced by granulosa cells may in turn act as a 
paracrine regulator to stimulate theca cell androgen production which in 
turn provides some substrate for E, synthesis by granulosa cells (Hsueh et 
aI., 1986; Hillier et aI., 1991). A similar mechanism could be speculated for 
changes in the intra-ovarian insulin-liKe growth factor (IGF) system, since it 
has been shown that IGF-1 is a potent stimulator of androgen synthesis by 
theca cells in culture (Hernandez et aI., 1988; Magoffin et aI., 1990; Bergh 
et aI., 1993). 
The present study clearly extends previous observations indicating that 
high intrafollicular E, concentrations may not be a conditio-sine-qua-non 
for ongoing maturation of follicles. A discrepancy between serum E,levels 
and follicle development has been observed comparing urinary FSH and 
human menopausal gonadotropin (HMG; with similar LH and FSH 
activity)(Couzinet et aI., 1988) and combining urinary FSH with long-term 
gonadotropin releasing hormone agonist cotreatment (Remorgida et aI., 
1989). In addition, a case history has been published dealing with a patient 
with 17a hydroxylase deficiency and therefore incapable of producing 
estrogens (Rabinovici et aI., 1991). Exogenous gonadotropins were able to 
induce growth of follicles up to the pre-ovulatory stage in this patient and 
oocytes could be fertilized in-vitro. Puncture of 3 follicles (13, 15, 18 mm in 
diameter) following rhFSH administration in subject 111 has shown that both 
E, and AD concentrations within the follicles were indeed extremely low as 
compared to intrafollicular levels in the late follicular phase under normal 
conditions (Schoot et aI., 1992b; Pac he et aI., 1992a). In the present study 
4 subjects exhibited extensive growth of at least 1 large follicle, whereas the 
number of medium-sized follicles also increased during rhFSH administration. 
However, in one patient (#5), follicle growth was disrupted even after an 
increase of daily dose of rhFSH. Although we feel that the physiological 
significance of this finding should be interpreted with great care, this study 
clearly demonstrates that follicles can be stimulated to growth to the pre-
ovulatory size without a concomitant rise in E, production. The assumption 
that FSH actions at the fOllicular level are to a great extent dependent on local 
up-regulation by E, is mainly based on in-vitro animal studies (Kessel et aI., 
1985) and could not be operative in-vivo in the human. In fact, so far there 
is doubt about the presence of E, receptors within the human ovary, whereas 
androgen receptors have been clearly demonstrated by immunocyto-
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chemistry (Straus, 1992). Although there is accumulating evidence that 
estrogens are not mandatory for follicle development in the human, it is welt 
established that under normal conditions estrogen levels are strongly 
correlated with follicle size (Templeton et aI., 1986). In line with these 
observations, it is believed that disturbed estrogen production is responsible 
for cessation of follicle maturation in polycystic ovary syndrome patients 
(Franks, 1989). It may be speculated that under normal conditions next to 
FSH other estrogen-associated factors (such as changes in the inhibin or 
IGF system) are responsible for further stimulation of follicle growth, and 
therefore the rise in estrogens is associated with, but not causally related 
to, follicle development. 
It may be concluded from the present study that: 1) rhFSH exhibits no 
intrinsic LH activity since a rise in serum androgen concentrations was 
absent. 2) rhFSH stimulation in hypogonadotropic women resulted in an 
immunoreactive INH rise which was similar to normal, whereas in contrast 
only a minor increase in E, concentrations could be observed. This indicates 
normal granulosa cell function and insufficient availability of androgens as 
substrate for aromatization. 3) Despite the minimal estrogen increase, 
ovarian follicles developed normally to the pre-ovulatory stage, confirming a 
dissociation between mitogenic and steroidogenic activity of FSH. 
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3 
Gonadotropin induction of ovulation 
according to a decremental dose 
regimen in polycystic ovary 
syndrome patients 
3.1 BACKGROUND STEP-DOWN CONCEPT 
A considerable proportion of patients who suffer from infertility and 
anovulation exhibit insufficient response to anti-estrogen medication. 
Urinary gonadotropins represent an effective second-line treatment for 
this group of patients. However, the incidence of complications caused by 
gonadotropin treatment in anovulatory patients is a major concern (see 
also sections 1.3.7 and 1.3.8). Due to direct stimulation of the ovaries, 
development of multiple follicles may lead to multiple pregnancies and 
ovarian hyperstimulation syndrome (Blankstein et aI., 1987). In as much 
as 50% of patients, complications (chiefly multiple pregnancies, ovarian 
hyperstimulation or early pregnancy wastage) do occur. Consequently, 
there is a clear need to test new concepts concerning regulation of follicle 
growth, and improve treatment outcome. Next to doses administered, 
numerous additional factors may affect the outcome of gonadotropin 
therapy, such as: 1) indication for treatment, 2) patient diagnosis and 
underlying endocrine abnormalities, 3) age and body weight of the patient, 
4) previous medication, 5) gonadotropin medication used (HMG orpFSH), 
6) adjuvant medication, 7) monitoring of ovarian response and 8) luteal 
support (for review see Fauser, 1993c). For a more detailed discussion 
see section 1.3 of this thesis. 
The objective of increasing the dosage of gonadotropins during 
conventional 'step-up' regimens for ovulation induction is to attain and 
continue the minimal dose required to initiate ovarian response. It was 
concluded that step-up dose regimens should be individualized: initial daily 
intramuscular doses of 1 or 2 ampules of gonadotropins, with dose increments 
of 1 ampule per day every 3 days in case of insufficient response. In practice, 
this means that if estrogen levels in serum rise or if a dominant follicle is 
observed by sonography, the 'effective' dose is sustained until ovulation is 
triggered by administering hCG. These step-up dose regimens have since 
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been applied by most clinicians (Thompsen & Hansen, 1970). Through the 
improvement of monitoring of ovarian response (sonography and hormone 
assays) (Schoot et aI., 1992c) success rates have increased, but the 
incidence of complications remains relatively high. 
In the mid-1980's a new method of stimulation was introduced, referred to 
as the 'low-dose, step-up' regimen (Seibel et aI., 1985). The initial dose was 
low (If, to 1 ampule/day), with no dose adjustmentfor 1-2 weeks. Subsequent 
dose increments (If, ampule/day) were applieq at weekly intervals if necessary. 
This empirical method was based on the concept of the 'FSH-threshold' for 
ovarian stimulation as described by Brown (section 1.2.4.) (Brown, 1978). It 
was hypothesized that the ovarian requirement for FSH operates in a narrow 
range. Only a minor increase of administered FSH resulting in serum levels 
just above the threshold would induce normal follicle growth, whereas a 
further increase would cause excessive stimulation (Scheele et aI., 1993). 
This minimal requirement of FSH could initiate growth of a synchronized 
'recruited' cohort of follicles (Hodgen, 1982). Recently - with the use of 
intravenous gonadotropin administration and rapid FSH serum measurement 
- the concept of an FSH-threshold requirement for follicle growlh has been 
further substantiated (Weissenbruch et aI., 1993; van der Meer et aI., 1994). 
Serum FSH concentrations below an empirical FSH threshold resulted in an 
absent estrogen rise whereas an increment of serum FSH level induced a 
serum E, rise and follicle growth. Combined results of 6 different studies using 
low-dose step-up regimens indicate an overall pregnancy rate of 15% per 
cycle, 11 % multiple pregnancies and a 39% miscarriage rate (Hult, 1991). 
The step-down principle for gonadotropin induction of ovulation is based 
on newly developed insights into the process of selection and growth of the 
dominant ovarian follicle in the normal cycle (for a review see Fauser et aI., 
1993; Fauser, 1994b). Key physiological considerations related to normal 
follicle development that may help to understand the ovarian response to 
exogenous gonadotropins under patho-physiological conditions are: 
1) A minimum stimulation of FSH above the threshold is needed to 
rescue follicles from atresia during the luteo-follicular transition (follicle 
recrUitment) (Hodgen, 1982). 
2) Decrease of serum FSH during the follicular phase is essential for 
development of a single dominant follicle and atresia of the remaining 
follicles from the recruited cohort (Zeleznik & Kubik, 1986). 
3) The dominant follicle continues to grow despite decreasing FSH 
presumably due to local (auto- or paracrine) up-regulation (section 1.2.4). 
Various aspects of recruitment and dominant follicle selection have been 
substantiated in-vivo in the monkey model (DiZerega & Hodgen, 1980; 
Zeleznik, 1981; Zeleznik & Kubik, 1986; Abbasi et aI., 1987) and some of 
these observations have also been confirmed in the human (Glasier et aI., 
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1989; Gougeon & Testart, 1990). If fOllicles reach a certain stage of 
development at a size of approximately 2-5 mm, they undergo atresia unless 
FSH levels are elevated (Gougeon, 1993). The number of recruited follicles 
is correlated to the duration of the period with serum FSH levels above 
threshold values (width of the FSH·gate) (Baird, 1987). Appropriate FSH 
stimulation will initiate granulosa cell activity and stimulate estrogen production. 
Normal follicles will gain dominance above 8-10 mm and produce significant 
amounts of E, only during further development until ovulation (Erickson et aI., 
1979). The remaining follicles will go into atresia, in part due to negative 
feedback actions of ovarian steroids on FSH release (Hillier, 1981; Baird, 
1987). It may be postulated that FSH induction of aromatase activity is 
enhanced by local factors only in the fOllicle destined to gain dominance 
(Fauser et aI., 1993). Due to (estrogen-mediated) up-regUlation, growth of the 
dominant follicle continues even with decreasing FSH serum levels, i.e. the 
FSH threshold of the dominant follicle decreases (Scheele, 1994).ln contrast, 
unaltered doses of exogenous gonadotropins following detection of the 
dominant follicle (as is the case in step-up regimens) can unintentionally 
disturb the selection process, and therefore stimulate continuous growth of 
non-dominant follicles. Continued recruitment and follicular growth following 
ongoing gonadotropin administration agrees with the 'FSH - gate' theory by 
Baird (Baird, 1987). This continued stimulation of the ovaries is intended 
during hyperstimulation prior to IVF, deliberately aiming at disruption of the 
selection process and resulting in multiple follicle development (Hughes et 
aI., 1992). The premises of this step·down dose regimen are: 
a) The initial dose has to be sufficient to surpass the threshold. 
b) FSH has to be kept above the threshold level for a certain period of time 
(the FSH-'window'). 
c) The decreasing levels of serum FSH levels during late fOllicular phase 
need to be sufficient to support dominant follicle growth. 
It is yet to be determined what can be gained from surpassing the threshold 
after an extended period of time, as is the case in the low-dose 'step-up' 
regimens. Studies in the rat demonstrate no significant change in the 
proportion of healthy follicles fOllowing bolus administration of gonadotropins 
compared with previous spontaneous cycles (Hirschfield, 1989). It should 
also be emphasized that the relatively long half-life of FSH (30-40 h; 
[Diczfaluzy & Harlin, 1988; Mizunuma et aI., 1990; Mannaerts et aI., 1993]) 
leads to steady-state levels of serum FSH following 5-7 days if similar daily 
doses are administered intramuscularly. Hence, FSH accumulates in serum 
and reaches maximum levels in the late follicular phase, contrary to normal 
circumstances. Mechanisms ensuring monofollicular development under 
normal conditions may be overruled and follicles may be rescued from atresia 
if serum FSH levels are elevated in the late follicular phase (Zeleznik et al., 
1985). In addition, during the course of prolonged elevated FSH levels, 
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additional follicles may be recruited and undergo further maturation, resulting 
in a more heterogeneous group of mature follicles and an extended period of 
ovulation (Abbasi et aI., 1987). Indeed, the magnitude of response during 
ovarian hyperstimulation for IVF appeared to be dependent on the magnitude 
of late follicular phase FSH accumulation (Ben Rafael et aI., 1986). LOW-dose 
step-up regimens may partly overcome these shortcomings since the FSH-
threshold will be surpassed to a minor extent and the FSH-window may not 
be as wide. However, it is not clear what can be gained from an extended 
period of time before the FSH threshold is reached (can the ovary be 
sensitized?) and still obtain maximum FSH levels in the late follicular phase. 
The first aim of our studies was to investigate the influence of decreasing 
doses of gonadotropins following the moment of 'presumed selection' in 
peos patients. The objective was to compare ovarian parameters 
(sonographic and endocrine data) during a step-down dose regimen with 
the effects of a continued (fixed) gonadotropin stimulation regimen for 
induction of ovulation (section 3.2). A retrospective study compared endocrine 
and sonographic parameters in peos patients exhibiting monofollicle 
development with the follicular phase of the normal menstrual cycle (section 
3.3). Furthermore, endocrine background data are provided to substantiate 
ovarian sensitivity to gonadotropins in orderto determine individual threshold 
dosage and to improve timing and adjustment of doses during a step-down 
dose regimen (section 3.4). 
3.2 GROWTH PATTERNS OF OVARIAN FOLLICLES DURING 
INDUCTION OF OVULATION WITH DECREASING DOSES OF 
HUMAN MENOPAUSAL GONADOTROPIN FOLLOWING 
PRESUMED SELECTION IN PCOS PATIENTS 
3.2.1 Introduction 
During the follicular phase of the normal menstrual cycle follicle-stimulating 
hormone (FSH) serum levels decrease gradually (Ross et aI., 1969; Fritz & 
Speroff, 1982; Hodgen, 1982). Mechanisms underlying the process of 
selection of the dominant follicle and subsequent monofollicular growth are 
largely unknown, but diminished stimulation of non-dominant follicles by 
relatively low FSH levels might play - next to intra-ovarian mechanisms -
important roles (Fritz & Speroff, 1982, Hodgen, 1982). Moreover, it appears 
that growth of the dominant follicle is less dependent on stimulation by FSH, 
possibly because of autocrine effects of high intrafollicular estrogen 
concentrations (Hsueh, 1986). Indeed, it was shown in the monkey that 
follicles can continue to mature in the presence of FSH concentrations unable 
to support the growth of less mature follicles (Zeleznik & Kubik, 1986). In 
addition, a step-down human menopausal gonadotropin (HMG) protocol 
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showed better synchronization of follicular rupture, with reduced chances 
for delayed ovulations (AbbaSi et aI., 1987). If ovarian function is stimulated 
by exogenous gonadotropins for induction of ovulation, increasing dose 
regimens are commonly used (Diamond & Wentz, 1986) and attempts have 
recently been described to induce monofollicular growth by low·dose 
incremental dose regimens (Suvat et aI., 1989). It may be hypothesized 
that increasing FSH levels during these treatment schedules unintentionally 
disturb the selection process, and therefore stimulate continuous growth of 
non·dominant follicles. Induction of multiple follicular development may 
underlay complications of treatment such as multiple pregnancy and ovarian 
hyperstimulation (Slankstein et aI., 1987). It is surprising, indeed, that as 
yet no systematic effort has been made to test this hypothesis in the human. 
The estimated FSH serum profile during the step·down dose regimen has 
been reported recently, (Mizunuma et aI., 1990) and preliminary clinical 
observations suggest the decremental dose regimen to be an alternative 
method for induction of ovulation in polycystic ovary syndrome (peOS) 
patients (Mizunuma et aI., 1991). Using repeated transvaginal sonography, 
the dominant follicle could be visualized at a size exceeding 9 mm in normal 
ovaries (pache et aI., 1990). The main objective of the present study was to 
investigate whether decreasing the HMG dose after presumed selection 
(based on sonographic criteria) combined with gonadotropin·releasing 
hormone (GnRH) analog treatment in peos patients, would diminish 
subsequent growth of non·dominant follicles, and still lead to ovulation. In 
addition, serum hormone profiles and growth patterns of ovarian follicles 
were compared with those obtained after a fixed HMG dose schedule, and 
in regularly cycling women. 
3.2.2 Materials and methods 
Subjects: Fourteen infertile patients (inlertility duration; 4.9 ± 2.0 (± SO) 
years) diagnosed as peos entered the study. Nine patients were amenorrheic, 
and 5 oligomenorrheic (cycle length 42.8 ± 3.1 days). Their mean age was 
27.6 ± 2.2 yrs, and mean body mass index (SMI) was 28.9 ± 5.6 kg/m'. They 
were all clomiphene resistant, defined as anovulation (diagnosed by basal 
body temperature, vaginal ovarian sonography, or progesterone estimates) 
during at least 3 months of 150 mg/d for 5 subsequent days of clomiphene 
citrate. peos was defined - according to strict clinical and biochemical 
criteria as published previously (Fauser et aI., 1991) as women presenting 
with infertility and oligo/amenorrhea, scoring positive in at least three out of 
four of the following criteria: 1) Obesity (SMI > 26 kg/m'), 2) Hirsutism 
(Ferriman & Gallwey score> 8), 3) Elevated androgen levels (free androgen 
index (FAI; testosterone (T) X 100 I sex hormone binding globulin) ,,5, and/ 
or dehydroepiandrosterone sulphate (DHEAS) " 10 I.lmol/L), 4) Polycystic 
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appearance of ovaries by sonography (pache etal., 1991 b). Mean luteinizing 
hormone (LH) levels were 7.9 ± 2.1 lUlL. In all these patients thyroid-
stimulating hormone levels and prolactin concentrations were within normal 
limits (data not shown). Seven regularly cycling women served as controls. 
Clinical and endocrine characteristics of PCOS patients and control women 
participating in this study are indicated in Table 4. 
Study protocol: This study was approved by the Ethics Review Committee of 
the Erasmus University/Dijkzigt Hospital and informed consent was obtained 
from all participating women. In all PCOS patients gonadotropin therapy was 
combined with and preceded by GnRH agonist treatment to prevent premature 
luteinization, as described by Dodson and colleagues (Dodson et aI., 19B7). 
Buserelin (Hoechst, Amsterdam, The Netherlands) was administered at a 
daily dose of 3 x 400 I1g intranasally (in), starting at the first day of a progestagen 
withdrawal bleeding. Three weeks later HMG (HumegonR; Organon, ass, The 
Netherlands) was added at a daily dose of 225 IU (= 3 ampules of 75 IU 
each) im for 2 days. All HMG administered during this study was derived from 
the same batch (#890421-018), to exclude the possibility of batch differences 
in bioavailable gonadotropins (Harlin et aI., 1986; Cook et aI., 1988). Starting 
at the first day of HMG administration, daily blood withdrawal Gust preceding 
Table 4 Clinical and endocrine characteristics of participating women 
presenting with peas (using a fixed and a decreasing HMG dose regimen) 
and regularly cycling controls. (Data are given as mean ± SO or median 
[range]). 
pcas pcas Controls 
(fixed dose) (decreasing dose) 
n 5 9 7 
BMI (kg/m') 30.3 ± 4.0 28.2 ± 6.3 21.7±2.3 
Amenorrhea 2 6 -' 
Cycle length (days) 42.5 ±5.5 43.0 ± 6.0 27.8 ± 2.0 
F-G score 19.4 ± 8.5 23.6 ± 9.9 5.4 ± 1.0 
LH (lUlL) 8.2 (3.7-12.5) 7.6 (4.4-18.8) 4.2 (2.4-6.4) 
FAI 8.2 (3.5-22.1) 6.0 (2.6-16.5) 1.8 (1.0-2.0) 
DHEAS (l1moIlL) 7.0± 2.2 8.4±1.0 _b 
': not applicable 
b: not available 
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HMG injections, and 24 h following the previous injection) and vaginalsonography 
were performed until human chorionic gonadotropin (hCG) administration. After 
2 days, HMG doses were decreased to 150 IU/day (= 2 amp) im in all patients. 
If at least 1 ovarian follicle exceeded a diameter of 9 mm, randomization for 2 
different treatment regimens was performed. To exclude the possible influence 
of bodyweight on treatment response, randomization was preceded by stratification 
on bodyweight (BMI "26, or> 26). Daily doses of 150 IU were continued in the 
fixed-dose group (n=5) and the dose was diminished to 751U/d in the decreasing-
dose group (n=9). Dosages remained unchanged in each group until at least one 
fOllicle attained a diameter of 18 mm or more. On that day buserelin and HMG 
medication was discontinued, and 10,000 IU of hCG (PregnyIR; Organon, Oss, 
The Netherlands) was administered im. If more than 4 follicles exhibited a 
diameter of > 15 mm, further stimulation was canceled. If growth of follicles was 
absent during 7 subsequent days after randomization further medication was 
also withheld. Vaginal ovarian sonographywas performed daily between 12:00 
and 16:00 P.M. by the same observer (DCS), according to previously validated 
methods (Pache et aI., 1990). A 5-MHz transvaginal transducer (Model 1550; 
Philips Medical Systems, Eindhoven, The Netherlands) was used. The diameter 
of small follicles was measured in 2 dimensions. If the mean of the longitudinal 
and anteroposterior diameter exceeded 7.0 mm, a diameter in the third lateral 
plane was added. Follicles were classified as small (mean size < 9 mm), medium-
sized (mean size between 9 and 13 mm), and large (mean size <: 13 mm), based 
on observations indicating that women with ovarian hyperstimulation present 
with elevated numbers of intermediate follicles (Blankstein et aI., 1987). 
Hormone assays: After withdrawal, blood was centrifuged within 30 min, 
and serum was stored at -20°C until assayed. Immunoreactive FSH serum 
levels were determined using a commercially available immunoradiometric 
assay (IRMA) kit (Medgenix, Fleurus, Belgium) as described previously 
(Fauser et aI., 1990). Data are expressed in terms of MRC 78/549 reference 
preparation, and intra- and interassay coefficients of variation were less 
than 3 and 8%, respectively. Estradiol (E,) levels were estimated by 
radioimmunoassay (RIA) (Fauser et aI., 1991b). Intra- and interassay 
coefficients of variation were 5 and 8%, respectively. 
Data analysis: Endocrine and sonographic data related to the first day of 
HMG administration (day 1) were compared with onset of menses in regularly 
cycling women. Data obtained during the interval between randomization 
and hCG administration were compared with those in the period following 
presumed selection in the control group (pache et aI., 1990). Results are 
presented as mean ± SEM, unless otherwise stated. Comparison of hormone 
patterns, following randomization, between the two treatment regimens and 
controls, was performed using Repeated Measurements Analysis of 
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Variance. In this analysis, E, levels were logarithmically transformed to 
eliminate skew distributions. Sonographic observations were compared 
using Mann-Whitney's test or Wilcoxon's test. P-values given are two-sided, 
and 0.05 was considered the limit of statistical significance. 
3.2.3 Results 
Clinical and endocrine observations in participating PCOS women and 
normal controls are depicted in Table 4 (above). Dose regimens, serum 
profiles of FSH and E, levels, and growth patterns of ovarian follicles of two 
PCOS patients, one randomized for the decreasing and one for the fixed 
HMG dose regimen, are shown in Fig. 4. Two women, both in the decreasing 
dose regimen group, failed to show ongoing follicular development above 14 
mm. Medication was discontinued in these patients and therefore information 
related to hCG administration could not be obtained (see Figs. 5, 6, and 7). 
Randomization (at least 1 follicle;, 9 mm) was performed on the fourth 
treatment day in 13 PCOS patients, and in the remaining woman on day 5. 
The interval between randomization and hCG injection was not significantly 
different comparing both treatment groups (3.6 ± 0.5 days for the fixed dose, 
and 4.7 ± 0.8 days for the decreasing'dose group). Proof of ovulation was 
obtained from all 12 patients who received hCG through sonography and mid-
luteal progesterone estimates, which all exceeded 25 nmollL (data not 
shown). 
Hormone estimates: On the first day of HMG injection, after 3 weeks of 
buserelin treatment, mean FSH concentration (3.4 ± 0.4 lUlL) in the PCOS 
group (n=14) was significantly lower as compared to the control group 
(5.4 ± 0.7 lUlL) at the onset of menses, whereas mean serum E, levels did 
not differ (PCOS group; 115 ± 10 pmollL, controls; 91 ± 7 pmoI/L). FSH levels 
in the treatment group reached levels similar to the control group (5.2 ± 0.5 
lUlL), within 1 day after starting HMG medication. During the first two days 
following the initiation of HMG administration, a clear increase in FSH levels 
was found (mean FSH at day 3: 7.6 ± 0.7 lUlL). At the day of randomization, 
a marked elevation in serum E, concentrations could be observed in PCOS 
patients (1844 ± 420 pmoIlL), significantly (p < 0.001) above normal 
concentrations (138 ± 15 pmoIlL). In retrospect, no hormonal differences 
were present on the day of randomization, between both treatment groups 
(data not shown). Following randomization, mean serum FSH levels in the 
fixed-dose group remained unchanged, whereas a significant (p < 0.001) 
decline of mean FSH concentrations in the decreasing·dose group (mean 
daily decrease 0.45 ± 0.01 lUlL) was found.lncontrols, asignificant (p < 0.001) 
decrease in FSH estimates could be observed during late follicular phase 
(mean daily decrease 0.36 ± 0.Q1 lUlL). Comparing the decrease of FSH 
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Figure 4 Buserelin and HMG medication schedule, daily FSH (lUlL) and 
E, (x 1000 pmol/L) serum levels, and numbers of large (;;' 13 mm), medium· 
sized (9-13 mm) and small « 9 mm) ovarian follicles, as estimated by vaginal 
sonography, in a peas patient from the fixed·dose (left panel) and the 
decreasing (right panel) HMG dose group, R = day of randomization, chosen 
as day of presumed selection. 
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Figure 5 Individual serum FSH levels (lUlL) in the fixed HMG dose group 
(upper panel), the decreasing HMG dose group (middle panel), and normal 
controls (lower panel). R (randomization) in both treatment groups and S 
(selection) in controls represents the day of presumed selection of the 
dominant follicle. FSH levels are indicated until hCG injection in both 
treatment groups and until 1 day before LH surge in controls; + indicates: 
follicle maturation arrest and cancellation of treatment in 2 women in the 
decreasing-dose group. 
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Figure 6 Individual serum estradiol levels (x 1000 pmol/L) in the fixed HMG 
dose group (upper panel). the decreasing HMG dose group (middle panel), 
and normal controls (lower panel). R (randomization) in both treatment 
groups and S (selection) in controls represents the dayof presumed selection 
of the dominant follicle. E, levels are indicated until hCG injection in both 
treatment groups and until 1 day before LH surge in controls; + indicates: 
follicle maturation arrest and cancellation of treatment in 2 women in the 
decreasing-dose group. 
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concentrations in the decreasing dose and control groups, no statistical 
difference was found (see Fig. 5). During the first two days following 
randomization, mean E, levels showed a similar increase in both treatment 
groups. Following the third day after randomization, mean E, concentrations 
decreased significantly (p < 0.001; average daily decrease: 26%) in the 
decreasing-dose group, whereas the E, levels in the fixed-dose group 
showed a significant increase (p < 0.001; average daily increase: 25%). A 
less pronounced, but significant increase was observed in the controls (see 
Fig. 6). 
Ovarian sonography: Following 3 weeks of buserelin treatment, both 
ovaries of PCOS patients contained 36 ± 4.B (± SO) follicles (mean size 
2.9 ± 0.3 mm). The mean total number of follicles increased towards the day 
of randomization to 55 ± 15, in the PCOS group. On the day of randomization, 
no significant differences existed in mean number of small ($ 9 mm) and 
medium-sized (9-13 mm) follicles comparing both treatment groups (Fig. 
7). Monitoring changes in ovarian follicles between randomization and the 
dayof hCG administration in the fixed-dose group revealed a significant initial 
increase in the number of small follicles, followed by a significant (p < 0.02) 
decline towards hCG administration. In the decreasing-dose group, the mean 
number of small follicles remained unchanged between randomization and 
hCG administration. The mean number of medium-sized follicles showed an 
increase during the first three days following randomization in both treatment 
groups (follicle number increase in fixed-dose group; 9.2 ± 3.3, decreasing-
dose group; 6.B ± 3.2). In subsequent days up to hCG administration, a 
further increase of medium-sized follicles was seen in the fixed-dose group 
(+3.3 ± 1.4), whereas a reduction was found in the decreasing-dose group 
(-3.0 ± 2.0). This difference, however, is just above the limit of statistical 
significance (p < 0.07). The number of large (" 13 mm) follicles (fixed-dose 
group; 3.1 ± 0.3, decreasing-dose group; 3.5 ± 0.2) was similar in both 
treatment groups. The mean number of follicles (7.4 ± 0.6) did not change 
throughout the follicular phase in control women (pache et al. 1990). 
3.2.4 Discussion 
Based on initial observations (Thompson & Hansen, 1970; Taymor et aI., 
1967) it seems that decreasing HMG dose regimens were as successful as 
fixed-dose schedules for gonadotropin induction of ovulation. During single 
(Seddon, 1970) and intermittent (Radwanska et aI., 19BO) dose regimens 
complication rates were noted to be elevated and success rates to be 
reduced. For reasons of presumed safety and efficacy, the fixed-dose and 
step-up dose regimens were generally accepted for HMG therapy. Until today 
all efforts to improve treatment schedules have focussed on the use of 
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different preparations (i.e. purified FSH instead of HMG), and monitoring of 
ovarian response bysonography and estrogen estimates during incremental-
dose regimens. Based on recently obtained insight in the regulation of 
ovarian function under normal conditions, it seems mandatory to reassess 
the possibility of reducing complication rates during induction of ovulation 
using decremental HMG dose regimens. 
Previously, transabdominal monitoring of ovarian function during induction 
of ovulation was restricted by limited resolution, and systematic efforts to 
carefully monitor growth patterns of all ovarian follicles have been rare 
(Diamond & Wentz, 1986). Using vaginal sonographyforthe characterization 
of ovarian changes during the normal menstrual cycle (pache et aI., 1990), 
it could be established that: 1) follicles as small as 2mm in size can be 
visualized, 2) the number of follicles (roughly 8/ovary) remains unchanged 
during different phases of the cycle, and 3) the dominant follicle can be 
observed consistently if the follicle diameter exceeds 9 mm. Furthermore, 
this method has been applied to characterize polycystic changes of ovaries 
in women presenting with cycle abnormalities (pache et al 1991b). 
Application of this technique also enables monitoring of changes in daily 
distribution of ovarian follicles during induction of ovulation by exogenous 
gonadotropins. Analysis of data was complicated by the inability to follow 
changes of individual follicles. An arbitrary classification of follicles into small, 
intermediate, and large was therefore required. GnRH analog treatment and 
subsequent pituitary desensitization was applied to minimize interference 
between administered HMG and endogenous gonadotropin secretion (Dodson 
et aI., 1987). Indeed, FSH levels in the pcas group after3 weeks of buserelin 
treatment were below normal, with a rapid increase following initiation of 
HMG administration. Inter-individual variation in absorption and clearance of 
HMG (Diczfaluzy & Harlin, 1988; Fauser & Hsueh, 1989) may underlay the 
wide range of observed serum FSH levels in both treatment groups (Fig. 5). 
In the decreasing-dose group, FSH levels signficantly diminished after 
randomization, similar to FSH concentrations in the late follicular phase of the 
normal cycle and different from the FSH pattern in the fixed-dose group. It has 
to be realized that, in contrast to normal circumstances, FSH levels exhibit 
diurnal variation in both treatment groups because of single daily injections. 
Based on pharmacokinetic simulation programs Mizunuma et al. (1990) 
estimated that maximum levels raise about 30% above concentrations at the 
time of injection. Moreover, it is not known at present whether immunoactive 
FSH levels measured following exogenous HMG represent similar bioactivity 
(Ben-Rafael et aI., 1986). Due to abnormal ovarian function in pcas women 
with cycle abnormalities and clomiphene resistance, ovarian response was 
expected to show a wide variation, and to be different from controls. 
Endogenous luteinizing hormone (LH) concentrations, and the use of 
gonadotropin preparations with different LH/FSH ratios may also affect 
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ovarian responses. Far greater total numbers of ovarian follicles were noted, 
and especially the great number of medium-sized follicles (which never 
exceeded 1 in normal cycles; see Fig. 7) was remarkable_ E, levels were 
similar at initiation of treatment as compared to controls, but at the day of 
presumed selection (4 days later) E, increments exceeded 1 O-fold. E,levels 
continued to rise in the fixed-dose group, whereas a significant decline of 
serum E, started 3 days after randomization in the decreasing-dose group. 
This may be related to the decrease in number of medium-sized follicles, 
suggesting that relatively low FSH levels cause maturation arrest offunctional 
medium-sized follicles. In 2 patients from the decreasing-dose group the 
leading follicle showed arrested maturation and E, output remained low, 
suggesting that FSH levels may have been to low. 
In summary, this study represents an attempt to systematically monitor 
ovarian response, by serum hormone estimates and vaginal sonography 
during gonadotropin induction. Obtained data suggest that a decreasing 
HMG dose regimen in combination with GnRH analog treatment may 
diminish unintended stimulation of medium-sized follicles. The observed 
decrease in circulating E,levels, concomitant with the reduction in number of 
medium-sized follicles in this group, further points to a functional decline in 
ovarian response_ The ovarian hyperstimulation syndrome can be 
predicted by the observed number of intermediate-sized follicles, as shown 
by Blankstein and colleagues (Blankstein et aI., 1987). Although the clinical 
relevance should be further tested by adjusting dose regimens in larger 
patient series, it may be suggested that the incidence of ovarian 
hyperstimulation (and presumably multiple pregnancies) can be reduced 
using decremental HMG dose regimens during gonadotropin induction. 
3.3 GROWTH OF THE DOMINANT FOLLICLE IS SIMILAR TO 
NORMAL IN GONADOTROPIN-STIMULATED PCOS PATIENTS 
EXHIBITING MONOFOLLICULAR DEVELOPMENT DURING A 
DECREMENTAL DOSE REGIMEN 
3.3.1 Introduction 
Patients suffering from anovulatory infertility and peos are frequently 
resistant to clomiphene citrate treatment and need gonadotropins to induce 
ovulation (Wang & Gemzell, 1980). In these patients arrested development 
of ovarian follicles appears to be due to disturbed selection of the dominant 
follicle. This concept of normal early follicle development is based on 
observations regarding aromatase activity of cultured granulosa cells 
(Erickson et aI., 1979), follicular fluid steroid hormone estimates (pache et 
aI., 1992b), and careful monitoring of ovarian function using transvaginal 
sonography (pache et aI., 1990; Pache et aI., 1992a). It therefore seems of 
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special interest to further explore developmental characteristics of follicles 
after selection has taken place in PCOS due to a transient elevation of 
serum follicle stimulating hormone (FSH) concentrations subsequent to 
exogenous gonadotropin administration. 
Assessment of growth rates of large ovarian follicles during multiple follicle 
development in gonadotropin-stimulated cycles is hampered by difficulties 
with recognizing individual follicles during successive sonographic 
investigations. Moreover - in sharp contrast to the late follicular phase during 
the normal menstrual cycle (Ylostalo et aI., 1979) - the correlation between 
serum estradiol (E,) levels and follicle size has disappeared if growth of mUltiple 
large follicles is observed under these conditions (Mango et aI., 1988). The aim 
of this study was to investigate the late follicular phase of PCOS patients 
exhibiting growth of one single dominant follicle following gonadotropin induction 
of ovulation using a decremental dose regimen and adjuvant gonadotropin 
releasing hormone (GnRH) agonist medication as previously described (Schoot 
et aI., 1992a). Observations in regularly cycling women served as the control. 
3.3.2 Materials and methods 
Subjects and study protocol: Seven (from a total groupof35) gonadotropin-
treated, infertile (duration; 4.7 ±1.5 (±SD)years) PCOS patients were included 
from our infertility clinic, based on the presence of not more than 1 follicle 
;:, 12mm diameter during gonadotropin induction of ovulation. Three patients 
were amenorrheic, and 4 oligomenorrheic (cycle length 44.7 ± 5. 1 days). 
Their mean age was 29.4 ± 3.2 years, and body mass index (BMI) 29.1 ± 4.9 
kg/m'. They a/l failed to ovulate using clomiphene citrate up to 150 mg daily 
during five consecutive days. PCOS was defined according to strict clinical 
(BMI, Ferriman Gallwey score), endocrine (elevated dehydroepiandrosterone 
sulphate [DHEAS] serum levels [;:, 10 mmol/l], and high Free Androgen Index 
[FAI= testosterone x 1001 sex hormone binding globulin {SHBG} ;:, 5]) criteria 
and polycystic appearance of ovaries by transvaginal sonography as published 
previously (Fauser et aI., 1991). Mean luteinizing hormone (LH) levels were 
7.9 ± 2.1 lUll, whereas FSH concentrations were 4.7 ± 1.4 lUll. Sonographic 
and endocrine data of seven healthy regularly cycling women (C) (mean age 
28.0 ± 1.2 years, BMI; 21.7 ± 2.3 kg/m', and cycle length; 28 ± 2 days) 
recruited through advertisement served as the control. 
This study was approved by the Ethics Review Committee of the Erasmus 
University/Dijkzigt Hospital and informed consent was obtained from a/l 
participating women. In all PCOS patients gonadotropin therapy was combined 
with and preceded by GnRH agonist (buserelin; Hoechst, Amsterdam, The 
Netherlands) treatment (3 x 400 mglday, intranasally). GnRH agonist 
treatment was started on the first day of a spontaneous or progestagen 
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withdrawal bleeding and was continued for a period of three weeks, followed 
by concomitant treatment with randomly chosen gonadotropins (HumegonR, 
[Organon Int, ass, The Netherlands] n=4; or MetrodinR, [Serono, Amsterdam, 
The Netherlands] n=3). Starting on the first day of gonadotropin administration, 
daily blood withdrawal (just preceding gonadotropin injections) and 
transvaginal sonography took place. Sonography was performed between 
12:00 and 16:00 P.M. by the same observer (DCS), according to previously 
validated methods (pache et aI., 1990). A 5-MHz transvaginal transducer 
(Model 1550; Philips Medical Systems, Eindhoven, The Netherlands) was 
used. Mean size of ovarian follicles (> 2 mm diameter) was computed 
measuring three dimensions (longitudinal, antero-posterior, and tranverse). 
The initial dose of gonadotropins was 150 or 225 IU/day im. The dose was 
decreased by'/' or 1 amp (=75 IU)/day if at least 1 follicle exceeded a 
diameter of 9 mm. Further decrease to 75 IU/day was continued until 
administration of human chorionic gonadotropin ([hCG] PregnylR; Organon 
Int). When the mean diameter of the dominant follicle exceeded 18 mm, 
buserelin and gonadotropins were discontinued, and 10,000 IU of hCG was 
administered. No luteal support was provided. 
Hormone assays: After withdrawal, blood was centrifuged within 30 min, 
and serum was stored at -20°C until assayed. FSH serum levels were 
determined using a commercially available immunoradiometric assay kit 
(Medgenix, Fleurus, Belgium) as described previously (Fauser et al., 1991). 
Dataare expressed in terms of MRC 78/549 reference preparation, and intra-
and interassay coefficients of variation were less than 3and 8%, respectively. 
Serum E,levels were estimated by radioimmunoassay (pache et aI., 1992b). 
Intra- and interassay coeffients of variation were 5 and 8%, respectively. 
Data analysis: Endocrine and sonographic data obtained on the last day 
before the spontaneous LH peak in controls were compared with data obtained 
on the day of hCG administration in PCOS patients (estimated interval between 
LH and ovulation 12 h, versus that between hCG and ovulation 36 h). 
'Presumed selection' was defined, based on previous studies under normal 
conditions (pache et aI., 1990), as the day that one follicle could be visualized 
at a size exceeding a mean diameterof 1 0 mm. The minimum size of a dominant 
follicle measured during gonadotropin induction of ovulation in PCDS 
patients was decided to be 12 mm due to the potential interference of one or 
more large (8-12 mm) secondary follicles. Results are presented as mean ± 
SD, unless otherwise stated. Comparison of hormone patterns between the 
treatment group and controls, was performed using Mann-Whitney's test and 
Repeated Measurements Analysis of Variance. Sonographic observations 
were compared using Mann-Whitney's test or Wilcoxon's test. P-values given 
are two-sided, and 0.05 was considered the limit of statistical significance. 
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3.3.3 Results 
an the day of presumed selection mean FSH levels in the control group were 
4.4 ± 0.8 lUlL, whereas FSH concentrations in the PC as group were 
6.8 ± 2.3 lUlL (p~0.3) (Fig. 8). FSH levels at the day before the LH surge in 
controls were not significantly different from those in the PC as group on the 
day of hCG administration (3.3 ± 1.8 lUlL in controls, versus 3.4 ± 2.2 lUlL in 
PCaS). Daily serum FSH levels in PC as patients decreased more rapidly as 
compared to controls (-0.3 ± 0.2lU/day in controls, versus -0.7 ± 0.4 IUlday 
in pcas; p< 0.02). Mean FSH levels on the first day of gonadotropin 
administration were not significantly different from the day of hCG 
administration in the pcas group (2.9 ± 1.6 lUlL, versus 3.4 ± 2.2 lUlL; 
p~0.06). 
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Figure 8 Daily changes in individual serum concentrations of FSH (lUlL) 
and E, (pmoI/L) on the days prior to the LH surge in 7 controls (left panel), 
and days before hCG administration in 7 gonadotropin-treated pcas patients 
(right panel). 
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Mean E, concentrations on the day of presumed selection in the treatment 
group were 255 ± 137 pmol/L compared to 211 ± 10B pmol/L in controls. No 
statistically significant differences were seen in daily increase (30% in 
controls and PCOS) and mean peak levels (B25 ± 94 pmol/L in controls, 
versus 937 ± 231 pmol/L in PCOS) of E, serum levels comparing both groups. 
The interval between the day of selection and the day before the spontaneous 
LH surge in controls, and the day of hCG administration in PCOS patients 
was not significantly different (6.7 ± 1.9 days in controls versus 5.4 ± 1.1 in 
PCOS). 
The mean diameter of the dominant follicle on the day before the LH 
peak in controls was 18.4 ± 1.0 mm, and 1 B.O ± 0.3 mm in PCOS on the day 
of hCG administration (Fig. 9). Mean daily growth of the dominant follicle 
(1.7±0.4 mm in controls, versus 1.9±0.6 mm in PCOS) was not significantly 
different. 
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Figure 9 Size (mm) of individual dominant follicles on days prior to the 
LH surge in 7 controls (left panel), and days before hCG administration in 7 
gonadotropin·treated PC OS women (right panel). 
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3.3.4 Discussion 
Based on previous studies (pache et aI., 1990), it is assumed that selection 
of the dominant ovarian follicle is disturbed in women suffering from PCOS. 
Normal FSH serum levels in the patients (Fauser et aI., 1991) are insufficient 
to induce adequate aromatase activity (Erickson et aI., 1979; Pache et aI., 
1992b) (i.e. the FSH threshold for fOllicle stimulation is augmented). In these 
patients, follicles can be stimulated to ongoing development by a transient 
increase of FSH serum concentrations subsequent to exogenous 
administration of gonadotropins. It has been demonstrated (Mango et aI., 
1988) that diminished stimulation of nondominant follicles beyond the day 
of presumed selection, by decreasing the daily dose of exogenous 
gonadotropins, reduces number and size of functional medium sized follicles. 
Moreover, follicles that have reached a certain stage of maturation will 
continue their development in the presence of decremental FSH serum 
concentrations (Mango et aI., 1988). 
Comparison of previous studies concerning fOllicle development in 
gonadotropin-induced cycles was hampered by differences in patient 
criteria, applied preparations and dose regimens (Sallam et aI., 1982; 
Schmidt et aI., 1981). In addition, the definition of "monofollicular" growth 
in induced cycles revealed discrepancies, partially due to the trans-
abdominal technique of sonography (Coleman et aI., 1988). Simultaneous 
development of secondary medium-sized fOllicles and differences in timing 
of hCG injections can explain differences in growth slopes, estrogen production 
and preovulatory size of large follicles (Templeton et al.,1986). Using 
pulsatile intravenous administration of FSH, in a low-dose, incremental dose 
regimen, follicle growth was also suggested to be similar to normal (Polson 
et aI., 1987). In the present study exhibiting decreasing serum FSH 
concentrations - due to the applied decremental dose regimen - it was 
demonstrated that growth and estrogen production by the dominant follicle is 
similar as compared to the normal menstrual cycle. This finding is in 
agreement with animal studies (Zeleznik & Kubik, 1986) suggesting that the 
dominant follicle is less dependent on FSH stimulation. This may be due to 
intra-ovarian auto- or paracrine up-regulation (Fauser & Hsueh, 1988). 
Although all gonadotropin-treated patients exhibiting monofollicular growth 
selected for this study fullilled the same strict criteria for definition of PCOS, 
it cannot be ruled out that this study includes only a specific proportion of all 
PCOS patients. It may be concluded from this preliminary study, that if 
monofollicular development occurs in gonadotropin-treated PCOS patients 
using decremental dose regimens (and adjuvant GnRH agonist treatment), 
growth and steroidogenic activity of the dominant follicle is indistinguishable 
from normal. Once formation of a dominant follicle has been induced by a 
transient increase in serum FSH, further development is normal despite 
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decreasing serum FSH levels. Serum FSH levels during the late follicular 
phase in gonadotropin-treated PC OS patients showed a return to early 
follicular FSH serum concentration and were similar to normal preovulatory 
levels. This gives further support to the notion that in at least a proportion 
of PCOS patients early follicle development is normal and only selection 
of the dominant follicle is disturbed. 
3.4 INITIAL ESTRADIOL RESPONSE PREDICTS OUTCOME OF 
EXOGENOUS GONADOTROPINS USING A STEP-DOWN 
DOSE REGIMEN FOR INDUCTION OF OVULATION IN 
PCOS PATIENTS 
3.4.1 Introduction 
Patients suffering from anovulation due to PCOS frequently exhibit 
insufficient response to clomiphene citrate therapy. Exogenous 
gonadotropins are subsequently administered, commonly in stepwise 
incremental doses ("step-up" regimens) (Thompson & Hansen, 1970). Daily 
dosages remain unchanged once response is judged to be adequate (Sagle 
et aI., 1991) i.e. the FSH threshold (Brown, 1978) for ovarian stimulation 
has been reached. However, this approach does not take into account the 
notion that the dominant follicle needs less FSH for ongoing development 
(Zeleznik & Kubik, 1986; Abbasi et aI., 1987) presumably due to intra-ovarian 
up-regUlation (Hsueh et al., 1984). It may be hypothesized that in step-up 
regimens accumUlation of FSH in the late follicular phase -due to the relative 
long half-life of FSH (Mizunuma et aI., 1990) - could unintentionally disturb 
the selection process, leading to development of multiple follicles (Ben-
Rafael et aI., 1986; Fauser et aI., 1993c). This in turn may underlay 
complications of treatment such as multiple pregnancy, and ovarian 
hyperstimulation (Blankstein et aI., 1987). In this context it has been 
reported that even during low-dose step-up regimens a considerable 
proportion of multiple follicle growth can be observed (Herman et aI., 1993). 
Recently, efforts to apply an alternative decreasing dose regimen revealed 
evidence that stimulation of secondary follicles is less pronounced during 
a step-down regimen (Schoot et aI., 1992a) and that monofollicular growth 
can be achieved in a considerable proportion of patients (Schoot et aI., 
1993). 
Ovarian response during conventional gonadotropin induction of 
ovulation is monitored by serum E, levels or pelvic ultrasound mainly 
focusing on the late follicular phase. Comparison of both rnonitoring 
techniques revealed no clear differences (Mango et aI., 1988). During 
previous studies (Schoot et aI., 1992a; Schoot et aI., 1993) using the step-
down approach (focusing on diminished interference with the selection 
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process) the decrease in gonadotropin doses administered was based on 
sonographic criteria only. This was related to observations under normal 
conditions where a dominant follicle could be visualized from a diameter 
of 9 mm upwards (pache et al., 1990) with only thereafter a considerable 
rise in serum E, levels (Fauser et aI., 1993a). A similar endocrine profile 
was found indeed in gonadotropin-treated pcas patients exhibiting 
monofollicular growth (Schoot et aI., 1993). However, the use of ultrasound 
alone in PCOS patients may be hampered by major inter-individual 
differences in E, biosynthesis following similar FSH stimulation (Caruso 
et aI., 1993). The present study involves an endocrine analysis of ovarian 
response during gonadotropin-induced cycles using a step-down dose 
regimen (and adjuvant gonadotropin releasing hormone [GnRH] -agonist 
treatment) based on sonographic criteria only in infertile anovulatory 
clomiphene-resistant peDS patients. 
3.4.2 Materials and methods 
Subjects: Twenty-eight infertile (duration; 4.5 ± 2.2 [SD] years) patients 
diagnosed as pcas participated after informed consent was obtained. This 
study was approved by the Ethics Review Committee of the Erasmus 
University/Dijkzigt Hospilal. pcas was defined - as published previously 
(Fauser et aI., 1991) - as women presenting with infertility and oligol 
amenorrhea, scoring positive in at least three out of four of the following 
criteria: 1) Obesity (body mass index [BMI] > 26 kg/m'), 2) Hirsutism (Ferriman 
& Gallwey score> 8), 3) Elevated androgen levels (free androgen index [FAI]; 
testosterone [T] X 100 I sex-hormone-binding globulin [SHBGJ) ;:, 5, andl or 
dehydroepiandrosterone sulphate (DHEAS);:' 10 ± moIlL), and 4) Polycystic 
appearance of ovaries by transvaginal sonography (pache et aI., 1992a). 
Luteinizing hormone (LH) concentrations in these patients were 7.9 ± 
0.6 lUlL (see Table 5). They were all clomiphene-resistant, defined as 
anovulation (diagnosed by basal body temperature, vaginal ovarian ultrasound, 
or progesterone serum estimates) during at least 3 months of 150 mg/d 
clomiphene citrate for 5 subsequent days. In all these patients thyroid-
stimulating hormone levels and prolactin concentrations were within normal 
limits (data not shown). 
Study protocol: In all pcas patients gonadotropin medication was 
combined with and preceded by GnRH agonist treatment to prevent 
premature luteinization (Dodson et aI., 1987) and reduce chances of 
interference between pituitary gonadotropins and exogenous medication. 
Buserelin (Hoechst, Amsterdam, The Netherlands) was administered at a 
daily dose of 3 x 400 I1g intranasally (in), starting on the first day of a 
progestagen withdrawal bleeding or spontaneous bleeding. After 
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Table 5 Clinical and endocrine (mean ± SEM) characteristics of 28 
anovulatory, clomiphene-resistant PCOS patients participating in this study. 
Age (years) 
BMI (kg/m') 
Amenorrhea (n) 
Polycystic ovaries (n)' 
LH (lUlL) 
FSH (lUlL) 
E, (pmol/L) 
T (pmol/L) 
FAI (Txl00/SHBG) 
DHEAS (/lmoI/L) 
27.4± 1.1 
28.4 ± 0.8 
14 
25 
7.9 ± 0.6 
4.3 ± 0.4 
216 ± 17 
2.8 ± 0.2 
10.6 ± 1.5 
6.8 ±0.6 
':number of patients presenting with polycystic appearance of ovaries as 
estimated by transvaginal sonography (pache et aI., 1992a). 
randomization, human menopausal gonadotropins (HMG) (HumegonR; 
Organon, Oss, The Netherlands) or purified urinary FSH (pFSH) (MetrodinR; 
Serono, Weesp, The Netherlands) was added 3 weeks later at an initial 
daily dose of 150 IU (~2 ampules of 75 IU each) im. Both HMG and pFSH 
administered during this study were derived from one batch (#890421-018 
and #90 G23, respectively) to exclude potential batch differences in 
bioavailable hormones (Cook et aI., 1988). Starting on the first day of 
gonadotropin administration, daily blood-withdrawal (just preceding im 
injections, and 24 h following the previous injection) and transvaginal 
sonography was performed until hCG (PregnylR; Organon, Oss, The 
Netherlands) administration. If at least 1 follicle exceeded a diameter of 
9 mm, daily doses of gonadotropins were reduced to 1'1, ampules for a fixed 
period of 2 consecutive days, followed by a further reduction to 75 IUlday 
im. Daily doses of 75 IU were continued and remained unchanged until at 
least one follicle (and no more than 3) attained adiameterof 18 mm or more. 
On that day buserelin and HMG medication was discontinued, and 10,000 
IU of hCG was administered im. If more than 3 follicles exhibited a diameter 
of > 15 mm, further stimulation was canceled. If growth of follicles was 
absent during 7 consecutive days medication was increased and these 
patients were considered to be drop-outs from the study. No luteal support 
was provided. Transvaginal ovarian sonography was performed daily 
between 12:00 and 16:00 P.M. by the same observer (DCS), according to 
previously validated methods (pache et aI., 1990). A 5-MHz transvaginal 
transducer (Model 1550; Philips Medical Systems, Eindhoven, The 
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Netherlands) was used. The diameter of small follicles was measured in 2 
dimensions. If the mean of the longitudinal and antero-posterior diameter 
exceeded 7 mm, a diameter in the third lateral plane was added. 
Hormone assays: After withdrawal, blood was centrifuged within 30 min, 
and serum was stored at -20°C until assayed. Immunoreactive FSH and 
LH serum levels were determined using a commercially available 
immunoradiometric assay (IRMA) kit (Medgenix, Fleurus, Belgium) as 
described previously (Fauser et ai., 1991). Data are expressed in terms of 
MRC 78/549 (FSH) and MRC 68/40 (LH) reference preparation, and intra-
and interassay coefficients of variation were less than 3 and 8% (FSH) and 
5 and 15 % (LH), respectively. All steroid hormones were measured by 
radioimmunoassay (RIA) as previously described (Fauser et ai., 1991). Intra-
and interassay coeffients of variation were less than 4 and 5% for SHBG, 
less than 5 and 8% for E" less than 3 and 5% for T, and less than 4 and 6% 
for DHEAS, respectively. 
Data analysis: Due to the absence of differences following extensive 
analysis in studied endocrine (Fig. 10) and sonographic (data not shown) 
parameters between both subgroups treated with HMG or pFSH, data of 
the two groups were pooled. Endocrine data obtained on the first day of 
gonadotropin administration (day 1) were compared with those obtained 
on day 3. Furthermore, data obtained on the day of first dose reduction 
were compared with those of day 1 of gonadotropin treatment as well as 
with data obtained at the moment of hCG administration. Sonographic 
observations and endocrine data were compared using Mann-Whitney's 
test or Wilcoxon's test. E, levels were logarithmically transformed to 
eliminate skew distributions. The probabilities of hyperresponse (E, 
exceeding 3000 nmol/L) (Schenker & Weinstein, 1978) and successful 
stimulation in relation to E,levels were assessed using logistic-regression. 
Results are presented as mean ± SEM or median and range (box and 
whisker plots (Brown & Swanson Beck, 1990), Fig. 11) unless stated 
otherwise. P-values given are two-sided, and 0.05 was considered the 
limit of statistical significance. 
3.4.3 Results 
Clinical and endocrine characteristics of 28 PC as patients participating in 
this study are depicted in Table 5 (above). There was no difference in 
endocrine or sonographic parameters tested between 14 patients treated 
with HMG or pFSH (data not shown). Following 3 weeks of buserelin 
treatment, serum E, (115 [43-263] nmol/L) and LH (2.2 [0.3-7.7] lUlL) levels 
lowered significantly (p < 0.001) as compared to pretreatment levels (E, (228 
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Figure 10 Individual daily follicular phase serum FSH and E, levels in 
pcas patients treated with HMG (n~11) or FSH (n~11) in a decremental 
dose regimen with adjuvant GnRH agonist medication. hCG represents day 
of hCG injection to induce ovulation. 
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Figure 11 Box and whisker plots indicating serum levels of FSH (upper 
panel) and E, (lower panel) on day 1 and 3 of gonadotropin administration, 
the day of maximum FSH concentrations and 2 days prior to and on the day 
of hCG administration. Boxes encompass 50% of the values between the 
25th and 75th percentiles. The whiskers give the range of the values. The 
horizontal line in the boxes gives the median value for the group. FSH 
concentrations day 3 vs day 1; p= 0_001. FSH concentrations day hCG vs 
day max; p=0.001. 
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[98-412] nmol/L; LH (8.1 [4.2-13.1] lUlL) in the total group studied. 
Immunoreactive FSH concentrations (3.6 [0.9-7.6] versus 4.2 [1.3-7.7] 
lUlL) showed no significant (p=O.4) changes following GnRH agonist treatment. 
In the overall group, 22 patients (HMG=11; pFSH=11) received hCG, 
whereas 6 patients (=21 %) were canceled from the study due to strict 
protocol criteria (absent folliCle growth during 7 days of 2 amps of 
gonadotropins [n=5] or deterioration of follicle development 1 day after 
gonadotropin dose reduction [n=1]). After receiving hCG, ovulation was 
confirmed by sonography and midluteal progesterone 37.1 ± 4.2 pmol/L 
serum assays. Individual daily follicular phase serum levels for FSH and E, 
are shown in Fig. 10. Duration of the follicular phase ranged between 5 and 
12 days (median 8 days), whereas the total number of ampules of 
gonadotropins administered was 13 [10-18]. Serum FSH concentrations 
increased significantly (p=0.001) on day 3 (5.9 [2.5-9.7] versus 3.6 [0.9-
7.6] lUlL on day 1) (Fig. 11). Further increase of serum FSH levels (6.2 [3-
10] lUlL) was observed towards the day of first dose reduction (day 4 [2-7] 
days). Maximum FSH levels (7.6 [3.9-1 0.9] lUlL) were reached after 4 [1-9] 
days of gonadotropin treatment, and due to reduction of exogenous 
gonadotropins administered, decreased to 4.7 (2.7-8.2) lUlL at the day of 
hCG administration. The interval between day of maximum FSH 
concentrations and day of hCG injection was 4 [O-9J days. Median daily 
decrease in serum FSH levels after maximum levels were reached was 10 
[3-19J %. Serum FSH concentrations on the day of hCG administration 
were still significantly (p=0.02) higher as compared to initial levels. 
Following GnRH-agonist pretreatment initial serum E, concentrations 
(115 [43-263J nmol/L) were significantly correlated (r=0.62; p=0.03) with the 
number of small ovarian follicles (both ovaries; 29 [20-42]). On day 3 the 
range of E, concentrations revealed 12-fold differences (1297 [247-3,178J 
nmol/L) whereas no correlation between E, and FSH levels was observed. 
On the day of first dose reduction serum E, concentrations did not correlate 
with serum FSH (r=0.32; p=0.2), and with the total number of follicles (r=0.26; 
p=OA). E, concentrations on the day of first dose reduction correlated 
significantly (r=0.72; p=0.001) with E, on day of hCG administration (1,793 
[279-18,414J nmoI/L). Increments of E,levels before hCG administration did 
not correlate with the absolute decrease in FSH serum concentrations 
following the day of gonadotropin dose reduction (r=0.05; p=OA), but did 
correlate (r=-0.6; p < 0.01) with the number of days of decreasing FSH levels. 
E,levels on day of hCG correlated (r=0.67; p < 0.05) with the number of large 
ovarian follicles (> 13 mm). 
Increase of serum E, on day 3 compared to day 1 (E, increase= E, day 31 
E, day 1) was significantly correlated (p < 0.001) to the chance of receiving 
hCG afterwards. No significant initial increase in E, concentrations was 
observed in those women with canceled cycles. E, increase until day 3 showed 
a stronger correlation with the chance of obtaining hCG than E,increase until 
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day 2. The predictive value for dropping out of this study due to follicle 
maturation arrest following the starting dose of 150 IU daily was related to the 
percentage of E, increase on day 3 (Fig. 12A). Serum E,levels on the day of 
first dose reduction correlated (r=0.65; p < 0.05) with E,concentrations on the 
day of hCG administration. The chance of E, exceeding 3,000 nmol/L on the 
day of hCG administration (ovarian hyperresponse) (Schenker & Weinstein 
1978) was significantly correlated (p < 0.005) with the concentration of E,on 
the day of dose reduction (Fig. 12B). Furthermore, non-responders 
demonstrated a significant (p=0.02) higher BMI compared to patients who 
received hCG (30.2 ± 0.9 versus 27.4 ± 0.7 kg/m'). 
3.4.4 Discussion 
Clinical application of exogenous gonadotropins using a decreasing dose 
regimen may be hampered by large inter-individual variability in serum 
FSH levels following similar doses (Harlin et aI., 1986) as well as differences 
in ovarian response to similar FSH stimulation (i.e. differences in FSH 
threshold). In practice, initially one has to administer an adequate quantity 
of gonadotropins to support ongoing growth and the formation of a 
dominant follicle. This is followed by a reduction in the dose in such a way 
that the selected follicle is sufficiently supported by FSH whereas further 
development of secondary follicles is not sustained (Fauser et aI., 1993b). 
Although large differences in serum FSH and E, concentrations after 
GnRH-agonist pretreatment were observed in the present study, the FSH 
pattern revealed a significant initial 2.1-fold increase, followed by 
decreasing serum concentrations of 10% per day for 4 days towards the 
day of hCG administration. Median length of the follicular phase was 8 
days using a total of only 13 ampules per cycle. This observation is in 
agreement with previous studies in the monkey model showing continued 
follicle growth despite decreased FSH stimulation of 12.5% daily (Zeleznik 
& Kubik, 1986). This study was also undertaken to investigate potential 
differences in ovarian steroid production and follicle growth, following 
administration of urinary gonadotropin preparations with low (pFSH) or 
high (HMG) LH content with combined adjuvant down-regulation of 
endogenous pituitary gonadotropin secretion in PC OS patients. Analogous 
to previous comparative reports (Homburg et aI., 1990) using step-up 
regimens, no significant differences in E,levels or follicular growth were 
observed comparing both groups. 
Former studies by our group (Fauser et aI., 1993C) and others 
(Mizunuma et aI., 1991) have suggested the step-down approach to be 
clinically safe and effective with acceptable pregnancy and complication 
rates. Effective application of a step-down regimen does require adequate 
tools to monitor ovarian function in order to: a) estimate effectivity of initial 
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Figure 12 (A) Probability of developing ongoing ovarian follicle growth and 
ovulation related to E, increment ([E,day 3]1 E,[day 1]) during the first 2 days 
of gonadotropin medication in 28 pcas patients using GnRH agonist and a 
step·down regimen for gonadotropin induction of ovulation. (8) Probability of 
developing ovarian hyperresponse (E,concenlrationS:2: 3,000 pmol/L on day 
of hCG administration) related to E, serum levels on the day of gonadotropin 
dose reduction (:2: 1 ovarian follicle :2: 9mm) in 22 ovulatory pcas patients 
using GnRH-agonist and a step·down regimen for gonadotropin induction of 
ovulation. 
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gonadotropin doses on an individual basis, b) decide when the first and 
subsequent decreases in dose should take place, and finally c) to time the 
administration of hCG. However, using gonadotropin step-up regimens, 
differences in response during the late follicular phase are not related to 
early follicular phase events but ratherto the number of days of gonadotropin 
administration and the total amount of ampules administered (i.e. magnitude 
of FSH accumulation). Since in the present study the mode of reduction 
of gonadotropins was similar for all subjects, it was possible to investigate 
the influence of the initial dosage on treatment outcome. No correlation 
could be observed between increments of serum FSH and E,concentrations 
on day 3 of gonadotropin administration. Differences in E,levels at the 
moment of comparable sonographic ovarian appearance (1 follicle c: 9mm, 
which was chosen as the day of initial dose reduction) were intriguing. 
Ovarian E,production seemed to be unpredictable and extremely variable 
following a relative short (3-4 days) period of gonadotropin stimulation in 
combination with commonly accepted "sufficient" sonographic response 
(1 follicle c: 9mm) to gonadotropins. Furthermore, the wide range in E, 
levels on this first day of dose reduction demonstrates a poor correlation 
between sonographic and estrogenic ovarian response in the early 
follicular phase during stimulated cycles. This has been mentioned 
previously (O'Herlihy et aI., 1982), but has not gained wide attention. It 
should be emphasized that the difference in the initial E, response is not 
related to observed differences in FSH serum concentrations. The major 
individual variability in E, response (indicating different FSH threshold) 
may reflect differences in underlying mechanisms of ovarian dysfunction 
in PCOS patients. As suggested previously a functional test to investigate 
individual ovarian sensitivity to clomiphene citrate (Navot et aI., 1987) or 
gonadotropins (Caruso et aI., 1993) may predict treatment outcome. It 
may therefore be suggested that measurement of serum FSH levels 
during gonadotropin induction of ovulation in PCOS patients is of limited 
clinical significance. Moreover, it is to be defined what can be gained from 
weekly incremental low-dose step-up regimens (Buvat et aI., 1989) where 
the FSH threshold is reached after an extended period of time. It cannot 
be excluded, however, that ovaries are sensitized for FSH stimulation 
using this regimen. We speculate that in step-down regimens the FSH 
threshold may be surpassed as long as this occurs for just a limited period 
oftime (short FSH window). In the present study, using follicle development 
as marker for the moment of dose reduction, the wide range in observed 
E,levels at the day of hCG suggests that in a considerable proportion of 
patients the dosage was still reduced too late. 
In summary, in the present study ovarian response was evaluated by 
serum hormone estimates and transvaginal sonography in PC OS patients 
using a gonadotropin step-down regimen for induction of ovulation. Obtained 
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data suggest that: a) FSH serum levels show a significant decrease following 
dose reduction of administered gonadotropins, b) despite decreasing FSH 
serum concentrations follicle growth is sustained and ovulation does occur, 
c) initial estrogenic response of gonadotropin-stimulated peas patients may 
reflect differences in underlying mechanisms of ovarian dysfunction, d) using 
a step-down dose regimen the initial E, increment can be used as a predictor 
of low response or hyperresponse and doses administered can be adjusted 
accordingly_ 
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4 
Conclusions 
This thesis has focused on two major issues: a) ovarian response during 
administration of recombinant human FSH (without LH activity) to 
hypogonadotropic volunteers, and b) ovarian effects of a step-down dose 
regimen for gonadotropin induction of ovulation in anovulatory, clomiphene-
resistant pcas patients. Fevold (using pituitary gonadotropin preparations) 
(Fevold, 1941) as well as Eshkol & Lunenfeld (using purified urinary 
extractions) (Eshkol & Lunenfeld, 1967) demonstrated in the rodent model 
differential effects of FSH and LH on ovarian steroidogenesis and 
folliculogenesis. Couzinet (Couzinet et aI., 1988) confirmed the synergism 
of the gonadotropins in hypo gonadotropic females using purified urinary 
FSH. Although bioactive LH remains present in low concentrations in purified 
urinary FSH preparations, results supported the two-cell two-gonadotropin 
hypothesis indicating that suffiCient amounts of LH are needed to stimulate 
theca cell androgen production, which in turn provides the substrate to be 
converted to estrogens by FSH-induced granulosa cell enzyme activity_ 
The recently developed recombinant FSH preparations (without LH 
bioactivity) provided the challenging opportunity to investigate separate 
effects of FSH and LH in hypogonadotropic females. Data presented in the 
first part of this thesis indicate the significance of sufficient amounts of LH-
next to FSH - for adequate E, production by ovarian follicles. Moreover, it 
suggests differential regulation of mitogenic activity and estrogen synthesis 
of the granulosa cell by FSH. FSH alone can induce growth of preovulatory 
follicles without stimulating E, synthesis_ It therefore seems questionable 
whether estrogen biosynthesis is mandatory for follicular development in 
the human. Effects of low intrafollicular E, levels on oocyte quality, the 
capacity to ovulate and to transform into a corpus luteum are unknown at 
present. In addition, rhFSH stimulation in hypogonadotropicwomen resulted 
in a rise in immunoreactive INH similar to the increase in INH serum levels 
in the follicular phase of regularly cycling women, indicating that granulosa 
cell function per se is normal. It may be speculated that follicle growth and 
rising E, levels are merely associated events and that the growth of the 
follicle is driven by other as yet unidentified factors. Growth of the dominant 
follicle continued despite decreasing serum FSH levels and appeared to be 
similar to normal regular cycle. The observed dissociation between follicular 
growlh and estrogen biosynthesis should elicit future research on the 
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significance of estrogens and other intra-follicular factors for growth of ovarian 
follicles. 
tn the second part of the present thesis, patients with infertility and 
anovulation due to pcas were investigated. Based on previous studies by 
our group it has been postulated that early follicle growth is normal and 
selection of the dominant follicle is disturbed in pcas patients (Fauser, 
1994b). 'Normal' serum FSH levels are observed in these pcas patients, 
suggesting that the necessary Intercycle rise in FSH does not occur (van 
Dessel et aI., 1995). Moreover, the minimal requirement of FSH for ongoing 
follicle stimulation (FSH-'threshold') may be increased in some patients 
due to intra-ovarian abnormalities. Sufficient amounts of exogenously 
administered gonadotropins can mimic the intercycle rise or overcome this 
elevated FSH-threshold, causing increased aromatase activity and 
stimulating other intra-ovarian mechanisms and subsequent follicle growth. 
However, gonadotropin administration to oligoamenorrheic patients 
frequently causes multiple follicle development and consequently 
complications such as multiple gestation and ovarian hyperstimulation. In 
normally menstruating women, estrogen feedback mechanisms reduce 
late follicular FSH levels in such a way that multiple dominant follicles rarely 
develop. The exception to this rule is families with dizygotic twins (Martin 
et aI., 1991). It has been shown in the monkey that interference with these 
feedback actions (Zeleznik et aI., 1985) indeed results in multiple follicle 
development. In addition to the FSH-threshold (minimal required level of 
serum FSH to start recruitment of follicles), the concept of the FSH-window 
has been introduced (the number of days that serum FSH concentrations 
remain above threshold levels) (Fauser et aI., 1993b; Fauser et al., 1994c). 
In a mono-ovulatory cycle, this is the period necessary to allow just one 
follicle to gain dominance. Preservation of the selected follicle due to local 
up-regUlation despite decreasing gonadotropin levels, ensures 
monofolliculardevelopment. ather follicles from the recruited cohort go into 
atresia, since FSH levels drop below their threshold. An extended opening 
of the 'FSH-window' may interfere with dominant follicle selection, eventually 
leading to dominance of multiple follicles and ongoing follicle recruitment. 
Incremental dose regimens - even if the slow incremental protocol is 
applied (Hull, 1991; Herman et aI., 1993) still cause iatrogeniccomplications. 
In an attempt to diminish gonadotropin-related complications, it was 
suggested to increase dosages of gonadotropins in a prudent way, slowly 
surpassing the individual FSH-threshold (Brown, 1978). As yet unknown 
factors influencing the individual FSH-threshold as well as differences in 
individual pharmacodynamics appeared to be of major importance. 
Complications may also be due to prolonged maintenance of FSH levels 
above threshold values (hence a wide FSH-window) in step-up regimens. 
This continued stimulation may cause ongoing growth of multiple follicles. 
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The clinical studies discussed in the third chapter of the present thesis 
represent attempts to systematically monitor ovarian response by serum 
hormone estimates and transvaginal sonography to: 
1) Testthe hypothesis that lowering serum FSH in the late follicular phase 
would result in reduced multiple follicle development and still lead to 
ongoing growth and ovulation of the dominant follicle. 
2) Find the appropriate starting dose and decremental steps for clinical 
use of step-down gonadotropin induction of ovulation. 
3) Compare patients with 'step-down' gonadotropins exhibiting mono-
follicle development with the unstimulated normal menstrual cycle. 
4) Provide endocrine background information regarding the step-down 
dose regimen focusing on FSH serum levels. 
5) Study the predictive value of early ovarian response regarding treatment 
outcome. 
Implementation of the step-down concept in gonadotropin induction of 
ovulation can theoretically influence the number of medium-sized follicles, 
and consequently the possible incidence of complications. However, several 
questions remain to be answered including: 1) How do we reach the 
threshold dose? (i.e. can we find a parameter to predict major differences in 
individual sensitivity to FSH, and adjust the starting dose accordingly), and 
2) When should gonadotropin doses be reduced? lt should be emphasized 
that single-center, non comparative data suggest that the step-down approach 
can be used in clinical practice and does result in a favourable outcome (van 
Santbrink et aI., 1995). 
In our initial study evaluating the step-down regimen, the chosen 
gonadotropin dose of 225 IU/d for all patients (as described in section 3.1), 
appeared to cause an extended period of elevated FSH levels. This resulted 
in absent or delayed effects on serum FSH concentrations and follicle growth 
following reduction of gonadotropin dosages. In the third study, large inter-
individual variations in sonographic and steroidogenic ovarian response to 
a standardized starting dose of gonadotropins were observed. No 
correlations between steroidogenic and sonographic ovarian changes were 
noticed. However, the increment in serum E, levels following two days of 
gonadotropin (150 IU/day) administration appeared to predict high and low 
responders to a step-down dose regimen. The dose regimen of administered 
exogenous gonadotropins, - step-up (stepwise search for effective dose) 
or step-down (immediate implementation of effective dose) - may not affect 
the number of recruited follicles. If a high standard dose of gonadotropins is 
administered at the start, parameters of ovarian response may help to 
individualize further dose adjustment. Since no objective predictors of ovarian 
responsiveness to initial gonadotropin dose are available, a challenge test 
prior to initiation of therapy might be useful. We feel, based on studies in 
this thesis, together with our experience in clinical patient care (van Santbrink 
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et aI., 1995), that the concept of decremental gonadotropin dose regimens 
for Induction of ovulation is promising. Step-down dose regimens may lead 
to reduction of clinical complications during gonadotropin induction of 
ovulation. However, one should be cautious at present and it is mandatory 
to increase the number of peos patients treated in a step·down fashion. 
Moreover, multi-center, comparative studies are needed in order to obtain 
conclusions that are meaningful for clinical practice. 
74 
5 
References 
Aakvaag A. (1969) Pathways in the biosynthesis of androstenedione in the 
human ovary in vitro. Acta Endocrinol. (Copenh.), 60, 517-526. 
Abbasi R., Kenigsberg D., Danforth D., Falk R.J. and Hodgen G.D. (1987) 
Cumulative ovulation rate in human menopausal/human chorionic 
gonadotropin-treated monkeys: step-up versus step-down dose 
regimens. Fertil. Steril., 47, 1019-1024. 
Adams J., Polson D.W. and Franks S. (1986) Prevalence of polycyctic 
ovaries in women with anovulation or idiopathic hirsutism. Br. Med. J., 
293, 355-359. 
Adashi E.Y., Resnick C.E., D'Ercole A.J., Svoboda M.E. and van Wijk J.J. 
(1985) Insulin-like growth factors as intra-ovarian regulators of granulosa 
cell growth and function. Endocr. Rev., 6,400-420. 
Adashi E.Y., ResnickC.E., Hernandez E.R., Svoboda M.E. and van WijkJ.J. 
(1989) Potential relevance of insulin-like growth factor I to ovarian 
physiology: from basic science to clinical application. Semin. Reprod. 
Endocr., 7, 94-99. 
Adashi E.Y. (1993) Growth hormone as a gonadotropin: in GnRH, GnRH 
analogs, Gonadotropins and Gonadal Peptides. Paris; Bouchard P. et al. 
(Eds.), Parthenon Publishing, Carnforth, UK, p 569-591. 
Albrecht A. (1956) Human urinary gonadotropin. Rec. Progr. Horm. Res., 
12,227-301. 
Anderson R.E., Cragun J.M., Chang RJ., Stanczyk F.Z. and Lobo R.A. 
(1989) A pharmacodynamic comparison of human urinary follicle 
stimulating hormone and human menopausal gonadotropin in normal 
women and polycystic ovary syndrome. Fertil. Steril., 52, 216-220. 
Archer D.F., Zeleznik A.J. and RockeUe H.E. (1988) Ovarian follicular 
maturation in women. II. reversal of estrogen inhibited ovarian 
folliculogenesis by human gonadotropin. Fertil. Steril., 50, 555-561. 
Aschheim S. and Zondek B. (1927) Das hormon des hypo-
physenvorderlappens testobject zum nachweis des hormons. KI. 
Wschr., 6,1332-1336. 
75 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Bachus K.E., Hughes C.L., Haney AF. et al. (1990) The luteal phase in 
polycystic ovary syndrome during ovulation induction with human 
menopausal gonadotropin with and without leuprolide acetate. Fertil. 
Steril., 54, 27-31. 
Baird D.T. and Fraser I.S. (1975) Concentrations of oestrone and oestradiol 
in follicular fluid and ovarian venous blood of women. Clin. Endocrinol. 
(Oxf.), 4, 259-266. 
Baird D.T. (1983) Factors regulating the growth of the preovulatory follicle in 
the sheep and human. J. Reprod. Fert., 69, 343-352. 
Baird D.T. (1987) A model for follicular selection and ovulation: lessons from 
superovulation. J. Steroid Biochem., 27,15-23. 
Baird D.T. (1991) The ovarian cycle. In: Ovarian Endocrinology, Hillier S.G. 
(Ed.) Blackwell Scientific Publications, London, 1-24. 
Ben-Rafael Z., Strauss J.F. III, Mastroianni L. and Flickinger G.L. (1986) 
Differences in ovarian stimulation in human menopausal gonadotropin 
treated women may be related to follicle-stimulating hormone 
accumulation. Fertil. Steril., 46, 586-591. 
Bentick B., Shaw R.w., Iffland C.A., Burford G. and Bernard A (1988) A 
randomized comparitive study of purified follicle stimulating hormone 
and human menopausal gonadotropin after desensitization with Buserelin 
for superovulation and in-vitro fertilization. Fertil. Steril., 50, 79-84. 
Bergh C., Carlsson B., Olsson J.H., Selleskog U. and Hillensj6 T. (1993) 
Regulation of androgen production in cultured human thecal cells by 
insulin like growth factor I and insulin. Fertil. Steril., 59, 323-331. 
Bertrand P.V., Butt W.R., Crooke A.C. and Sutaria U.D. (1971) Analysis of 
variables in treatment of anovulation with human gonadotropins. 
Endocrinol. Exp., 22, 19-29. 
Billig H., Furuta I. and Hsueh AJ. (1993) Estrogens inhibit and androgens 
enhance ovarian granulosa cell apoptosis. Endocrinology, 5, 2204-2212. 
Blankstein J., Shalev J., Saadon T., Kukia E.E., Rabinovici J., Pariente C., 
Lunenfeld B., Serr D.M. and Mashiach S. (1987) Ovarian hyper-
stimulation syndrome: prediction by number and size of preovulatory 
ovarian follicles. Fertil. Steril., 47, 597-602. 
Blumenfeld Z. and Lunenfeld B. (1989) The potentiating effect of growth 
hormone on follicle stimulation with human menopausal gonadotropin in 
a panhypopituitary patient. Fertil. Steril., 52, 328-331. 
Boime I., Keene J., Matzuk M.M., LaPoit P. and Hsueh A.J.W. (1990) 
Expression of recombinant human FSH and LH in mammalian cells: a 
source of potential agonists and antagonists for controlling fertility. In: 
FSH alone in ovulation induction; Lunenfeld B. (Ed.) Parthenon Publishing, 
Carnforth, UK, p 45-62. 
76 
REFERENCES 
Boime I. Fares F., LaPolt P.A., Nishimori K., Perlas E. and Hsueh A.J.W. 
(1992) Structure-function studies of gonadotropins using site directed 
mutagenesis and gene transfer: design of a long-acting follitropin 
agonist. In: GnRH, GnRH Analogs, Gonadotropins and Gonadal 
Peptides; Bouchard P. et aI., (Eds.) Parthenon Publishing, Carnforth, UK, 
p 347-357. 
Bordt J., Hanker J.P. and Schneider H.P.G. (1986) Ultrasound controlled 
gonadotropin therapy of anovulatory infertility. Fertil. Steril., 46, 818-
822. 
Borth R., Lunenfeld B. and de Watteville H. (1954) Activite menotrope d'une 
extrait d'urines de femmes en menopause. Experientia, 40, 266-268. 
Borth R., Lunenfeld B., Riotton G. and de Watteville H. (1957) Activite 
gonadotrope d'un extrait des femmes en menopause. Experientia, 13, 
115-116. 
Brown J.B. (1955) Achemical method fordeterminationof oestriol, oestrone, 
and oestradiol in human urine. Biochem. J., 60,185-193. 
Brown J.B., Macleod S., Macnaughton C., Smith M.A. and Smyth A (1968) 
A rapid method of measuring oestrogens in human urine using a semi-
automatic extractor. J. Endocrinol., 40, 5-11. 
BrownJ.B., Evans J.H., Adey F.T., Taft H.P. and Townsend L. (1969) Factors 
influencing the induction of fertile ovulation with human gonadotropins. J. 
Obstet. Gynaecol. Brit. Comm., 76, 289-297. 
Brown J.B. (1978) Pituitary control of ovarian function-concepts derived 
from gonadotrophin therapy. Aust. N.Z. J. Obstet. Gynaecol., 18,47-54. 
Brown R.A. and Swanson Beck .J. (1990) Medical statistics and 
microcomputers. Br. Med. J., 13-15. 
Butler J.K. (1969) Time course of urinary oestrogen estimation after various 
schemes of therapy with human follicle stimulating hormone. Proc. R. 
Soc. Med., 62, 19-34. 
Buvat J., Buvat-Herbaut M., Marcolin G., Dehaene J.L., Verbecq P. and 
Renouard O. (1989) Purified follicle stimulating hormone in polycystic 
ovary syndrome: slow administration is safer and more effective. Fertil. 
Steril., 52, 553-559. 
Cabau A, and Bessis R. (1981) Monitoring of ovulation induction with 
human menopausal gonadotropin and human chorionic gonadotropin by 
ultrasound. Fertil. Steril., 36, 178-182. 
Carey H. (1976) Induction of ovulation resulting in notuplet pregnancy. Aust. 
NZ. J. Obstet. Gynaecol., 16, 200-202. 
77 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Caruso A., Fortini A., Fulghesu A.M., Pistilli E., Cuccinelli F., Lanzone A. and 
Mancuso S. (1993) Ovarian sensitivity to follicle stimulating hormone 
during the follicular phase of the human menstrual cycle and in patients 
with polycystic ovarian syndrome. Fertil. Steril., 59,115-120. 
Caspi E., Levin S., Bukovsky I. and Weinraub Z. (1974) Induction of ovulation 
with human gonadotropins after clomiphene failure in menstruating 
ovulatory infertility patients. Israel J. Med. Sci., 10,249-255. 
Channing C.P., Cagliano P., Tanabe K., Fortuy A. and Cortes-Prieto J. (1985) 
Demonstration of a gradient in inhibin activity,oestrogen, progesterone and 
androstenedione in follicular fluid, ovarian vein blood and peripheral 
blood of normal women. Fertil. Steril., 43,142-145. 
Chappel S.C., Ulloa-Aguirre A. and Coutifaris C. (1983) Biosynthesis of 
follicle stimulating hormone. Endocr. Rev., 4,179-210. 
Chappel S.C. and Howles C. (1991) Reevaluation of the roles of luteinizing 
hormone and follicle stimulating hormone in the ovulatory process. Hum. 
Reprod., 9, 1206-1212. 
Charbonnel B., Krempf M., Blanchard P. et al. (1987) Induction of ovulation 
in polycystic ovary syndrome with a combination of a luteinizing hormone-
releasing hormone analog and exogenous gonadotropins. Fertil. Steril., 
47,920-927. 
Check J.H. (1980) Treatment of cervical factor with combined high dose 
estrogen and human menopausal gonadotropin. Fertil. Steril., 33, 562-565. 
Check J.H., Nowroozi K., Chase J.S., Nazari A., Shapse D. and Vaze M. 
(1990) Ovulation induction and pregnancies in 100 consecutive women 
with hypergonadotropic amenorrhea. Fertil. Steril., 53, 811-816. 
Chikazawa K., Araki S., and Tamada T. (1986) Morphological and 
endocrinological studies on follicular development during the human 
menstrual cycle. J. Clin. Endocrinol. Metab., 62, 305-313. 
Chong A.P., Rafael R.W. and Forte C.C. (1986) Influence of weight in the 
induction of ovulation with human menopausal gonadotropin and human 
chorionic gonadotropin. Fertil. Steril., 46,599-603. 
Coble V.D., Kohler P.O., Cargille C.M. and Ross G.T. (1969) Production 
rates and metabolic clearance rates of human follicle stimulating hormone 
in premenopausal and postmenopausal women. J. Clin.lnvest., 48, 359-
369. 
Cole H.H. and Hart G.H. (1930) The potency of blood serum of mares in 
progressive stages of pregnancy in effecting the sexual maturity of rats. 
Am. J. Obstet. Gynecol., 93, 57-60. 
Coleman B.G., ArgerP.H., Grumbach K., Menard M.K., Mintz M.C. and Allen 
K.S. (1988) Transvaginal and transabdominal sonography: prospective 
comparison. Radiology, 168, 639-643. 
78 
REFERENCES 
Col lip J.B., Selye H. and Thomson D.L. (1933) Observations on the effect 
of hypophysectomy on lactation. Nature, 131, 56-58 
Cook A.S., Webster B,W., Terranova P.F. and Keel B.A. (1988) Variation in 
the biologic and biochemical characteristics of human menopausal 
gonadotropin. Fertil. Steril., 49, 704-712. 
Couzinet B., Lestrat N., Brailly S., Forest M. and Schaison G. (1988) 
Stimulation of ovarian follicular maturation with pure follicle stimulating 
hormone in women with gonadotropin deficiency. J. Clin. Endocrinol. 
Metab., 66, 552-556. 
Crooke AC., Sutaria U.D. and Bertrand P. (1971) Comparison of daily with 
twice weekly injections of follicle stimulating hormone for treatment of 
failure of ovulation. Am. J. Obste\. Gynecol., 111, 405-412. 
Dahl K.D., Jia X.C. and Hsueh AJ.W. (1989) Granulosa cell aromatase 
bioassay for follicle-stimulating hormone. Methods Enzymol., 168, 414-
422. 
Davoren B. and Hsueh AJ. W. (1986) Growth hormone increases ovarian 
levels of immunoreactive sometidin-cl insulin-like growth factor-I in vivo. 
Endocrinology, 118, 888-890. 
Diamond M.P. and Wentz A.C. (1986) Ovulation induction with human 
menopausal gonadotropins. Obste\. Gynecol. Surv., 41,480-490. 
Diczfaluzy E. and Harlin J. (1988) Clinical-pharmacological studies on 
human menopausal gonadotrophin. Hum. Reprod., 3, 21-27. 
Dizerega G.S. and Hodgen G.D. (1981) Folliculogenesis in the primate 
ovarian cycle. Endocr. Rev., 2, 27-49. 
Dodson W.C., Hughes C.L., Whitesides D.B. and Haney AF. (1987) The 
effect of leuprolide acetate on ovulation induction with human menopausal 
gonadotropins in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 
65,95-100. 
Dodson W.C., Hughes C.L., Yancy S.E. and Haney A.F. (1989) Clinical 
characteristics of ovulation induction with human menopausal 
gonadotropins with and without leuprolide acetate in polycystic ovary 
syndrome. Fertil. Steril., 52, 915-918. 
Dor J., Itzkovic D.G. and Mashiach S. (1980) Cumulative conception rates 
following gonadotropin therapy. Am. J. Obste\. Gynecol., 136, 102-105. 
Dor J., Ben-Shlomo I., Lunenfeld B., Pariente C., Levran D., Karasik A., 
Seppala M. and Mashiach S. (1992) Insulin like growth factor-I (IGF-I) 
may be not essential for ovarian follicualr development: Evidence from 
IGF-I deficiency. J. Clin. Endocrinol. Metab., 74, 539-542. 
Edwards R.G., Fowler R.E., Gore-Langton R.E., Gosden R.G., Jones E.C., 
Readhead C. and Steptoe P.C. (1977) Normal and abnormal growth of 
follicles in mouse, rat and human ovaries. J. Reprod. Fertil., 51,237-263. 
79 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Eissa M.K., Hudson K., Docker M.F., Sawers R.S. and Newton J.R. (1985) 
Ultrasound follicle diameter measurement; an assessment of 
interobserver and intraobserver variation. Fertil. Steril., 44, 751-754. 
EI Roey A, Chen X., Roberts V.J., LeRoith D., Roberts C.T. and Yen S.C.C. 
(1993) Expression of Insulin-like Growth Factor (IGF-I) and IGF-II and 
the IGF-I, IGF-II, and insulin receptor genes and localization of the gene 
products in the human ovary. J. Clin. Endocrinol. Metab., 77,1411-1418. 
Engle E.T. (1929) Ovarian responses. Differences elicited by treatment with 
urine from pregnant women and by freshly implanted anterior lobe. Am. 
J. Med. Assoc., 93, 276-277. 
Erickson G.F., Hsueh AJ,W., Quigley M.E., Rebar R,W. and Yen S.S.C. 
(1979) Functional stUdies of aromatase activity in human granulosa cells 
from normal and polycystic ovaries. J. Clin. Endocrinol. Metab., 49, 514-
519. 
Erickson G.F., Wang C. and HsuehAJ.W. (1979) FSH induction offunctional 
LH receptors in granulosa cells cultured in a chemically defined medium. 
Nature, 279, 336-338. 
Erickson G.F. and Yen S.S.C. (1984) New data on follicle cells in polycystic 
ovaries: a proposed mechanism for the genesis of cystic follicles. Semin. 
Reprod. Endocr., 2, 231-243. 
Erickson G.F. (1986) An analysis of follicular development and ovum 
maturation. Semin. Reprod. Endocrinol., 4, 233-254. 
Eshkol A. and Lunenfeld B. (1967) Purification and separation of follicle 
stimulating hormone (FSH) and luteinizing hormone from human 
menopausal gonadotrophin; III. Effects of a biologically apparently pure 
FSH preparation on ovaries and uteri of intact immature mice. Acta 
Endocrinol. (Copenh.), 54, 91-95. 
Evans H.M., Gustus E.L. and Simpsom M.E. (1933) The growth and gonad-
stimulating hormones of the anterior hypophysis. University of California 
Press, Berkeley, California. 
Falck B. (1959) Site of production of oestrogen in the rat ovary as studied in 
microtransplants. Acta Physiol. Scand., 163, 1-100. 
Farine D., Mashiach S., Ben-Rafael Z., OelsnerG., Blankstein J., Lunenfeld 
B. and Serr D.M. (1982) Retrospective evaluation of human menopausal 
gonadotropin and human chorionic gonadotropin induction of ovulation 
in galactorrheic and hyperprolactinemic women. Fertil. Steril., 38,187-
189. 
Fauser B.C.J.M. and Hsueh AJ.W. (1988) Growth factors: intragonadal 
regulation of differentiated functions. In: Imura H, Chizume K, Yoshida 
S, (Ed.) Progress in Endocrinology. Amsterdam: Elsevier Science 
Publishers, 451-456 (Excerpta Medica; vol. 1 ). 
80 
REFERENCES 
Fauser B.C.J.M. and Hsueh AJ.w. (1989) Bioassays of gonadotropins: 
Background and clinical applications. In Serono Symposia, Structure-
function relationship of gonadotropins, vol 65, edited by D. Bellet, J.M. 
Bidart. New York, Raven Press, p 123-136. 
FauserB.C.J.M., Soto D., Czekala N.M. and Hsueh A.J.w. (1989) Granulosa 
cell aromatase bioassays: changes of bioactive FSH levels in the female. 
J. Steroid Biochem., 33, 721-726. 
Fauser B.C.J.M., Bogers J.W.J., Hop W.C.J. and de Jong F.H. (1990) 
Bioactive and immunoreactive FSH in serum of normal and oligospermic 
men. Clin. Endocrinol. (Oxf.), 32, 433-442. 
Fauser B.C.J.M., Pache T.D., Lamberts S.w.J., Hop W.C.J., de Jong F.H. 
and Dahl K.D. (1991) Serum bioactive and immunoreactive luteinizing 
hormone and follicle-stimulating hormone levels in women with cycle 
abnormalities, with or without polycystic ovarian disease. J. Clin. 
Endocrinol. Metab., 73, 811-817. 
Fauser B.C.J.M. and de Jong F.H. (1993) Gonadotropins in polycystic ovary 
syndrome. Ann. N.Y. Acad. Sci., 687, 150-161. 
Fauser B.C.J.M., Pache T.D. and Schoot D.C. (1993a) Dynamics of human 
follicle development. In: Ovarian cells interaction: genes to physiology, 
Hsueh AJW and Schomberg D (Eds.), Serono International Symposia 
Series, Raven Press, New York, p 134-147. 
Fauser B.C.J.M., Donderwinkel P. and Schoot D.C. (1993b) The step-down 
principle in gonadotrophin treatment and the role of GnRH analogues. 
Baill. Clin. Obstet. Gynaecol., 7, 309-330. 
Fauser B.C.J.M. (1993c) Clinical use of gonadotropins in women. In: GnRH, 
GnRH Analogs, Gonadotropins and Gonadal Peptides; Bouchard P. 
et al. (Eds.), Parthenon Publishing, Carnforth, UK, p 467-480. 
Fauser B.C.J.M. (1994a) Step-down follicle stimulating hormone regimens 
in polycystic ovary syndrome. In: Ovulation Induction: Basic Science and 
Clinical Advances; Filicori M. and Flamigni C. (Eds.) Elsevier Science 
B.V., Amsterdam, p 153-162. 
Fauser B.C.J.M. (1994b) Observations in favor of normal early follicle 
development and disturbed dominant follicle selection in polycystic ovary 
syndrome. Gynecol. Endocrinol., 8, 75-82. 
Fauser B.C.J.M. (1994c) Polycystic ovary syndrome: normal and abnormal 
follicle development. In Ovarian Endocrinopathies; Schats & Schoemaker 
(Eds.) Parthenon Publishing, Carnforth, UK, p 117-127. 
Fevold H.L., Hisaw F.L., Hellbaum A and Hertz R. (1933) Anterior lobe or 
anterior lobe-like sex hormone combinations on growth of ovaries of 
immature rats. Proc. Soc. Exp. BioI. Med., 30, 914-916. 
81 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Fevold H.L. (1941) Synergism of follicle stimulating and luteinizing hormone 
in producing estrogen secretion. Endocrinology, 28, 33-36. 
Finkler R.S. (1949) Evaluation of hormonal and radiation therapy in 190 
cases of functional sterility and secondary amenorrhoea. Am. J. Obste!. 
Gynecol., 58, 559-564. 
Fleming R., Adam A.H., Barlow D.H., Black W.P., Macnaughton M.C. and 
Coutts J.R.T. (1982) A new systematic treatment for infertile women with 
abnormal hormone profiles. Br. J. Obste!. Gynaecol., 89, 80-83. 
Fleming R., Haxton M.J., Hamilton M.P.R., McCune G.S., Black W.P., 
Macnaughton M.C. and Coutts J.R.T. (1985) Succesful treatment of 
infertile women with oligomenorrhoea using combination of LHRH agonist 
and exogenous gonadotropins. Br. J. Obste!. Gynaecol., 92, 369-373. 
Fleming R. and CouttsJ.R.T. (1988) LHRH analogues for ovulation induction, 
with particular reference to polycystic ovary syndrome. Baill. Clin. Obstet. 
Gynecol., 2, 677-678. 
Forman G.F., Robinson J., Yudkin P., Egan D., Reynolds K. and Barlow 
D.H. (1991) What is the true follicular diameter: an assesment of the 
reproducibility of transvaginal ultrasound monitoring in stimulated cycles. 
Fertil. Steril., 56, 989-992. 
Franchimont P. (1971) Secretion normale et pathologique de la 
somatotrophine et des gonadotrophines humaines. Masson, Paris, 
p 83-92 
Franchimont P. and Burger H. (1975) Production and metabolism of the 
gonadotropins. In: Human growth hormone and gonadotrophins in health 
and disease. North Holland Publishing Co Amsterdam, p.111-124. 
Franks S. (1989) Polycystic ovary syndrome: a changing perspective. Clin. 
Endocrinol. (Oxf.), 31, 87-120. 
Frasier S.D. and Foley T.P. (1994) Clinical Review 58: Creutzfeldt-Jacob 
Disease in recipients of pituitary hormones. J. Clin. Endocrinol. Metab., 
6,1277-1284. 
Freundl G., Terinde R., Dis!lerW., Baumeister A., HerbergerJ. and Kozlowski 
P. (1981) Serum levels of oestradiol-17P and luteinizing hormone related 
to follicular growth as monitored by ultrasound in women with normal 
menstrual cycles. Acta Endocrinol., 96,370-376. 
Friesen H.C. and Tolis G. (1977) The use of bromocriptine inthe galactorrhea 
ammenorrhea syndromes - the Canadian cooperative 
study. Clin. Endocrinol. (Suppl.), 6, 91-99. 
Fritz M.A. and Speroff L. (1982) The endocrinology of the menstrual cycle: 
The interaction of folliculogenesis and neuroendocrine mechanisms. 
Fertil. Steril., 38, 509-529. 
82 
REFERENCES 
Friilich M., Brand E.C. and van Hall E.V. (1976) Serum levels of unconjugated 
aetiocholanolone, androstenedione, testosterone, dehydroepi-
androsterone, aldosterone, progesterone, and oestrogens during the 
normal menstrual cycle. Acta Endocrinol. (Copenh.), 81, 548-562. 
Funduk-Kurjak B. and Kurjak A. (1982) Ultrasound monitoring of follicular 
maturation and ovulation in normal menstrual cycle and in ovulation 
induction. Acta Obstet. Gynecol. Scand., 61,329-335. 
Galway A.B., Hsueh A.J.W., Keene J.L., Yamoto M., Fauser B.C.J.M. and 
Boime I. (1990) In vitro and in vivo bioactivity of recombinant foilicle-
stimulating hormone and partially deglycosylated variants secreted by 
transfected eukaryotic cell lines. Endocrinology, 127, 93-99. 
Garcia J.E., Jones G.E. and Wentz CA (1977) The use of clomiphene 
citrate. Fertil. Steril., 28, 707-717. 
Gemzell C. and Roos P. (1966) Pregnancies following treatment with human 
gonadotropins. Am. J. Obstet. Gynecol., 94, 490-496. 
Gilling-Smith C. & Franks S. (1993) Advances in induction of ovulation. 
Curro Opin. Obstet. Gynecol., 2, 136-140. 
Glasier A.F., Baird D.T. and Hillier S.G. (1989) FSH and control of follicular 
growth. J. Steroid Biochem., 32,1670-1671. 
Golan A., Ron-el R., Herman A., Soffer O.Y., Weinraub Z. and Caspi E. 
(1989) Ovarian hyperstimulation syndrome: an update review. Obstet. 
Gynecol. Surv., 44, 430-440. 
Gorlitzky GA, Kase N.G. and Speroff L. (1972) Ovulation and pregnancy 
rates with clomiphene citrate. Obstet. Gynecol., 39, 389-396. 
Gougeon A. (1982) Rate of follicular growth in the human ovary. In Follicular 
Maturation and Ovulation; Rolland R. et aI., (Eds.), Excerpta Medica, 
Amsterdam, p 155-163. 
Gougeon A., and Testart J. (1990) Influence of human menopausal 
gonadotropin on the recruitment of human ovarian follicles. Fertil. Steril., 
54, 848-852. 
Greenblatt A.B., Barfield W.E., Jungck E.J. and Ray A.W. (1961) Induction 
of ovulation with MRLl41. Preliminary report. JAMA, 178,101-106. 
Grot jan H.E., Zalesky D.O., Stumpf T.T, Kinder J.E. and Nett T.M. (1992) 
Does gonadotropin heterogeinity playa Significant role in regulating 
reproductive function? In: GnRH, GnRH Analogs, Gonadotropins and 
Gonadal Peptides. Bouchard P. et al. (Eds.), Parthenon Publishing, 
Carnforth, UK, p 397-409. 
Hackeloer B.J. 1978 Ultrasonic demonstration of follicular development. 
Lancet, i, 941-945. 
83 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Hamblen E.C. and Davies C.D. (1945) Treatment of hypoovarianism by the 
sequential and cyclic administration of equine and chorionic 
gonadotropins. Am. J. Obstet. Gynecol. 50,137-141. 
Hamilton-Fairley D., Kiddy D., Watson H., Sagle M. and Franks S. (1991) 
Low dose gonadotrophin therapy for induction of ovulation in women with 
polycystic ovary syndrome. Hum. Reprod., 6, 1096-1099. 
Hancock K.W., Stitch S.R" Oakey R.E., Scott J.S., Levell M.J. and Ellis 
F.R. (1970) Ovulation stimulation. Problems of prediction of response 
to gonadotrophins. Lancet, ii, 482-485. 
Haning R.V., Austin C.W., Kuzma D.L., Shapiro S.S. and ZweibeIW.J. (1982) 
Ultrasound evaluation of estrogen monitoring for induction of ovulation 
with menotropins. Fertil. Steril., 37, 627-632. 
Haning R.V., Austin CW., Carlson I.H., Kuzma D.L., Shapiro S.S. and 
Zweibel W.J. (1983) Plasma estradiol is superior to ultrasound and urinary 
estriolglucuronide as a predictor of ovarian hyperstimulation during 
induction of ovulation with menotropins. Fertil. Steril., 40, 31-36. 
Haning R.V., Boehlein L.M., Carlsson I.H, et al. (1984) Diagnosis specific 
serum 17P estradiol (E2) upper limits for treatment with menotropins 
using 1251 direct E2 assay. Fertil. Steril., 42, 882-887. 
Harlin J., Kahn S.A. and Diczfaluzy E. (1986) Molecular composition of 
luteinizing hormone and follicle stimulating hormone in commercial 
gonadotropin preparations. Fertil. Steril., 46, 1055-60. 
Healy D.L., Kovacs G.T., Pepperell R.J. and Burger H.G. (1980) A normal 
cumulative conception rate after human pituitary gonadotropin. Fertil. 
Steril., 34, 341-345. 
Hedon B., Bringer J., Arnal F., Humeau C., Boulot P., Audibert F., Benos P., 
Neveu S., Mares P., Laffargue F. and Viala J.L. (1991) The use of GnRH 
agonist with HMG for induction or stimulation of ovulation. Baill. Clin. 
Obstet. Gynecol., 5, 577-587. 
O'HerlihyC., deCrespignyL.J., LopataA., Johnston I., Houl! I. and Robinson 
H.P. (1980) Preovulatory follicular size: a comparison of ultrasound and 
laparoscopic measurements. Fertil. Steril., 34, 24-26. 
O'Herlihy C., Evans J.H" Brown J.B., de Crespigny L.J. and Robinson H.P. 
(1982) Use of ultrasound in monitoring ovulation induction with human 
pituitary gonadotropins. Obstet. Gynecol., 60, 577-584. 
Herman A., Ron-EI R., Golan A., SofferY., Bukovsky I. and Caspi E. (1993) 
Overstimulated cycles under lOW-dose gonadotrophins in patients with 
polycystic ovary syndrome: Characterization and management. Hum. 
Reprod., 8,30-34. 
84 
REFERENCES 
Hernandez E.R., Resnick C.E., Svoboda M.E., van Wijk J.J., Payne DW. 
and Adashi E.Y. (1988) Somatomedin-CI insulin-like growth factor as an 
enhancer of androgen biosynthesis by cultured rat ovarian cells. 
Endocrinology, 122, 1603-1612. 
Hild-Petito S., Stouffer R.L. and Brenner R.M. (1988) Immonocytochemical 
localization estradiol and progesterone receptors in the monkey 
throughout the menstrual cycle. Endocrinology, 123,2896-2905. 
Hillier S.G., Reichert L.G. and Van Hall E.V. (1981) Control of preovulatory 
follicular estrogen biosynthesis in the human ovary. J. Clin. Endocrinol. 
Metab. 52, 847-856. 
Hillier S.G., Harlow C.R. and Shaw H.J. (1988) Cellular aspects of 
preovulatory folliculogenesis in primate ovaries. Hum. Reprod. 3, 507-
511. 
Hillier S.G., Yong E.L., Illingworth P.J., Baird D.T., Schwall R.H. and Mason 
A.J. (1991) Effect of recombinant inhibin on androgen synthesis in 
cultured human thecal cells. Mol. Cell. Endocrinol. 75, R1-R6 
Hirschfield A.N. (1982) Rescue of atretic follicles in vitro and in vivo. BioI. 
Reprod., 40,181-186. 
Hisaw F.L. (1947) Development of the Graafian follicle and ovulation. 
Physiol. Rev., 27, 95-119. 
Hodgen G.D. (1982) The dominant ovarian follicle. Fertil. Steril., 38, 281-
298. 
Hoffman D.I., Lobo RA, Campeau J.D., Tsai H.M., Holmberg EA, Ono T., 
Frederick J.J., Pfatt L.D. and diZerega G.S. (1985) Ovulation induction in 
clomiphene resistant anovulatory women: Differential follicular response 
to purified urinary follicle-stimulating hormone versus purified urinary 
FSH and luteinizing hormone. Fertil. Steril., 60, 922-926. 
Homburg R., Esilel A, Abdalla H.1. and Jacobs H.S. (1988) Growth hormone 
facilitates ovulvtion induction by gonadotropins. Clin. Endocrinol. (Ox!.) 
29,113-117. 
Homburg R., Eshel A., Kilborn J., Adams J. and Jacobs H.S. (1990) 
Combined luteinizing hormone releasing hormone analogue and 
exogenous gonadotropins for the treatment of infertility associated with 
polycystic ovaries. Hum. Reprod., 5, 32-35. 
Hompes P.GA, van Weissenbruch M.M., Burger C.W. and Schoemaker J. 
(1986) The additional use of buserelin in HMG-HCG induction in PCO: A 
double blind controlled study. Prog. Clin. BioI. Res., 225, 391-399. 
Hsueh A.JW., Adashi E.Y., Jones P.B.C. and Welsh T.H. (1984) Hormonal 
regulation of the differentiation of cultured granulosa cells. Endocr. Rev., 
5,76-127. 
85 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Hsueh AJ.w. (1986) Paracrine mechanisms involved in granulosa cell 
differentiation. J. Clin. Endocrinol. Metab., 15, 117-127. 
Hsueh AJ.W., Dahl K.D., Vaughan J., Tucker E., Rivier J., Bardin C.w. and 
Vale W. (1986) Heterodimers and homodimers of inhibin subunits have 
different paracrine action in the regulation of luteinizing hormone-
stimulated androgen biosynthesis. Proc. Natl. Acad. Sci., 84, 5082-5085. 
Hughesdon P.E. (1982) Morphology and morphogenesis of the Stein-
Leventhal ovary and so-called "hyperthecosis". Obste!. Gynecol. Surv., 
37,59-77. 
Hughes E.G., Federkow D.M., Daya S., Sagle M., de Koppel P. and Collins 
J. (1992) Routine use of gonadotrpin releasing hormone agonist prior to 
in vitro fertilisation and gamete intra faloppian tube transfer: a meta-
analysis of randomized controlled trials. Fertil. Steril., 58, 888-896. 
Hull M.G.R. (1989) Polycystic ovarian disease: clinical aspects and 
prevalence. Res. Clin. Forums, 11, 21-30. 
Ibrahim Z.H.Z., Matson PL, Buck P. and Lieberman BA (1991) The use of 
biosythetic human growth hormone to augment ovulation induction with 
buserelin acetate/human menopausal gonadotropin in women with a 
poor ovarian response. Fertil. Steril., 55, 202-204. 
Igarashi M. and Matsumoto S. (1957) Induction of human ovulation by 
individualized gonadotrophin therapy in two phases. Am. J. Obste!. 
Gynecol., 79, 1294-1298. 
Insler V., Melmed H., Eichenbrenner I., Serr D.M. and Lunenfeld B. (1972) 
The cervical score; a simple semiquantitative method for monitoring of 
the menstrual cycle. In!. J. Gynecol. Obste!., 10, 6:223-228. 
Itskovitz J. and Sealey J.E. (1987) Ovarian prorenin renin-angiotensin 
system. Obste!. Gynecol. Surv., 42, 545-549. 
Jacobson A and Marshall J.R. (1969) Ovulation response rate with human 
menopausal gonadotropins of vaying FSH/LH ratios. Fertil. Steril., 20, 
171-175. 
Jacobs H.S., Bouchard P., Conway G.S., Homburg R., Lahlou N., Mason 
B., Ostergaard H., Owen E.J. and Shoham Z. (1991) Role of growth 
hormones in infertility. Horm. Res. 36, 61-65. 
Jia X. and Hsueh A.J.W. (1984) Homologous regulation of hormone 
receptors: luteinizing hormone increases its own receptors in cultured 
rat granulosa cells. Endocrinology, 115, 2433-9. 
Jia X.C., Kalmijn J. and Hsueh Z.J.W. (1986) Growth hormone enhances 
follicle stimulating hormone induced differentiation of cultured rat 
granulosa cells. Endocrinology, 118, 1401-1409. 
Johnson T.R. and Peterson E.P. (1979) Gonadotropin induced pregnancies 
following 'premature ovarian failure'. Fertil. Steril., 31, 351-356. 
86 
REFERENCES 
Keene J.L., Matzuk M.M., Otani T., Fauser B.C., Galway A.B., Hsueh A.J. 
and Boime I. (1989) Expression of biologically active human fOllitropin in 
Chinese hamster ovary cells. J. BioI. Chem., 246, 4769-4775. 
Kerin J.F., Edmonds O.K., Warnes G.M., Cox L.W., Seamark R.F., Matthews 
C.D., Young G.B. and Baird D.T. (1981) Morphological and functional 
relations of graafian follicle growth to ovulation in women using ultrasonic, 
laparoscopic and biochemical measurements. Br. J. Obste!. Gynaecol., 
88, 1-90. 
Kessel B., Liu Y.X., Jia X.C. and Hsueh A.J.W. (1985) Autocrine role of 
estrogens in the augmentation of luteinizing hormone receptor formation 
in cultured rat granulosa cells. BioI. Reprod., 32, 1038-1050. 
Kistner R.W. (1976) Sequential use of clomiphene citrate and human 
menopausal gonadotropin in induction of ovulation. Fertil. Steril., 27, 
72-77. 
Kloosterboer H.J. (1994) Biological characteristics of recombinant FSH 
isohormones. Hum. Reprod. 9, suppl 4, abs 119, p 52-53. 
Kovacs G.T., Dennis P.M., Shelton R.J., Outch K.H., McLean R.A., Healy 
D.L. and Burger H.G. (1984) Induction of ovulation with human pituitary 
gonadotropins: a 12 years experience. Med. J. Aus!., 140, 575-579. 
Kratochwil A., Urban G.V. and Friedrich F. (1972) Ultrasonic tomography of 
the ovaries. Ann. Chir. Gynaecol., 61,211-214. 
Kratochwil A., Jentsch K. and Bresina K. (1973) Ultraschall· anatomie des 
weiblichen Beckens und ihre klinische Bedeutung. Arch. Gynaekol., 
214, 273-275. 
Kurachi K., Aono T., Suzuki M., Hirano M., Kobayashi T. and Kaibara M. 
(1985) Results of HMG (Humegon)·HCG therapy in 6096 treatment 
cycles of 2166 Japanese women with anovulatory infertility. Eur. J. 
Obste!. Gynecol. Reprod. BioI., 19,43-51. 
Lahlou N., Le Nestour E., Chanson P., Seret·Begue D., Bouchard P., Roger 
M. and Warnet A. (1993) Inhibin and follicle stimulating hormone levels 
in gonadotroph adenomas: evidence of a positive correlation with tumour 
volume in men. Clin. Endocrinol. (Oxf.), 38, 301-309. 
Lamb E.J. and Cruz A. (1972) Data collection and analysis in an infertility 
practice. Fertil. Steril., 23, 310-315. 
Lanzone A., Fulghesu A.M., Spina M.A., Apa R., Menini E., Caruso A. and 
Mancuso S. (1987) Succesfull induction of ovulation and conception with 
combined gonadotropin'releasing hormone agonist plus purified follicle 
stimulating hormone in patients with polycystic ovarian disease. J. Clin. 
Endocrinol. Metab., 65, 1253-1258. 
87 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Leathum J.H. and Rakoff A.E. (1948) Anti hormones due to equine 
gonadotrophins. Endocrinology, 8, 262-268. 
Leerentveld R.A., v. Gent I., v.d. Stoep M., Alberda A.T.H. and Wladimiroff 
J.w. (1984) Comparison of graafian follicle dimensions as determined by 
static and real-time sector scanning. Fertil. Steril., 42, 292-301. 
Leerentveld R.A. (1988) Ultrasound and plasma 17P oestradiol in the follicular 
phase- particular in I.V.F. cycles. Thesis Academic Hospital Dijkzigt & 
Erasmus University Rotterdam, The Netherlands. 
Leonard S.L. and Smith P.E. (1934) The hypophyseal-like qualities of the 
gonadotropic principle found in the urine of certain individals. Am. J. 
Physiol., 108,22-32. 
Louwerens B. (1969) The clinical significance of FSH/LH ratio in 
gonadotropin preparations of human origin. Acta Obstet. Gynecol. Scand., 
[suppl.) 48, 31-36. 
Lunenfeld B., Menzi A. and Volet B. (1960) Clinical effects of a human 
postmenopausal gonadotropin. Rass. Clin. Ter Sci. Affini, 59,213-216. 
Lunenfeld B. and Insler V. (1974) Classification of ammenorrhoeic states 
and their treatment by ovulation induction. Clin. Endocrin. (Oxf.), 3, 
223-237. 
Lunenfeld B. and InslerV. (1978) Gonadotropins. In: DiagnosisandTreatment 
of Functional Infertility. Lunenfeld B. and Insler V. (Eds.) Berlin, Thieme 
Verlag p 76-80. 
Lunenfeld B., Mashiach S. and Blankstein J. (1985) Induction of ovulation 
with gonadotrophins. In Shearman R.P. (Ed.) Clin. Reprod. Endocrinol., 
New York, Churchill Livingstone p 523-533. 
MacGregor A.H., Johnson J.E. and Bunde C.A. (1968) Further clinical 
experience with clomiphene citrate. Fertil. Steril., 19,616-620. 
Magoffin D.A., Kurtz K.M. and Erickson G.F. (1990) Insulin-like growth 
factor-I selectively stimulates cholesterol side-chain cleavage expression 
in ovarian theca-interstitial cells. Mol. Endocrinol., 4, 489-496. 
Mannaerts B., de Leeuw R., Geelen J., van Ravenstein A., van Wezenbeek 
P., Schuurs A. and Kloosterboer H. (1991) Comparative in vitro and in 
vivo studies on the biological characteristics of recombinant human 
follicle stimulating hormone. Endocrinology, 129,2623-2630. 
Mannaerts B., Shoham Z., Schoot B., Bouchard P., Harlin P., Fauser B., 
Jacobs H., Rombout F. and Coelingh Bennink H.J.T. (1993) Single-dose 
pharmacokinetics and pharmacodynamics of recombinant human follicle-
stimulating hormone (Org 32489) in gonadotropin deficient volunteers. 
Fertil. Steril., 59, 108-114. 
88 
REFERENCES 
Mango D., Scirpa P., Spina M.A., Battaglia F., Tartaglia E., Manna P., Ricci 
S. and lacona T. (1988) Ultrasonic and endocrinologic relationships in 
spontaneous and induced follicular phase. J. Endocrinol. Invest., 11, 
7-13. 
Marrs R.P., March C.M. and Mishell D.R. (1980) A comparison of clinical 
and laboratory methods in monitoring human menopausal gonadotropin 
therapy. Fertil. Steril., 34, 542-547. 
Marshall J.R., Jacobson A. and Hammond C.B. (1969) Dose response 
relationships of ovulation induction with human menopausal 
gonadotropins. J. Clin. Endocrinol. Metab., 29, 106-111. 
Martin N.G., Robertson D.M., Chenevix-Trench G., de Kretser D.M., Osborne 
J. and Burger H.G. (1991) Elevation of follicular phase inhibin and 
luteinizing hormone levels in mothers of dizygotic twins suggests 
nonovarian control of human multiple ovulation. Fertil. Steril., 56, 469-
474. 
McArdle C.R., Seibel M.M., Weinstein F., Nickerson C. and Taymor M.L. 
(1983) Induction of ovulation monitored by ultrasound. Radiology, 148, 
809-812. 
McFaul P.B., Traub A.I. and Thompson W. (1990) Treatment of clomiphene 
citrate-resistant polycystic ovary syndrome with pure follicle stimulating 
hormone or human menopausal gonadotropin. Fertil. Steril., 53, 792-797. 
McLachlan R.I., Robertson D.M .. Healy D.L., Burger H.G. and de Kretser 
D.M. (1987) Circulating immunoreactive inhibin levels during the normal 
human menstrual cycle. J. Clin. Endocrinol. Metab., 65,954-961. 
McNatty K.P., Makris A., DeGrazia C., Osthanondh R. and Ryan K.J. (1979) 
The production of progesterone, androgens, and estrogens by granulosa 
cells, thecal tissue and stromal tissue from the human ovaries in vitro. J. 
Clin. Endocrinol. Metab .. 49, 687-699. 
McNatty K.P. (1979) Relationship between plasma prolactin and the 
endocrine microenvironment of the developing follicle. Fertil. Steril., 32, 
1547-1558. 
McNatty K.P., Moore Smith D., Makris A., Osthanondh R. and Ryan KJ. 
(1979) The microenvironment of the follicle: inter-relationships among 
the steroid levels in antral fluid, the population of granulosa cells and the 
status of the oocyte in vivo and in vitro. J. Clin. Endocrinol. Metab., 49, 
851-860. 
Meldrum D.R. (1991) Low dose follicle stimulating hormone therapy for 
polycystic ovarian disease. Fertil. Steril., 55, 1039-1040. 
Menigish T., Nakamura K. and Takakura Y. (1991) Cloning and sequencing 
of the human FSH receptor cDNA. Biochem. Biophys. Res. Commun., 
175,1125-1130. 
89 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Merkus J.M.W.M., Bots R.S.G.M., Peeters M.F., Prak F., Kerkhof M. and 
Dullemen H. (1990) Hetovariumhyperstimulatiesyndrome. Ned. Tijdschr. 
Geneesk. 134,944-946. 
Midgley AR. (1973) Autoradiographic analysis of gonadotrophin binding to 
rat ovarian tissue sections. Adv. Exp. Med. BioI., 36, 365-378. 
Miller W.L. (1988) Molecular biology of steroid hormone synthesis. Endocr. 
Rev., 9, 295-318. 
Miro F. and Hillier S.G. (1992) Relative effects of activin and inhibin on 
steroid hormone synthesis in primate granulosa cells. J. Clin. Endocrinol. 
Metab., 75,1556-1561. 
Mizunuma H., Takagi T., Honjyo S., Andoh K., Ibuki Y. and Igarashi M. (1990) 
Clinical pharmacodynamics of urinary FSH and its application for 
pharmacokinetic stimulation program. Fertil. Steril., 53, 440-445. 
Mizunuma H., Takagi T., Yamada K., Andoh K., Ibuki Y. and Igarashi M. 
(1991) Ovulation induction by step down administration of purified urinary 
FSH in patients with polycystic ovarian syndrome. Fertil. Steril., 55, 
1195-1159. 
Moses M., Bogowsky H., Anteby E., Lunenfeld B., Rabau E., Serr D., David 
A and Salomy M. (1965) Thromboembolic phenomena after ovarian 
stimulation with human menopausal gonadotropin. Lancet, ii, 1213-1214. 
Nakamura Y., Yoshimura Y., Tanabe K. and lizuka R. (1986) Induction of 
ovulation with pulsatile subcutaneous administration of human 
menopausal gonadotropin in anovulatory infertile women. Fertil. Steril., 
46,46-53. 
Navot D., Rosenwaks Z. and Margalioth E.J. (1987) Prognostic assessment 
of female fecundity. Lancet, ii, 645-647. 
Navot D., Relou A and Birkenfeld T. (1988) Risk factors and prognostic 
variables in the ovarian hyperstimulation syndrome. Am. J. Obste!. 
Gynecol., 159, 210-215. 
Neuwirth R.S., Turksoy R.N. and Vandewiele R.L. (1965) Acute Meig's 
syndrome secondary to ovarian stimulation with human menopausal 
gonadotropins. Am. J. Obste!. Gynecol., 91, 977-980. 
Nitschke-Dabelstein S., Sturm G., Hackeloer B.J., Daume E. and Buchholz 
R. (1980) Welchen stellenwert besitzt die endocrinologische Uberwachung 
in der Gonadotropin-stimulierung anovulatorischer Patientinnen - ein 
Vergleich zwischen endocrinologischen und ultrasonografischen 
Parametern. Geburtsh. u. Frauenheilk., 40, 702-712. 
Out H.J., Mannaerts B.M.J., Coelingh Bennink H.J.T. and Driessen S.G.A.J., 
for the European Puregon Collaborative IVF Study Group (1995). A 
Prospective randomized assessor blind multicenter study comparing 
recombinant and urinary follicle stimulating hormone (PuregonR versus 
MetrodinR) in in vitro fertilization. In press. 
90 
REFERENCES 
Pache T.D., Wladimiroff J.W., de Jong F.H., Hop W.C. and Fauser B.C.J.M. 
(1990) Growlh patterns of nondominant follicles during the normal 
menstrual cycles. Fertil. Steril., 54, 638-642 b. 
Pache T.D., Hop W.C.J., Schipper J., Wlamimirofl J.W. and Fauser B.C.J.M. 
(1991) Tranvaginal sonography and abnormal ovarian appearance in 
menstrual cycle disturbances. Ultrasound Med. BioI., 17,589-593. 
Pache T.D. and Fauser B.C.J.M. (1991) Arrest of follicular maturation in the 
polycystic ovary syndrome: Endocrine and sonographic aspects. Exp. 
Clin. Endocrinol. (Life Sci. Adv.), 10, 1-6. 
Pache T.D., Hop W.C.J., de Jong F.H., Leerentveld R.A., van Geldorp H., 
van de Kamp T.M.M., Gooren L.J.G. and Fauser B.C.J.M. (1992a) 17-P 
estradiol, androstenedione, and inhibin levels in fluid from individual 
follicles of normal and polycystic ovaries, and in ovaries from androgen 
treated female to male transsexuals. Clin. Endocrinol. (Oxf.), 36, 565-
571. 
Pache T.D., Wladimiroff J.W., de Jong F.H., Hop W.C. and Fauser B.C.J.M. 
(1992b) How to discriminate between normal and polycystic ovaries. 
Radiology, 183,421-423. 
Pache T.D. (1993) Disturbed growth and selection of the human ovarian 
follicle. Thesis, Erasmus University Rotterdam, Pasmans Offsetdrukkerij 
The Hague, The Netherlands. 
Padmanabhan V., Chappel S.C. and Beitins I.Z. (1987) An improved in-
vitro bioassay lor follicle stimulating hormone (FSH): suitable for 
measurement 01 FSH in unextracted human serum. Endocrinology, 
121,1089-1098. 
Padmanabhan V., Lang L.L., Sonstein J., Kelch R.P. and Beitins I.Z. (1990) 
Modulation of serum follicle-stimulating hormone bioactivity and isoform 
distribution by estrogenic steroids in normal women and in dysgenesis. 
J. Clin. Endocrinol. Metab., 67, 465-473. 
Palmer A. (1957) Chorionic gonadotropin its place in the treatment of 
infertility. Fertil. Steril., 8, 220-226 
Peters H. (1979) The human ovary in childhood and early maturity. Eur J. 
Obstet. Gynecol. Reprod. BioI., 9, 137-144. 
Peters H., Byskov A.G., Lintem-Moore S., Faber M. and Andersen M. 
(1973) The effect 01 gonadotrophin on follicle growth initiation in the 
neonatal mouse ovary. J. Reprod. Fertil., 35, 139-141. 
Petrikovsky B.M. and Vintzileos A.M. (1989) Management and outcome of 
multiple pregnancy of high fetal order: literature review. Obstet. Gynecol. 
Surv., 44, 578-84. 
91 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Pittaway D.E. and Wentz A.C. (1983) Evaluation of the exponential rise of 
serum estradiol concentrations in human gonadotropin-induced cycles. 
Fertil. Steril., 40, 763-767. 
Polson D.W., Mason H.D., Saldanha M.B.Y. and Franks S. (1987) Ovulation 
of a single dominant follicle during treatment with low-dose pulsatile 
follicle stimulating hormone in women with polycystic ovary syndrome. 
Clin. Endocrinol., 26, 205-212. 
Polson D.w., Adams J., Wadsworth J. and Franks S. (1988) POlycystic 
ovaries - a common finding in normal women. Lancet, i, 870-72. 
Rabau E., David A., Serr D.M., Mashiach S. and Lunenfeld. (1967) Human 
menopausal gonadotropins for anovulation and sterility. Results of 7 
years of treatment. Am. J. Obstet. Gynecol., 1, 92-98. 
Rabinovici J., Blankstein J., Goldman B., Rudak E., Dor Y., Pariente C., 
Geier A., Lunenfeld B. and Mashiach S. (1991) In vitro fertilization and 
primary embryonic cleavage are possible in 17ex-hydroxylase deficiency 
despite extremely low intrafollicular 17-P estradiol. J. Clin. Endrocrinol. 
Metab., 68, 693-697. 
Radwanska E., Hammond J., Hammond M. and Smith P. (1980) Current 
experience with a standardized method of human menopausal 
gonadotropin/human chorionic gonadotropin administration. Fertil. Steril., 
53,510-517. 
Raj S.G., Berger M.J., Grimes E.M. and Taymor M.L. (1977) The use of 
gonadotropins for the induction of ovulation in women with polycystic 
ovarian disease. Fertil. Steril., 28, 1280-1284. 
Rajaniemi H. and Vanha-Perttula T. (1972) Specific receptor for LH in the 
ovary: evidence by autoradiography and tissue fractionation. 
Endocrinology, 97, 670-677. 
RandaIlJ.M., Fisk N.M., McTavish A. and Templeton A.A. (1989) Transvaginal 
ultrasonic assessment of endometrial growth in spontaneous and 
hyperstimulated cycles. Br. J. Obstet. Gynaecol., 96, 954-959. 
Rao M.C., Rees Midgley A. Jr. and RichardsJ.S. (1978) Hormonal regulation 
of ovarian cellular proliferation. Cell., 14,71-8. 
Regan L., Owen E.J. and Jacobs H.S. (1990) Hypersecretion of luteinising 
hormone, infertility, and miscarriage. Lancet, 336, 1141-1144. 
Remorgida V., Veturini P.L., Anserini P., Lanera P. and De Cecco L. 
Administration of pure follicle stimulating hormone during gonadotropin 
releasing hormone agonist therapy in patients with clomiphene resistant 
polycystic ovarian disease: Hormonal evaluations and clinical 
perspectives. Am. J. Obstet. Gynecol., 160, 108-113. 
92 
REFERENCES 
Richards J.S. (1975) Estradiol receptor content in rat granulosa cell during 
follicular development: modification by estradiol and gonadotropins. 
Endocrinology, 97,1143-1150. 
Robertson D.M. and Steel S.J. (1972) The measurement of plasma oestradiol 
and progesterone in women with amenorrhoea treated with 
gonadotrophins. Acta Endocrinol. (Copenh.), 69, 608-616. 
Rosemberg E. and Nwe T.T. (1968) Induction of ovulation with human 
postmenopausal gonadotropins. Experience with 23 patients. Fertil. 
Steril., 19, 197-202. 
Ross G.T., Cargille C.M., Lipsett M.B., Rayford P.L., Marshall J.R., Trott 
C.A. and Rodbard D. (1969) Pitiutary and gonadal hormones in women 
during spontaneous and induced ovulatory cycles. Rec. Progr. Horm. 
Res., 26, 1-55. 
Saal W., Glowania H.J., Hengst W. and Happ J. (1991) Pharmacodynamics 
and pharmacokinetics after sUbcutaneous and intramuscular injection of 
human chorionic gonadotropin. Fertil. Steril., 56, 225-229. 
Sagle M.A., Hamillon-Fairley D., Kiddy D.S. and Franks S. (1991) A 
comparative, randomized study of low-dose human menopausal 
gonadotropin and follicle-stimulating hormone in women with polycystic 
ovarian syndrome. Feriil. Steril., 55, 56-60. 
Sallam H.N., Marinho A.O., Collins W.P., Rodeck C.H. and Campbell S. 
(1982) Monitoring gonadotropin therapy by real-time ultrasonic scanning 
of ovarian follicles. Br. J. Obstet. Gynaecol., 89, 155-159. 
Schenker J.G. and Weinstein D. (1978) Ovarian hyperstimulation syndrome: 
a current survey. Feriil. Steril., 30, 255-268. 
Scheele F., Hompes P.G.A., van der Meer M., Schoute E. and Schoemaker 
J. (1993) The effects of a gonadotrophin releasing hormone agonist on 
treatment with low dose follicle stimulating hormone in polycystic ovary 
syndrome. Hum. Reprod., 8, 699-704. 
Scheele F. (1994) Gonadotrophin-releasing hormone agonist in ovulation 
induction. Thesis, Free University Amsterdam. 
Schmidt W., von Holst T., Garoff L., Gabelmann J. and Kubli F. (1981) 
Monitoring Hmg-stimulated follicular development by real-time 
ultrasound. Eur. J. Obstet. Gynecol. Reprod. BioI., 12,95-105. 
Schoemaker J., Wentz CA, Jones G.S., Dubin N.H. and Sapp K. (1978) 
Stimulation of follicular growth with "pure" FSH in a patient with anovulation 
and elevated LH levels. Obstet. Gynecol., 51, 270-276. 
Schoemaker J., Weissenbruch M.M., Scheele F. and van der Meer. (1993) 
The threshold concept in clinical ovulation induction. Baill. Clin. Obstet. 
Gynaecol., 7, 297-308. 
93 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Schoot D.C., Pache T.D., Hop W.C., de Jong F.H. and Fauser B.C.J.M. 
(1992a) Growth patterns of ovarian follicles during induction of ovulation 
with decreasing doses of human menopausal gonadotropin following 
presumed selection in polycystic ovary syndrome. Fertil. Steri/., 57, 
1117-1120. 
Schoot D.C, Coelingh Bennink H.J.T., Mannaerts B.M.J.L., Lamberts S.w.J., 
Bouchard P. and Fauser B.C.J.M. (1992b) Human recombinant follicle-
stimulating hormone induces growth of preovulatory follicles without 
concomitant increase in androgen and estrogen biosynthesis in a woman 
with isolated gonadotropin deficiency. J. Clin. Endocrinol. Metab., 74, 
1471-1473. 
Schoot D.C., Pijlman B., Stijnen T. and Fauser B.C.J.M. (1992c) Effects of 
GnRH agonist addition to gonadotropin induction of OVUlation in PCOS 
patients. Eur. J. Obstet. Gynaecol. Reprod. BioI., 45, 53-58. 
Schoot D.C. and Fauser B.C.J.M. (1992d) Monitoring of follicular 
development during induction of ovulation using exogenous 
gonadotropins. Exp. Clin. Endocrinol., (Life Science Advances), 11, 
303-306. 
Schoot D.C., Hop W.C., Pache T.D., de Jong F.H. and Fauser B.C.J.M. 
(1993) Growth of the dominant follicle is similarto normal in gonadotrophin 
stimulated polycystic ovary syndrome patients exhibiting monofollicular 
development during a decremental dose regimen. Acta Endocrinol. 
(Kbh.), 129, 126-129. 
Schwartz M., Jewelewicz R., Dyrenfurth I., Tropper P. and VandeWiele R. 
(1980) The use of human menopausal and chorionic gonadotropins for 
induction of ovulation. Am. J. Obstet. Gynecol., 138, 801-807. 
Schwartz M. and Jewelewicz R. (1981) The use of gonadotropins for 
induction of ovulation. Fertil. Steril. 35, 3-12. 
Seddon R.J. (1970) The ovarian response in women to large single injections 
of human menopausal gonadotrophin and human chorionic gonadotropin. 
J. Reprod. Fertil.. 23, 299-305. 
Seibel M.M., McArdle C., Smith D. and Taymor M.L. (1985) Ovulation 
induction in polycystic ovary syndrome with urinary follicle stimulating 
hormone or human menopausal gonadotropin. Fertil. Steril., 43, 703-708. 
Seibel M.M., Kamrava M.M., McArdle C. and TaymorM.L. (1985) Treatment 
of PCOD with chronic low-dose FSH: Biochemical and ultrasound 
correlations. Int. J. Fertil., 29, 39-43. 
Sharma V., Williams J., Collins W., Ridle A., Mason B. and Whitehead M. 
(1987) A comparison of treatments with exogenous FSH to promote 
folliculogenesis in patients with quiescent ovaries due to the continued 
administration of an LHRH agonist. Hum. Reprod., 2, 553-556. 
94 
REFERENCES 
Shoham Z., Balen A., Patel A. and Jacobs H.S. (1991) Results of ovulation 
induction using human menopausal gonadotropin or purified follicle-
stimulating hormone in hypogonadotropic hypogonadism patients. 
Fertil.Steril., 56, 1048-1053. 
Shoham Z., Mannaerts B., InslerV. and Coelingh Bennink H. (1993) Induction 
of follicular growth using recombinant follicle stimulating hormone in two 
volunteer women with hypogonadotropic hypogonadism. Fertil. Steril., 
59,738-743. 
Smith P.E. and Engle E.T. (1927) Experimental evidence regarding role of 
anterior pituitary in development and regulation of genital system. Am. J. 
Ana!., 40,159-217. 
Spiegel A.M., Gierschik P., Levine MA and Downs R.W. (1985) Clinical 
implications of guanine nucleotide-binding proteins as receptor-effector 
couplers. N. Engl. J. Med., 312, 26-33 
Stanger J.D. and Yovich J.L. (1985) Reduced in vitro-fertilization of human 
oocytes from patients with raised basal luteinizing hormone levels during 
the follicular phase. Br. J. Obste!. Gynaecol., 92,385-393. 
Steelman S.L. and Pohley F.M. (1953) Assay of the follicle stimulating 
hormone based on the augmentation with human chorionic gonadotropin. 
Endocrinology, 53, 604-611. 
Stone B.A. and Marrs R.P. (1991) Growth hormone in serum of women 
during the menstrual cycle and during controlled hyperstimulation. Fertil. 
Steril., 56, 52-58. 
Storring P.L. (1992) Assaying glycoprotein hormones influence of 
glycosylation on immuno-reactivity. Trends in Biotechnology, 10, 427-
431. 
Strauss J.F. (1992) Does estradiol act as a local regulator of follicular growth 
and development? In: The role and uses of FSH in induction of ovulation. 
Ares Serono, Geneva, p 12-22. 
Tal J., Paz B., Samberg I., Lazarov N. and Sharf M. (1985) Ultrasonic and 
clinical correlates of menotropin versus sequential clomiphene citrate: 
Menotropin therapy for induction of ovulation. Fertil. Steril., 44, 342-
348. 
Tanbo T., Dale P.O., Kjekshus E., Haug E. and Abyholm T. (1990) Stimulating 
with human menopausal gonadotropin versus follicle stimulating hormone 
after pituitary suppression in polycystic ovarian syndrome. Fertil. Steril., 
53, 798-803. 
Taymor M.L., Berger M.L., Thompson I.E. and Karam K.S. (1972) Hormonal 
factors in human ovulation. Am. J. Obste!. Gynecol., 114, 445-453. 
95 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
TaymorM.L., Sturgis S.P., Goldstein D.P. and Lieberman B. (1967) Induction 
of ovulation with human postmenopausal gonadotropin. Ferti/' Steri/', 18, 
181-188. 
Templeton A., Messinis /'E. and Baird D.T. (1986) Characteristics of the 
ovarian follicles in spontaneous and stimulated cycles in which there 
was an endogenous luteinizing hormone surge. Ferti/. Steri/', 46, 
1113-7. 
Thompson C.R. and Hansen L.M. (1970) Pergonal (menotropins): a 
summary of clinical experience in the induction of ovulation and 
pregnancy. Fertil. Steri/', 21, 844-853. 
Toner J.P., Philput C., Jones G.C. and Muasher S.J. (1991) Basal follicle 
stimulating hormone (FSH) levels is a better predictor of in vitro 
fertilization (IVF) performance than age. Ferti/' Steri/', 55, 784-789. 
Tredway M.L., Sturgis S.H., Goldstein D. and Lieberman B. (1967) Induction 
of ovulation with human postmenopausal gonadotropin. II/, Effect of 
varying dosage schedules on estrogen and pregnanediol excretion 
levels. Fertil. Steril., 18, 181-190. 
Tredway D.R., Goebelsman U. and Thomeycroft /'H. (1974) Monitoring 
induction of ovulation with human menopausal gonadotropin by a rapid 
estrogen radioimmunoassay. Am. J. Obste!. Gyneco/., 120, 1035-1040. 
Van Damme M.P., Robertson D.M. and Diczfalusy E. (1974) An improved in 
vitro bio-assay method for measuring luteinizing hormone (LH) activity 
using mouse Leydig cell preparations. Acta Endocrino/.(Kbh.), 77, 655-
660. 
van der Meer M., Hompes P.GA, Scheele F., Schoute E., Veersema S. 
and Schoemaker J. (1994) Follicle stimulating hormone (FSH) dynamics 
of low dose step-up ovulation induction with FSH in patients with 
polycystic ovary syndrome. Hum. Reprod., 9,1612-1617. 
van Dessel T.J.H.M., Schoot D.C., Schipper J., Dahl K.D. and Fauser 
B.C.J.M. (1995) Circulating immunoreactive and bioactive FSH levels 
in anovulatory infertile women during gonadotropin induction of 
ovulation applying a decremental dose regimen. Submitted. 
van Santbrink E.J.P., Hop W.C., van Dessel T.J.H.M., de Jong F.H. and 
Fauser B.C.J.M. (1995a) Decremental follicle stimulating hormone and 
dominant follicle development during the normal menstrual cycle. Fertil. 
Steril., In Press 
van Santbrink E.J'p., Donderwinkel P.F.J. van Dessel T.J.H.M. and Fauser 
B.C.J.M. (1995b) Gonadotrophin induction of ovulation using a step-
down dose regimen: single-center clinical experience in 82 patients. 
Hum. Reprod., In Press 
96 
REFERENCES 
Vargyas J.M., Marrs R., Kletzky O. and Mishell D. (1982) Correlation of 
ultrasonic measurement of ovarian follicular size and serum estradiol 
levels in ovulatory patients following clomiphene citrate for in vitro 
fertilization. Am. J. Obstet. Gynecol., 144,569-576. 
Venturoli S., Paradisi R., Fabbri R. et al. (1984) Comparison between human 
urinary follicle stimulating hormone and human menopausal gonadotropin 
treatment in polycystic ovary. Obstet. Gynecol., 148,508-512. 
Venturoli S., Orsini L.F., Paradisi R., Fabbri R., Porcu E., Magrini O. and 
Flamigni C. (1986) Human urinary follicle-stimulating hormone and 
human menopausal gonadotropin in induction of multiple follicle growth 
and ovulation. Fertil. Steril., 45, 30-35. 
Walmer O.K., Haney A.F. and Dodson W.C. (1989) Ovarian hyperstimulation 
in polycystic ovary syndrome during therapy with leuprolide acetate. 
Fertil. Steril., 52, 858-859. 
Wang C.F. and Gemzell C. (1980) The use of human gonadotropins for 
induction of ovulation in women with polycystic ovary disease. Fertil. 
Steril., 33, 479-86. 
Webb-Wilson G.J. and Arronet G.H. (1977) Ovulation induction using 
human menopausal gonadotropins: an evaluation of a variable dosage 
regimen. Int. J. Fertil., 22, 225-231. 
Weissenbruch M.M. (1990) Gonadotropins for induction of ovulation: 
Immunological, pharmalogical and clinical studies. Thesis, Free University 
Amsterdam, Almelo. Offset drukkery N.O.T., The Netherlands. 
Weissenbruch M.M., Schoemaker H.C., Drexhage H.A. and Schoemaker 
J. (1993) Pharmacodynamics of human menopausal gonadotrophins 
(HMG) and follicle stimulating hormone (FSH) The importance of the 
FSH level in initiating follicular growth. Hum. Reprod., 8, 813-821. 
Westergaard L., Christensen I.J. and McNally K.P. (1986) Steroid levels in 
ovarian follicular fluid related to follicle size and health status during the 
normal menstrual cycle in women. Hum. Reprod., 1, 227-232. 
Wetzels L.C.G. (1983) Ultrasonographical aspects of follicle growth. Thesis, 
State University Limburg, The Netherlands, p 15-28. 
Williams P.C. (1940) Effect of stilboestrol on the ovaries of hypo-
physectomized rats. Nature, 145, 388-392. 
Wilson E.A., Jawad M.J. and Hayden T.L. (1982) Rates of exponential 
increase of serum estradiol concentrations in normal and human 
menopausal gonadotropin-induced cycles. Fertil. Steril., 37, 46-50. 
Wong P.C. and Asch R.H. (1986) The pulsatile administration of luteinizing 
hormone-releasing hormone (LH-RH) for induction of ovulation. Int. J. 
Fertil., 30,11-27. 
97 
EXOGENOUS FSH AND HUMAN OVARIAN FOLLICLES 
Wu C.H. (1978) Monitoring of ovulation induction. Ferti!. Steri!., 30, 617-
630. 
Wu C.H. (1977) Plasma hormones in human gonadotropin induced ovulation. 
Obste!. Gyneco!., 49, 208-313. 
Yen S.S.C., Llerena 0., Little B. and Pearson O.H. (1970) Disappearance 
rates of endogenous follicle stimulating hormone in the serum following 
surgical hypofysectomy in man. J. Clin. Endocrino!., 30, 325-329. 
Yen S.S.C., Llerena O. and Pearson O.H. (1968) Disappearance rate of 
endogenous luteinizing hormone and chorionic gonadotropin in man. J. 
Clin. Endocrino!., 28, 1763-1767. 
Yen S.S., Vela P. and Ryan K.J. (1970) Effect of clomiphene citrate in 
polycystic ovary syndrome. J. Clin. Endocrino!. Metab., 31, 7-15. 
YI6stalo P., R6nnberg L. and JoupilJa P. (1979) Measurement of the ovarian 
follicle by ultrasound and estradiol levels during spontaneous and induced 
cycles. Ferti!. Steri!., 31, 651-655. 
Yong E.L., Baird D.T., Yates R., Reichert L.E. and Hillier S.G. (1992) 
Hormonal regulation of the growth and steroidogenic function of the 
human granulosa cells. J. Clin. Endocrino!. Metab., 74, 842-849. 
Zeleznik AJ. (1981) Premature elevation of sytemic estradiol reduces 
serum follicle stimulating hormone and lengthens the follicular phase of 
the menstrual cycle in rhesus monkeys. Endocrinology, 109, 352-358. 
Zeleznik AJ. and Hillier S.G. (1984) The role of gonadotropins in the 
selection of the dominant follicle. Clin. Obste!. Gyneco!., 27, 927-940. 
Zeleznik A.J., Hutchison J.S. and Schuler H.M. (1985) Interference with 
the gonadotropin supressing actions of estradiol in macaques over-
rides the selection of a single preovulatory follicle. Endocrinology, 117, 
991-999. 
Zeleznik A.J. and Kubik C.J. (1986) Ovarian responses in macaques to 
pulsatile infusion of follicle-stimulating hormone (FSH) and luteinizing 
hormone: Increased sensitivity of the maturing follicle to FSH. 
Endocrinology, 119, 2025-2032. 
Zimmerman R., Soar B., Braendle W., Lehmann, Weise H.C. and Bettendorf 
G. (1982) Gonadotropin therapy of femaly infertility. Analysis of results 
of 416 cases. Gynecol. Obste!. Invest., 14, 1-18. 
Zondek B. (1930) Uber die function des hypophysen vorderlappens. K!. 
Wschr., 9, 393-397. 
98 
6 
Summary 
Chapter 1 
This chapter starts with a general introduction covering highlights in the 
history of glycoprotein hormones, especially FSH. Improvements in the 
process of purification of gonadotropic hormones are discussed. The newly 
developed human recombinant follicle-stimulating hormone (rhFSH) offers 
therapeutical and investigational potential. 
Interaction of gonadotropic hormones on ovarian target tissue level is 
discussed. FSH appears to be mandatory for recruitment of ovarian follicles, 
whereas estrogen production of the growing dominant follicle plays an 
important role in the process of selection. Development of multiple ovarian 
follicles during gonadotropin induction of ovulation in infertile peos patients 
is hypothesized to be the result of increased or sustained FSH levels 
following the moment of presumed selection. This hypothesis of temporary 
FSH stimulation to minimize ongoing growth of secondary follicles is called 
the 'FSH window' concept. Analogous to the normal menstrual cycle, it is 
believed that development of secondary ovarian follicles is less pronounced 
in a dose regimen where FSH decreases following selection of the dominant 
ovarian follicle ('step·down' dose regimen for gonadotropin induction of 
ovulation). 
An historical overview of 30 years of gonadotropin induction of ovulation 
represents developments in treatment; i.e. gonadotropin preparations, dose 
regimens, monitoring facilities and adjuvant medication. Although success 
rates of gonadotropin induction of ovulation have improved, complications 
are still of great concern to clinicians. 
Chapter 2 
Section 2.1 Some background information with regard to human 
recombinant FSH is provided. The lack of intrinSic LH activity of this 
compound provides the opportunity to investigate separately the roles of 
FSH and LH with regard to folliculogenesis and steroid production. 
Section 2.2 To evaluate the importance of LH for normal estrogen production 
and subsequent development of ovarian follicles, a woman with isolated 
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gonadotropin deficiency was monitored during rhFSH administration with 
respect to ovarian follicular growth and steroid production. During the first 
week (75 IU/day rhFSH im), a significant rise in serum FSH (4.9 lUlL) was 
observed in the absence of changes in serum E, concentrations (36-76 
pmoI/L). During the following five days, 150 IU/day rhFSH was administered 
resulting in a further increase of serum FSH levels (maximum 8.5 lUlL). 
Development of multiple follicles - maximum diameter 22 mm as observed 
by transvaginal sonography - emerged together with a minor rise in E,levels 
(from 76 to 236 pmol/L) and with a minimal increase in endometrial thickness 
(below 6 mm). Six days following the last injection of rhFSH, aspiration of 3 
follicles (13, 15 and 18 mm) was performed and low intrafollicular AD « 675 
nmol/L) and E, « 9400 pmollL) concentrations, as compared to normal 
follicles, were found. 
These first data on rhFSH administration in the human suggest that: a) 
FSH alone can induce growth of preovulatory follicles, b) follicle growth 
does occur in the presence of subnormal E, levels, c) LH is needed for 
adequate AD biosynthesis as substrate for aromatase activity. This indicates 
that growth and steroidogenic granulosa cell activity may be differentially 
regulated. 
Section 2.3 Seven females suffering from hypogonadism due to previous 
hypophysectomy, isolated gonadotropin deficiency or Kallman syndrome 
volunteered to participate in a study to assess ovarian response following 
multiple-dose administration of rhFSH (Org 32489). Mean baseline serum 
FSH and LH levels were 0.25 «0.05-1.15) lUlL and 0.06 «0.05-0.37) 
lUlL, respectively. Subjects received daily im injections of rhFSH for 3 weeks 
(week 1: 75 IU/d, week 2: 150 IU/d, week 3: 225 IU/d). Blood sampling and 
sonographic investigations were performed on alternate days. Steady-state 
FSH concentrations were reached approximately 3 to 5 days after alterations 
of doses administered. Maximum FSH levels were between 7.1 and 11.8 lUI 
L, whereas serum LH concentrations remained unchanged. Due to the 
abscense of follicle development and lack of a rise in immunoreactive INH 
(presumably due to early ovarian failure) in 2 subjects, analysis of ovarian 
response was restricted to 5 volunteers. Serum androstenedione (AD) levels 
showed no significant changes during rhFSH administration. Although 
serum immunoreactive INH concentrations reached normal, late follicular 
levels (659 [388-993] U/L), serum E, revealed only a minor increase (77 [18-
210] pmoIlL). Moreover, growth of (multiple) ovarian follicles was observed 
up to preovulatory sizes (> 15 mm) in these patients. 
It may be concluded from the present study that: 1) rhFSH exhibits no 
intrinsic LH activity, 2) rhFSH stimulation in hypogonadotropic women 
resulted in an immunoreactive INH rise which was similar as compared to 
normal, whereas in contrast only a minor increase in E, concentrations was 
observed (suggesting normal granulosa cell function, and low availability of 
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androgens as a substrate for aromatization), and 3) despite the minimal 
estrogen increase, ovarian follicles developed normally to the preovulatory 
stage. 
Chapter 3 
Section 3. 1 During treatment of anovulation with exogenous gonadotropins, 
a high incidence of complications (mainly multiple pregnancies and ovarian 
hyperstimulation) is observed. Since ovarian response may vary from 
patient to patient and from one cycle to the other, careful monitoring is 
mandatory. Frequent determinations of serum E,levels may be of help in this 
respect. However, high estrogen levels can be caused by a single dominant 
follicle or by a number of smaller ones. 
The importance of the 'FSH- threshold' and 'FSH- window' concepts with 
regard to gonadotropin induction of ovulation is dicussed.ln normal regularly 
cycling women decreasing serum FSH levels are observed following selection 
of the dominant follicle. This concept was tested in anovulatory peas 
patients, by inducing follicle growth giving exogenous gonadotropins in a 
decreasing dose regimen. This would potentially stimulate growth of follicles 
during a restricted time (to prevent multiple follicle development) with 
reduced interference in the selection process. Accurate monitoring of follicle 
development is possible since the recent introduction of transvaginal pelvic 
sonography. Insight in ovarian changes comparing different gonadotropin 
dose regimens may eventually lead to better understanding of regulation of 
ovarian function. In addition, this may lead to more effective prevention of 
multiple follicle development with subsequent reductions in complication 
rates. 
Section 3.2 Data presented in this study indicate that ovulation can be 
induced in peas patients using GnRH analogs combined with HMG in a 
decreasing dose regimen. Based on the observed decline in numbers of 
functional, medium-sized follicles comparing a fixed versus a decreasing 
dose regimen, it may be speculated that the risk of ovarian hyperstimulation 
during gonadotropin induction of ovulation in peas patients may be reduced 
under circumstances where stimulation by FSH is reduced in the late 
follicular phase. 
Section 3.3 The aim of this study was to investigate the late follicular phase 
of 7 gonadotropin-treated peas patients exhibiting monofollicular growth, 
and compare developmental characteristics with the dominant follicle in 7 
control women with regular menstrual cycles. Daily serum FSH levels in 
peas patients decreased more rapidly as compared to controls (-0.3 ± 0.2 
IU/day in controls, versus -0.7 ± 0.4 IU/day in peas; p< 0.02). No 
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statistically significant differences were seen in daily increase (30% in 
controls and peOS) and mean peak levels (825 ± 94 pmol/L in controls, 
versus 937 ± 231 pmollL in peOS) of E, serum levels comparing both 
groups. Mean daily growth of the dominant follicle (1.7 ± 0.4 mm in controls, 
versus 1.9 ± 0.6 mm in peOS) was not significantly different. 
It is concluded that in peos patients using a decreasing dose regimen 
gonadotropin plus adjuvant GnRH-agonists, levels of serum FSH are 
decremental and growth of a single ovarian follicle is demonstrated. In 
addition, growth of the dominant follicle and estrogen production in peos 
patients are not significantly different from follicle growth under normal 
conditions. 
Section 3.4 Daily ovarian E, production and follicle growth (by transvaginal 
ultrasound) were investigated during gonadotropin administration of HMG 
or pFSH for induction of ovulation in 28 peos patients suffering from 
clomiphene-resistant anovulation. In contrast to regular increasing dose 
regimens, gonadotropins were administered in a 'step-down' fashion 
combined with GnRH-a in an attempt to reduce the incidence of multiple 
follicle development and subsequent complications. No differences were 
observed in ovarian response comparing HMG versus pFSH administration. 
Growth of ovarian follicles was sustained and ovulation achieved in the 
majority of patients despite a significant decrease in serum FSH levels of 
10% per day. Major variability in early E, increase (not related to differences 
in FSH serum concentrations) without changes in ovarian follicle number 
and size suggests differences in ovarian sensitivity to FSH stimulation. 
Early E, increments predict chances of ovarian hyperresponse or 
hyporesponse (absent follicle maturation) during gonadotropin induction in 
the applied step-down fashion. 
These findings suggest that gonadotropin induction of ovulation according 
to a decremental dose regimen may be useful for clinical practice and 
underline the significance of monitoring early E, response to further improve 
treatment outcome. 
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Samenvatting 
Hoofdsluk 1 
Oit hoofdstuk begint met een algemene inleiding met historisch overzicht 
over de zuivering van gonadotrope hormonen, m.n. FSH. Het recent 
ontwikkelde humaan recombinant follikel stimulerend hormoon (rhFSH) 
biedt naast een aanvulling van therapeutische mogelijkheden een unieke 
kans om fysiologisch onderzoek te verrichten. 
Verschillende effecten van gonadotrope hormonen op ovarieel weefsel 
worden besproken. FSH lijkt onmisbaar in het proces van recrutering 
(,recruitment') van ovariiile follikels, terwijl tijdens de selectie van de 
dominante follikel oestrogenen een belangrijke rol spelen. Tijdens 
conventionele gonadotrofine toediening voor inductie van ovulatie in het 
kader van infertiliteits behandeling bij peo patienten stijgen of stabiliseren 
serum FSH spiegels na het moment van selektie van de dominante follikel. 
Het ontstaan van meerdere ovariele follikels wordt beschouwd als een gevolg 
van aanhoudende FSH stimulatie. Naaranalogie aande normale menstruele 
cyclus lijkt ontwikkeling van secundaire ovariiile follikels minder sterk indien 
FSH in de laatste dagen van de follikulaire fase dalende is. 
Een historisch overzicht van dertig jaar ovulatie inductie met behulp van 
gonadotrofines wordt gegeven (o.a. gonadotrofine preparaten, doserings-
schema's, monitoring en adjuvante medicatie). De kans op succes van 
behandeling neemt toe, de complicaties (meerling zwangerschapen ovarieel 
hyperstimulatie syndroom) blijven echter in de praktijk veel zorgen geven. 
Hoofsluk 2 
paragraaf 2. 1 Enige achtergrond informatie met betrekking tot humaan 
recombinant FSH (rhFSH) wordt gegeven. Het gebrek aan intrinsieke LH 
activiteit van rhFSH biedt de mogelijkheid om de afzonderlijke rol van FSH 
en LH voor follikelgroei en steroidogenese te onderzoeken. 
paragraaf 2.2 Om de waarde van LH voor oestrogeen produktie en 
ontwikkeling van ovariiile follikels te onderzoeken werden ovariiile 
veranderingen (follikels en steroidogenese) tijdens toediening van rhFSH bij 
een vrouw met ge'lsoleerde gonadotrofine uitval vastgelegd. Tijdens de 
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eerste week (75 IU rhFSH/dag im) bleek een significante stijging van serum 
FSH (4.9 lUlL), zanderveranderingen in serum oestradiol (E,) concentraties 
(36-76 pmoI/L). De serum FSH spiegel nam toe (maximum 8.5 lUlL) 
gedurende de volgende vijf dagen (150 IU rhFSH/dag). Multiple follikels-
maximum diameter 22 mm (transvaginale echoscopie) - werden zichtbaar 
zonder een bijpassende stijging in E, concentratie (76-236 pmollL) en 
zander duidelijke toename van de tot ale endometrium dikte (minder dan 6 
mm). Zes dagen na de laatste injectie met rhFSH werden 3 follikels (13,15 
and 18 mm) leeggezogen. Lage intrafollikulaire AD « 675 nmol/L) en E, 
« 9,400 pmol/L) concentraties - vergeleken met normale follikels - werden 
gevonden. Deze eerste data betreffende rhFSH toediening bij de mens 
geven aan dat: a) FSH ontwikkeling van preovulatoire follikels kan induceren, 
b) follikelgroei in de ova ria kan optreden in aanwezigheid van lage E, 
spiegels, c) LH nodig is voor adequate biosynthese van AD zodat het als 
substraat kan dienen voor aromatase activiteit. De hiergenoemde bevindingen 
geven aan dat verschillende activiteiten van de granulosacel (groei en 
steroidproductie) verschillend gereguleerd worden. 
Paragraaf 2.3 Zeven vrijwilligsters met hypogonadotroop hypogonadisme 
als gevolg van hypofysectomie, ge'lsoleerde hypofysaire gonadotrofine 
uitval of syndroom van Kallman participeerden in een studie waarin ovariiile 
response werd vastgesteld na toediening van multiple dosis rhFSH (Org 
32489). Uitgangswaarden voor FSH en LH in het serum waren respectivelijk 
0.25 « 0.05-1.15) lUlL en 0.06 « 0.05-0.37) lUlL. De vrijwilligsters kregen 
dagelijks im injecties met rhFSH gedurende 3 weken (week 1: 75 IU/d, week 
2: 150 IU/d, week 3: 225 IU/d). Bloed afname en echoscopische 
onderzaekingen werden drie maal per week uitgevoerd. Steady state 
concentraties van FSH werden bereikt ongeveer 3 tot 5 dagen nadat de 
dagelijks toegediende dosis was opgehoogd. Hoogste individuele serum 
FSH spiegels bij rhFSH dosering bleken tussen 7.1 en 11.8IU/L. Serum LH 
concentraties bleven onveranderd laag. De analyse van ovarium respons 
werd beperkt tot die 5 deelnemende vrouwen waarbij follikelgroei werd 
aangetoond. In 2 vrouwen werd geen follikelgroei gezien en bleek geen 
verandering in immunoreaktief INH opgetreden; waarschijnlijk tengevolge 
van premature ovarium uitval. Serum AD levels lieten wienig verandering 
zien tijdens rhFSH toediening. Alhoewel serum immunoreactief INH 
concentraties bleken overeen te komen met laat folliculaire spiegels (659 
[388-993J U/L), toonde serum E, weinig toename (77 [18-21OJ pmoI/L). In 
tegenstelling hiermee groeiden meerdere ovariiile follikels door tot 
preovulatoire afmetingen (>15 mm). 
Uit deze studie mag worden geconcludeert dat: 1) rhFSH geen LH 
activiteit bezit, 2) stimulatie met rhFSH in hypogonadotrope vrouwen resulteert 
in toename van immunoreactive INH concentraties (vergelijkbaar met de 
normale cyclus), terwijl slechts een geringe toename in serum E, concentraties 
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optrad (suggererend dat er bij normale functie van de granulosacellen een 
geringe beschikbaarheid van androgenen is en, 3) ondanks zeer geringe 
toename van E, ovariele follikels in staat zijn doorle groeien tot preovulatoire 
groolle. 
Hoofdstuk3 
Paragraaf 3.1 Tijdens behandeling van anovulatie en kinderwens met 
gonadotrofines wordt een hoge incidentie van complicaties 
(meerlingzwangerschappen en ovariele hyperstimulatie) vastgesteld. 
Vanwege grote verschillen in respons tussen patienten en behandelings-
cycli onderling is nauwgezette controle noodzakelijk. Herhaaldelijke 
bepalingen van serum E, kunnen in dit opzicht behulpzaam zijn. Hoge serum 
E, spiegels kunnen echter door enkele grote maar ook door vee I middelgrote 
ovariele follikels worden geproduceerd. 
Het concept van 'FSH- drempel' en 'FSH- venster' met betrekking tot 
ovulatie inductie met gonadotropines wordt besproken. Naar analogie aan 
de normale menstruele cyclus waarbij in de follikulaire fase een daling van 
het serum FSH wordt vastgesteld, werd besloten in anovulatoire pea 
patienten dit concept te testen door toediening van gonadotrofines in 
afnemende hoeveelheid. Verondersteld werd dat hierdoor de periode van 
stimulatie van follikel groei zou afnemen met als gevolg preventie van groei 
van multiple follikels door verminderde beinvloeding van het proces van 
selectie van de dominante follikel. 
Recente ontwikkeling van transvaginale echoscopie maakt accurate 
monitoring van follikelgroei in het ovarium mogelijk. Vergelijking van ovarium 
respons tussen verschillende doseringsschema's voor gonadotrofines is 
hierdoor mogelijk. Tevens wordt meer inzicht geboden in de functie van het 
ovarium tijdens inductie van ovulatie met gonadotrofines. Wellicht wordt 
een meer effectieve preventie van overmatige groei van follikels hierdoor 
mogelijk hetgeen kan helpen bij de vermindering van de complicaties van 
behandeling. 
Paragraaf 3.2 Uit de gepresenteerde gegevens van deze studie blijkt dat 
ovulatie inductie mogelijk is bij patienten met pea na gebruik van een dalend 
doseringsschema voor gonadotrofines ('step-down'schema) in combinatie 
met GnRH-agonisten. Deze 'step-down' behandeling wordt vergeleken met 
een ander gonadotrofine behandelingsschema (onveranderde hoeveelheid; 
'fixed-dose') in een vergelijkbare groep pea patienten. Een afname van de 
aantallen functionele middelgrote follikels tijdens de 'step-down' dosering 
wordt vastgesteld. Er word! gespeculeerd dat risico's samenhangend met 
groei van multipele follikels (en complicaties van behandeling) mogelijk 
minder vaak voorkomen na een 'step-down' schema. 
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Paragraaf 3.3 Vergelijkend onderzoek van biometrische en hormonale 
parameters tijdens de laat follikulaire fase wordt beschreven in 7 met 
gonadotrofines behandelde PCO patienten met monofollikulaire groei en 
van 7 regelmatig menstruerende vrouwen (controles). Serum FSH spiegels 
in PCO patienten daalden sneller dan in de controlegroep (-0.3 ± 0.2 lUI 
dag in controlegroep, versus -0.7 ± 0.4 IU/dag in PCO groep; P< 0.02). 
Geen statistisch significante verschillen werden vastgesteld m.b.1. dagelijkse 
E, toename (30% in beide groepen) en gemiddelde maximum E, spiegels 
(825 ± 94 pmol/l: controlegroep; 937 ± 231 pmol/l in PCO-groep). Ook de 
gemiddelde dagelijkse groei van de dominante follikel was niet verschillend 
(1.7 ± 0.4 mm: controlegroep; 1.9 ± 0.6 mm PCO-groep). 
Uit de gepresenteerde gegevens van deze studie blijkt wederom dat 
ovulatie inductie mogelijk is bij PCO-patienten, na gebruik van een dalend 
doseringsschema voor gonadotrofines ('step-down' schema) in combinatie 
met GnRH-a. Tevens blijkt uit de gegevens dat groei en E, productie van de 
dominante follikel in PCO-patienten tijdens het beschreven ovulatie inductie 
schema niet significant verschilt van follikelgroei onder normale 
omstandigheden. 
Paragraaf 3.4 Dagelijks onderzoek (serum E, spiegels en transvaginale 
echoscopie) werd verricht tijdens gonadotrofine toediening (HMG of pFSH) 
voor ovulatie inductie in 28 clomifeen resistente anovulatoire PCO-patienten. 
In tegenstelling tot de gangbare dose ring voor gonadotrofines (toenemende 
doses ='step-up') werden gonadotrofines toegediend volgens het 'step-
down' model. Geen verschillen werden gevonden tussen de groepen met 
pFSH (n=18) en HMG (n=18). Groei van follikels werd vastgesteld en 
ovulatie trad op in een meerderheid van de patienten ondanks significant 
dalende serum FSH spiegels (1O% per dag). Grote variabiliteit in vroeg-
follikulair optredende E, stijging (niet gecorreleerd met serum FSH 
concentraties) zonder zichtbare veranderingen in aantal en diameter van 
ovariele follikels suggereert verschillen in gevoeligheid voor FSH stimulatie. 
Vroege E, stijging (tot dag 2) voorspelt de kans op ovariele respons 
(hyperresponsl hyporespons) tijdens gonadotrofine toediening in het 
beschreven 'step-down' doseringsschema. 
Deze observaties bevestigen de mogelijke klinische toepasbaarheid van 
het step-down schema voor gonadotrofine ovulatie inductie en onderstrepen 
het nut van meting van vroege E, respons terverbetering van toepasbaarheid 
van het genoemde doseringsschema. 
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